Released this past November, the list is based on data collected from the Web of Science and highlights some of the world’s most influential scientific minds by naming the researchers whose publications over the previous decade have included a high number of Highly Cited Papers placing them among the top 1% most-cited.
\\n\\n
We wish to congratulate all of the researchers named and especially our authors on this amazing accomplishment! We are happy and proud to share in their success!
IntechOpen is proud to announce that 191 of our authors have made the Clarivate™ Highly Cited Researchers List for 2020, ranking them among the top 1% most-cited.
\n\n
Throughout the years, the list has named a total of 261 IntechOpen authors as Highly Cited. Of those researchers, 69 have been featured on the list multiple times.
\n\n\n\n
Released this past November, the list is based on data collected from the Web of Science and highlights some of the world’s most influential scientific minds by naming the researchers whose publications over the previous decade have included a high number of Highly Cited Papers placing them among the top 1% most-cited.
\n\n
We wish to congratulate all of the researchers named and especially our authors on this amazing accomplishment! We are happy and proud to share in their success!
Note: Edited in March 2021
\n'}],latestNews:[{slug:"webinar-introduction-to-open-science-wednesday-18-may-1-pm-cest-20220518",title:"Webinar: Introduction to Open Science | Wednesday 18 May, 1 PM CEST"},{slug:"step-in-the-right-direction-intechopen-launches-a-portfolio-of-open-science-journals-20220414",title:"Step in the Right Direction: IntechOpen Launches a Portfolio of Open Science Journals"},{slug:"let-s-meet-at-london-book-fair-5-7-april-2022-olympia-london-20220321",title:"Let’s meet at London Book Fair, 5-7 April 2022, Olympia London"},{slug:"50-books-published-as-part-of-intechopen-and-knowledge-unlatched-ku-collaboration-20220316",title:"50 Books published as part of IntechOpen and Knowledge Unlatched (KU) Collaboration"},{slug:"intechopen-joins-the-united-nations-sustainable-development-goals-publishers-compact-20221702",title:"IntechOpen joins the United Nations Sustainable Development Goals Publishers Compact"},{slug:"intechopen-signs-exclusive-representation-agreement-with-lsr-libros-servicios-y-representaciones-s-a-de-c-v-20211123",title:"IntechOpen Signs Exclusive Representation Agreement with LSR Libros Servicios y Representaciones S.A. de C.V"},{slug:"intechopen-expands-partnership-with-research4life-20211110",title:"IntechOpen Expands Partnership with Research4Life"},{slug:"introducing-intechopen-book-series-a-new-publishing-format-for-oa-books-20210915",title:"Introducing IntechOpen Book Series - A New Publishing Format for OA Books"}]},book:{item:{type:"book",id:"869",leadTitle:null,fullTitle:"Olive Oil - Constituents, Quality, Health Properties and Bioconversions",title:"Olive Oil",subtitle:"Constituents, Quality, Health Properties and Bioconversions",reviewType:"peer-reviewed",abstract:"The health-promoting effects attributed to olive oil, and the development of the olive oil industry have intensified the quest for new information, stimulating wide areas of research. This book is a source of recently accumulated information. It covers a broad range of topics from chemistry, technology, and quality assessment, to bioavailability and function of important molecules, recovery of bioactive compounds, preparation of olive oil-based functional products, and identification of novel pharmacological targets for the prevention and treatment of certain diseases.",isbn:null,printIsbn:"978-953-307-921-9",pdfIsbn:"978-953-51-4368-0",doi:"10.5772/1378",price:159,priceEur:175,priceUsd:205,slug:"olive-oil-constituents-quality-health-properties-and-bioconversions",numberOfPages:524,isOpenForSubmission:!1,isInWos:1,isInBkci:!0,hash:"b26e27a335ddfd64f9583593dbd8ceb5",bookSignature:"Boskou Dimitrios",publishedDate:"February 1st 2012",coverURL:"https://cdn.intechopen.com/books/images_new/869.jpg",numberOfDownloads:142579,numberOfWosCitations:256,numberOfCrossrefCitations:65,numberOfCrossrefCitationsByBook:5,numberOfDimensionsCitations:272,numberOfDimensionsCitationsByBook:17,hasAltmetrics:1,numberOfTotalCitations:593,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"February 22nd 2011",dateEndSecondStepPublish:"March 22nd 2011",dateEndThirdStepPublish:"July 27th 2011",dateEndFourthStepPublish:"August 26th 2011",dateEndFifthStepPublish:"December 24th 2011",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6,8,9",editedByType:"Edited by",kuFlag:!1,featuredMarkup:null,editors:[{id:"77212",title:"Dr.",name:"Dimitrios",middleName:null,surname:"Boskou",slug:"dimitrios-boskou",fullName:"Dimitrios Boskou",profilePictureURL:"https://mts.intechopen.com/storage/users/77212/images/3142_n.jpg",biography:"Dimitrios Boskou received his diploma in chemistry from the School of Chemistry, Aristotle University of Thessaloniki, Hellas; his Philosophy Doctor degree from the University of London, UK; and his degree of Doctor of Science from the School of Chemistry, Aristotle University of Thessaloniki, Hellas. He served as an assistant, lecturer, assistant professor, associate professor, professor and head of the Laboratory of Food Chemistry and Technology, School of Chemistry, Aristotle University of Thessaloniki (1970–2006). From 1986 to 1998, he was a member of the IUPAC Commission on Oils, Fats, and Derivatives. In the years 1995–2005, he served as a member of the Supreme Chemical Council, Athens. From 1995 to 2012, he was a member of the Scientific Committee for Food of the European Commission and a member and expert of the Food Additives Panel of the European Food Safety Authority. His achievements are: over 90 published papers and reviews; author and editor of 8 books; author of 22 chapters in books related to major and minor constituents of fats, natural antioxidants, olive oil and frying of food; and contributor to international scientific encyclopedias and the Lexicon of Lipid Nutrition, a joint IUPAC/IUNS work.",institutionString:null,position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"2",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"327",title:"Food Safety",slug:"food-safety"}],chapters:[{id:"27024",title:"Volatile and Non-Volatile Compounds of Single Cultivar Virgin Olive Oils Produced in Italy and Tunisia with Regard to Different Extraction Systems and Storage Conditions",doi:"10.5772/28699",slug:"volatile-and-non-volatile-compounds-of-single-cultivar-virgin-olive-oils-produced-in-italy-and-tunis",totalDownloads:3101,totalCrossrefCites:2,totalDimensionsCites:3,hasAltmetrics:0,abstract:null,signatures:"Cinzia Benincasa, Kaouther Ben Hassine,Naziha Grati Kammoun and Enzo Perri",downloadPdfUrl:"/chapter/pdf-download/27024",previewPdfUrl:"/chapter/pdf-preview/27024",authors:[{id:"75035",title:"Dr.",name:"Enzo",surname:"Perri",slug:"enzo-perri",fullName:"Enzo Perri"},{id:"83499",title:"Dr.",name:"Cinzia",surname:"Benincasa",slug:"cinzia-benincasa",fullName:"Cinzia Benincasa"},{id:"124199",title:"Dr.",name:"Kaouther",surname:"Ben Hassine",slug:"kaouther-ben-hassine",fullName:"Kaouther Ben Hassine"},{id:"124200",title:"Dr.",name:"Naziha Grati",surname:"Kammoun",slug:"naziha-grati-kammoun",fullName:"Naziha Grati Kammoun"}],corrections:null},{id:"27025",title:"Olive Oil Composition: Volatile Compounds",doi:"10.5772/28512",slug:"oil-composition-volatiles",totalDownloads:6964,totalCrossrefCites:2,totalDimensionsCites:20,hasAltmetrics:0,abstract:null,signatures:"Marco D.R. Gomes da Silva, Ana M. Costa Freitas, Maria J. B. Cabrita and Raquel Garcia",downloadPdfUrl:"/chapter/pdf-download/27025",previewPdfUrl:"/chapter/pdf-preview/27025",authors:[{id:"74131",title:"Prof.",name:"Marco",surname:"Gomes Da Silva",slug:"marco-gomes-da-silva",fullName:"Marco Gomes Da Silva"},{id:"75471",title:"Prof.",name:"Ana Maria",surname:"Costa Freitas",slug:"ana-maria-costa-freitas",fullName:"Ana Maria Costa Freitas"},{id:"75472",title:"Prof.",name:"Maria João",surname:"Bastos Cabrita",slug:"maria-joao-bastos-cabrita",fullName:"Maria João Bastos Cabrita"},{id:"75474",title:"Dr.",name:"Raquel",surname:"Garcia",slug:"raquel-garcia",fullName:"Raquel Garcia"}],corrections:null},{id:"27026",title:"Optical Absorption Spectroscopy for Quality Assessment of Extra Virgin Olive Oil",doi:"10.5772/30275",slug:"optical-absorption-spectroscopy-for-quality-assessment-of-extra-virgin-olive-oil",totalDownloads:10611,totalCrossrefCites:2,totalDimensionsCites:11,hasAltmetrics:1,abstract:null,signatures:"Anna Grazia Mignani, Leonardo Ciaccheri,Andrea Azelio Mencaglia and Antonio Cimato",downloadPdfUrl:"/chapter/pdf-download/27026",previewPdfUrl:"/chapter/pdf-preview/27026",authors:[{id:"81724",title:"Dr.",name:"Leonardo",surname:"Ciaccheri",slug:"leonardo-ciaccheri",fullName:"Leonardo Ciaccheri"},{id:"122261",title:"Dr.",name:"Anna Grazia",surname:"Mignani",slug:"anna-grazia-mignani",fullName:"Anna Grazia Mignani"},{id:"122267",title:"Dr.",name:"Andrea Azelio",surname:"Mencaglia",slug:"andrea-azelio-mencaglia",fullName:"Andrea Azelio Mencaglia"},{id:"122270",title:"Dr.",name:"Antonio",surname:"Cimato",slug:"antonio-cimato",fullName:"Antonio Cimato"}],corrections:null},{id:"27027",title:"Analysis of Olive Oils by Fluorescence Spectroscopy: Methods and Applications",doi:"10.5772/30676",slug:"analysis-of-olive-oils-by-fluorescence-spectroscopy-methods-and-applications",totalDownloads:6585,totalCrossrefCites:16,totalDimensionsCites:54,hasAltmetrics:1,abstract:null,signatures:"Ewa Sikorska, Igor Khmelinskii and Marek Sikorski",downloadPdfUrl:"/chapter/pdf-download/27027",previewPdfUrl:"/chapter/pdf-preview/27027",authors:[{id:"83679",title:"Dr.",name:"Ewa",surname:"Sikorska",slug:"ewa-sikorska",fullName:"Ewa Sikorska"},{id:"87499",title:"Prof.",name:"Igor",surname:"Khmelinskii",slug:"igor-khmelinskii",fullName:"Igor Khmelinskii"},{id:"87500",title:"Dr.",name:"Marek",surname:"Sikorski",slug:"marek-sikorski",fullName:"Marek Sikorski"}],corrections:null},{id:"27028",title:"Metal Determinations in Olive Oil",doi:"10.5772/29286",slug:"metal-determinations-in-olive-oil",totalDownloads:7060,totalCrossrefCites:1,totalDimensionsCites:7,hasAltmetrics:0,abstract:null,signatures:"Sema Bağdat Yaşar, Eda Köse Baran and Mahir Alkan",downloadPdfUrl:"/chapter/pdf-download/27028",previewPdfUrl:"/chapter/pdf-preview/27028",authors:[{id:"77186",title:"Dr.",name:"Sema",surname:"Bağdat Yaşar",slug:"sema-bagdat-yasar",fullName:"Sema Bağdat Yaşar"},{id:"83390",title:"MSc.",name:"Eda",surname:"Köse Baran",slug:"eda-kose-baran",fullName:"Eda Köse Baran"},{id:"83391",title:"Prof.",name:"Mahir",surname:"Alkan",slug:"mahir-alkan",fullName:"Mahir Alkan"}],corrections:null},{id:"27029",title:"Sensory Analysis of Virgin Olive Oil",doi:"10.5772/29650",slug:"the-sensory-analysis-of-virgin-olive-oil",totalDownloads:4827,totalCrossrefCites:7,totalDimensionsCites:25,hasAltmetrics:0,abstract:null,signatures:"Alessandra Bendini, Enrico Valli,Sara Barbieri and Tullia Gallina Toschi",downloadPdfUrl:"/chapter/pdf-download/27029",previewPdfUrl:"/chapter/pdf-preview/27029",authors:[{id:"78741",title:"PhD.",name:"Alessandra",surname:"Bendini",slug:"alessandra-bendini",fullName:"Alessandra Bendini"},{id:"78748",title:"Dr.",name:"Tullia",surname:"Gallina Toschi",slug:"tullia-gallina-toschi",fullName:"Tullia Gallina Toschi"},{id:"78750",title:"MSc.",name:"Sara",surname:"Barbieri",slug:"sara-barbieri",fullName:"Sara Barbieri"},{id:"78751",title:"MSc.",name:"Enrico",surname:"Valli",slug:"enrico-valli",fullName:"Enrico Valli"}],corrections:null},{id:"27030",title:"Quality Evaluation of Olives, Olive Pomace and Olive Oil by Infrared Spectroscopy",doi:"10.5772/30679",slug:"quality-evaluation-of-olives-olive-pomace-and-olive-oil-by-near-infrared-spectroscopy-nir-",totalDownloads:6208,totalCrossrefCites:0,totalDimensionsCites:1,hasAltmetrics:0,abstract:null,signatures:"Ivonne Delgadillo, António Barros and Alexandra Nunes",downloadPdfUrl:"/chapter/pdf-download/27030",previewPdfUrl:"/chapter/pdf-preview/27030",authors:[{id:"83709",title:"Prof.",name:"Ivonne",surname:"Delgadillo",slug:"ivonne-delgadillo",fullName:"Ivonne Delgadillo"},{id:"83732",title:"Dr.",name:"António",surname:"Barros",slug:"antonio-barros",fullName:"António Barros"},{id:"83736",title:"Prof.",name:"Alexandra",surname:"Nunes",slug:"alexandra-nunes",fullName:"Alexandra Nunes"}],corrections:null},{id:"27031",title:"Innovative Technique Combining Laser Irradiation Effect and Electronic Nose for Determination of Olive Oil Organoleptic Characteristics",doi:"10.5772/30615",slug:"innovative-technique-combining-laser-irradiation-effect-and-electronic-nose-for-determination-of-org",totalDownloads:2237,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"K. Pierpauli, C. Rinaldi, M. L. Azcarate and A. Lamagna",downloadPdfUrl:"/chapter/pdf-download/27031",previewPdfUrl:"/chapter/pdf-preview/27031",authors:[{id:"83339",title:"Dr.",name:"Carlos Alberto",surname:"Rinaldi",slug:"carlos-alberto-rinaldi",fullName:"Carlos Alberto Rinaldi"}],corrections:null},{id:"27032",title:"Traceability of Origin and Authenticity of Olive Oil",doi:"10.5772/28458",slug:"traceability-of-origin-and-authenticity-of-olive-oil-by-molecular-approaches",totalDownloads:4757,totalCrossrefCites:1,totalDimensionsCites:8,hasAltmetrics:1,abstract:null,signatures:"Zohreh Rabiei and Sattar Tahmasebi Enferadi",downloadPdfUrl:"/chapter/pdf-download/27032",previewPdfUrl:"/chapter/pdf-preview/27032",authors:[{id:"73947",title:"Dr",name:"Zohreh",surname:"Rabiei",slug:"zohreh-rabiei",fullName:"Zohreh Rabiei"},{id:"83581",title:"Prof.",name:"Sattar",surname:"Tahmasebi Enferadi",slug:"sattar-tahmasebi-enferadi",fullName:"Sattar Tahmasebi Enferadi"}],corrections:null},{id:"27033",title:"Quality Assessment of Olive Oil by 1H-NMR Fingerprinting",doi:"10.5772/28701",slug:"quality-assessment-of-olive-oil-by-1h-nmr-fingerprinting",totalDownloads:4095,totalCrossrefCites:1,totalDimensionsCites:5,hasAltmetrics:0,abstract:null,signatures:"Rosa M. Alonso-Salces, Margaret V. Holland,Claude Guillou and Károly Héberger",downloadPdfUrl:"/chapter/pdf-download/27033",previewPdfUrl:"/chapter/pdf-preview/27033",authors:[{id:"75037",title:"Dr.",name:"Rosa Maria",surname:"Alonso-Salces",slug:"rosa-maria-alonso-salces",fullName:"Rosa Maria Alonso-Salces"},{id:"83881",title:"MSc.",name:"Margaret Veronica",surname:"Holland",slug:"margaret-veronica-holland",fullName:"Margaret Veronica Holland"},{id:"83883",title:"Dr.",name:"Claude",surname:"Guillou",slug:"claude-guillou",fullName:"Claude Guillou"},{id:"122493",title:"Dr.",name:"Károly",surname:"Héberger",slug:"karoly-heberger",fullName:"Károly Héberger"}],corrections:null},{id:"27034",title:"Cultivation of Olives in Australia",doi:"10.5772/36235",slug:"cultivation-of-olives-in-australia",totalDownloads:3788,totalCrossrefCites:0,totalDimensionsCites:1,hasAltmetrics:0,abstract:null,signatures:"Rodney J. Mailer",downloadPdfUrl:"/chapter/pdf-download/27034",previewPdfUrl:"/chapter/pdf-preview/27034",authors:[{id:"107591",title:"Dr.",name:"Rodney",surname:"Mailer",slug:"rodney-mailer",fullName:"Rodney Mailer"}],corrections:null},{id:"27035",title:"Consumer Preferences for Olive-Oil Attributes: A Review of the Empirical Literature Using a Conjoint Approach",doi:"10.5772/30390",slug:"consumer-preferences-for-olive-oil-attributes-a-review-of-the-empirical-literature-using-a-conjoint-",totalDownloads:5135,totalCrossrefCites:6,totalDimensionsCites:18,hasAltmetrics:0,abstract:null,signatures:"José Felipe Jiménez-Guerrero, Juan Carlos Gázquez-Abad,Juan Antonio Mondéjar-Jiménez2 and Rubén Huertas-García",downloadPdfUrl:"/chapter/pdf-download/27035",previewPdfUrl:"/chapter/pdf-preview/27035",authors:[{id:"82386",title:"Dr.",name:"Juan Carlos",surname:"Gázquez-Abad",slug:"juan-carlos-gazquez-abad",fullName:"Juan Carlos Gázquez-Abad"},{id:"82391",title:"Dr.",name:"José Felipe",surname:"Jiménez-Guerrero",slug:"jose-felipe-jimenez-guerrero",fullName:"José Felipe Jiménez-Guerrero"},{id:"82393",title:"Dr.",name:"Juan Antonio",surname:"Mondéjar-Jiménez",slug:"juan-antonio-mondejar-jimenez",fullName:"Juan Antonio Mondéjar-Jiménez"},{id:"82394",title:"Dr.",name:"Rubén",surname:"Huertas-García",slug:"ruben-huertas-garcia",fullName:"Rubén Huertas-García"}],corrections:null},{id:"27036",title:"New Olive-Pomace Oil Improved by Hydrothermal Pre-Treatments",doi:"10.5772/28742",slug:"new-pomace-olive-oil-improved-by-hydrothermal-treatment",totalDownloads:4146,totalCrossrefCites:1,totalDimensionsCites:15,hasAltmetrics:0,abstract:null,signatures:"G. Rodríguez-Gutiérrez, A. Lama-Muñoz, M.V. Ruiz-Méndez, F. Rubio-Senent and J. Fernández-Bolaños",downloadPdfUrl:"/chapter/pdf-download/27036",previewPdfUrl:"/chapter/pdf-preview/27036",authors:[{id:"75199",title:"Dr.",name:"Juan",surname:"Fernández-Bolaños",slug:"juan-fernandez-bolanos",fullName:"Juan Fernández-Bolaños"},{id:"126006",title:"Dr.",name:"Guillermo",surname:"Rodriguez-Gutierrez",slug:"guillermo-rodriguez-gutierrez",fullName:"Guillermo Rodriguez-Gutierrez"},{id:"126008",title:"Dr.",name:"Antonio",surname:"Lama-Muñoz",slug:"antonio-lama-munoz",fullName:"Antonio Lama-Muñoz"},{id:"126010",title:"Dr.",name:"Mª Victoria",surname:"Ruíz-Méndez",slug:"ma-victoria-ruiz-mendez",fullName:"Mª Victoria Ruíz-Méndez"},{id:"126012",title:"Ms.",name:"Fátima",surname:"Rubio-Senent",slug:"fatima-rubio-senent",fullName:"Fátima Rubio-Senent"}],corrections:null},{id:"27037",title:"Genetic Improvement of Olives, Enzymatic Extraction and Interesterification of Olive Oil",doi:"10.5772/29015",slug:"genetic-improvement-of-olives-enzymatic-extraction-and-interesterification-of-olive-oil",totalDownloads:3397,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Fabiano Jares Contesini, Camilo Barroso Teixeira, Paula Speranza,Danielle Branta Lopes, Patrícia de Oliveira Carvalho,Hélia Harumi Sato and Gabriela Alves Macedo",downloadPdfUrl:"/chapter/pdf-download/27037",previewPdfUrl:"/chapter/pdf-preview/27037",authors:[{id:"76197",title:"Dr",name:"Fabiano",surname:"Contesini",slug:"fabiano-contesini",fullName:"Fabiano Contesini"},{id:"84046",title:"Mr.",name:"Camilo",surname:"Teixeira",slug:"camilo-teixeira",fullName:"Camilo Teixeira"},{id:"84047",title:"Ms.",name:"Paula",surname:"Speranza",slug:"paula-speranza",fullName:"Paula Speranza"},{id:"84049",title:"Ph.D.",name:"Danielle",surname:"Lopes",slug:"danielle-lopes",fullName:"Danielle Lopes"},{id:"84050",title:"Mrs.",name:"Patrícia",surname:"Carvalho",slug:"patricia-carvalho",fullName:"Patrícia Carvalho"},{id:"135620",title:"Dr.",name:"Hélia",surname:"Sato",slug:"helia-sato",fullName:"Hélia Sato"},{id:"135621",title:"PhD.",name:"Gabriela",surname:"Macedo",slug:"gabriela-macedo",fullName:"Gabriela Macedo"}],corrections:null},{id:"27038",title:"Olive Oil Mill Waste Treatment:Improving the Sustainability of the Olive Oil Industry with Anaerobic Digestion Technology",doi:"10.5772/28583",slug:"anaerobic-treatment-of-olive-oil-mill-wastes-improving-the-sustainability-of-the-olive-oil-industry",totalDownloads:7562,totalCrossrefCites:2,totalDimensionsCites:11,hasAltmetrics:0,abstract:null,signatures:"Bárbara Rincón, Fernando G. Fermoso and Rafael Borja",downloadPdfUrl:"/chapter/pdf-download/27038",previewPdfUrl:"/chapter/pdf-preview/27038",authors:[{id:"74541",title:"Dr.",name:"Barbara",surname:"Rincon",slug:"barbara-rincon",fullName:"Barbara Rincon"}],corrections:null},{id:"27039",title:"Potential Applications of Green Technologies in Olive Oil Industry",doi:"10.5772/27888",slug:"potential-applications-of-green-technologies-in-olive-oil-industry",totalDownloads:5388,totalCrossrefCites:1,totalDimensionsCites:1,hasAltmetrics:0,abstract:null,signatures:"Ozan Nazim Ciftci, Deniz Ciftci and Ehsan Jenab",downloadPdfUrl:"/chapter/pdf-download/27039",previewPdfUrl:"/chapter/pdf-preview/27039",authors:[{id:"71967",title:"Dr.",name:"Ozan Nazim",surname:"Ciftci",slug:"ozan-nazim-ciftci",fullName:"Ozan Nazim Ciftci"},{id:"83477",title:"MSc.",name:"Deniz",surname:"Ciftci",slug:"deniz-ciftci",fullName:"Deniz Ciftci"},{id:"120041",title:"MSc.",name:"Ehsan",surname:"Jenab",slug:"ehsan-jenab",fullName:"Ehsan Jenab"}],corrections:null},{id:"27040",title:"Microbial Biotechnology in Olive Oil Industry",doi:"10.5772/28263",slug:"microbial-biotechnology-in-olive-oil-industry-",totalDownloads:14288,totalCrossrefCites:2,totalDimensionsCites:6,hasAltmetrics:0,abstract:null,signatures:"Farshad Darvishi",downloadPdfUrl:"/chapter/pdf-download/27040",previewPdfUrl:"/chapter/pdf-preview/27040",authors:[{id:"73283",title:"Dr.",name:"Farshad",surname:"Darvishi",slug:"farshad-darvishi",fullName:"Farshad Darvishi"}],corrections:null},{id:"27041",title:"Metabolism and Bioavailability of Olive Oil Polyphenols",doi:"10.5772/30632",slug:"metabolism-and-bioavailability-of-olive-oil-polyphenols",totalDownloads:3673,totalCrossrefCites:1,totalDimensionsCites:11,hasAltmetrics:0,abstract:null,signatures:"María Gómez-Romero, Rocío García-Villalba, Alegría Carrasco-Pancorbo and Alberto Fernández-Gutiérrez",downloadPdfUrl:"/chapter/pdf-download/27041",previewPdfUrl:"/chapter/pdf-preview/27041",authors:[{id:"83442",title:"Dr.",name:"Alegria",surname:"Carrasco-Pancorbo",slug:"alegria-carrasco-pancorbo",fullName:"Alegria Carrasco-Pancorbo"},{id:"84030",title:"Dr.",name:"Maria",surname:"Gomez-Romero",slug:"maria-gomez-romero",fullName:"Maria Gomez-Romero"},{id:"84031",title:"Dr.",name:"Rocio",surname:"Garcia-Villalba",slug:"rocio-garcia-villalba",fullName:"Rocio Garcia-Villalba"},{id:"84033",title:"Prof.",name:"Alberto",surname:"Fernandez-Gutierrez",slug:"alberto-fernandez-gutierrez",fullName:"Alberto Fernandez-Gutierrez"}],corrections:null},{id:"27042",title:"Oleocanthal: A Naturally Occurring Anti-Inflammatory Agent in Virgin Olive Oil",doi:"10.5772/28723",slug:"oleocanthal-a-naturally-occurring-anti-inflammatory-agent-in-virgin-olive-oil",totalDownloads:7181,totalCrossrefCites:5,totalDimensionsCites:22,hasAltmetrics:0,abstract:null,signatures:"S. Cicerale, L. J. Lucas and R. S. J. Keast",downloadPdfUrl:"/chapter/pdf-download/27042",previewPdfUrl:"/chapter/pdf-preview/27042",authors:[{id:"75123",title:"Prof.",name:"Russell",surname:"Keast",slug:"russell-keast",fullName:"Russell Keast"}],corrections:null},{id:"27043",title:"Biological Properties of Hydroxytyrosol and Its Derivatives",doi:"10.5772/30743",slug:"biological-properties-of-hydroxytyrosol-and-its-derivatives",totalDownloads:8225,totalCrossrefCites:2,totalDimensionsCites:23,hasAltmetrics:0,abstract:null,signatures:"José G. Fernández-Bolaños, Óscar López, M. Ángeles López-García and Azucena Marset",downloadPdfUrl:"/chapter/pdf-download/27043",previewPdfUrl:"/chapter/pdf-preview/27043",authors:[{id:"84025",title:"Dr.",name:"José G.",surname:"Fernández-Bolaños",slug:"jose-g.-fernandez-bolanos",fullName:"José G. Fernández-Bolaños"},{id:"84258",title:"Dr.",name:"Óscar",surname:"López",slug:"oscar-lopez",fullName:"Óscar López"},{id:"84284",title:"MSc",name:"M. Ángeles",surname:"López-García",slug:"m.-angeles-lopez-garcia",fullName:"M. Ángeles López-García"},{id:"84287",title:"MSc.",name:"Azucena",surname:"Marset",slug:"azucena-marset",fullName:"Azucena Marset"}],corrections:null},{id:"27044",title:"Differential Effect of Fatty Acids in Nervous Control of Energy Balance",doi:"10.5772/29140",slug:"differential-effect-of-fatty-acids-in-nervous-control-of-energy-balance",totalDownloads:2530,totalCrossrefCites:0,totalDimensionsCites:1,hasAltmetrics:0,abstract:null,signatures:"Christophe Magnan, Hervé Le Stunff and Stéphanie Migrenne",downloadPdfUrl:"/chapter/pdf-download/27044",previewPdfUrl:"/chapter/pdf-preview/27044",authors:[{id:"76646",title:"Prof.",name:"Christophe",surname:"Magnan",slug:"christophe-magnan",fullName:"Christophe Magnan"},{id:"84655",title:"Dr.",name:"Stephanie",surname:"Migrenne",slug:"stephanie-migrenne",fullName:"Stephanie Migrenne"}],corrections:null},{id:"27045",title:"Meat Products Manufactured with Olive Oil",doi:"10.5772/31412",slug:"effect-of-replacing-animal-fat-with-olive-oil-on-the-quality-for-processed-meat-products",totalDownloads:4279,totalCrossrefCites:2,totalDimensionsCites:7,hasAltmetrics:0,abstract:null,signatures:"S.S. Moon, C. Jo, D.U. Ahn, S.N. Kang, Y.T.Kim1 and I.S. Kim",downloadPdfUrl:"/chapter/pdf-download/27045",previewPdfUrl:"/chapter/pdf-preview/27045",authors:[{id:"81453",title:"Dr.",name:"Sungsil",surname:"Moon",slug:"sungsil-moon",fullName:"Sungsil Moon"},{id:"82555",title:"Prof.",name:"Ilsuk",surname:"Kim",slug:"ilsuk-kim",fullName:"Ilsuk Kim"}],corrections:null},{id:"27046",title:"Meat Fat Replacement with Olive Oil",doi:"10.5772/29506",slug:"meat-fat-replacement-with-olive-oil-technological-quality-and-health-aspects-",totalDownloads:3181,totalCrossrefCites:0,totalDimensionsCites:2,hasAltmetrics:0,abstract:null,signatures:"Basem Mohammed Al-Abdullah, Khalid M. Al-Ismail, Khaled Al-Mrazeeq, Malak Angor and Radwan Ajo",downloadPdfUrl:"/chapter/pdf-download/27046",previewPdfUrl:"/chapter/pdf-preview/27046",authors:[{id:"78175",title:"Prof.",name:"Basem",surname:"Al-Abdullah",slug:"basem-al-abdullah",fullName:"Basem Al-Abdullah"}],corrections:null},{id:"27047",title:"Biocatalyzed Production of Structured Olive Oil Triacylglycerols",doi:"10.5772/28713",slug:"biocatalyzed-production-of-structured-olive-oil-triacylglycerols",totalDownloads:2581,totalCrossrefCites:0,totalDimensionsCites:4,hasAltmetrics:0,abstract:null,signatures:"Laura J. Pham and Patrisha J. Pham",downloadPdfUrl:"/chapter/pdf-download/27047",previewPdfUrl:"/chapter/pdf-preview/27047",authors:[{id:"75092",title:"Dr.",name:"Laura",surname:"Pham",slug:"laura-pham",fullName:"Laura Pham"},{id:"127719",title:"Dr.",name:"Patrisha",surname:"Pham",slug:"patrisha-pham",fullName:"Patrisha Pham"}],corrections:null},{id:"27048",title:"Olive Oil as Inductor of Microbial Lipase",doi:"10.5772/30109",slug:"olive-oil-as-inductor-of-microbial-lipase",totalDownloads:3865,totalCrossrefCites:8,totalDimensionsCites:12,hasAltmetrics:0,abstract:null,signatures:"Marie Zarevúcka",downloadPdfUrl:"/chapter/pdf-download/27048",previewPdfUrl:"/chapter/pdf-preview/27048",authors:[{id:"80891",title:"Dr.",name:"Marie",surname:"Zarevúcka",slug:"marie-zarevucka",fullName:"Marie Zarevúcka"}],corrections:null},{id:"27049",title:"Olive Oil-Based Delivery of Photosensitizers for Bacterial Eradication",doi:"10.5772/30623",slug:"olive-oil-based-delivery-of-photosensitizers-for-bacterial-eradication",totalDownloads:3125,totalCrossrefCites:3,totalDimensionsCites:4,hasAltmetrics:0,abstract:null,signatures:"Faina Nakonechny, Yeshayahu Nitzan and Marina Nisnevitch",downloadPdfUrl:"/chapter/pdf-download/27049",previewPdfUrl:"/chapter/pdf-preview/27049",authors:[{id:"23436",title:"Dr.",name:"Marina",surname:"Nisnevitch",slug:"marina-nisnevitch",fullName:"Marina Nisnevitch"},{id:"40921",title:"Dr.",name:"Yeshayahu",surname:"Nitzan",slug:"yeshayahu-nitzan",fullName:"Yeshayahu Nitzan"},{id:"80487",title:"Prof.",name:"Faina",surname:"Nakonechny",slug:"faina-nakonechny",fullName:"Faina Nakonechny"}],corrections:null},{id:"27050",title:"Olive Oil Sector in Albania and Its Perspective",doi:"10.5772/27948",slug:"olive-oil-sector-in-albania-and-its-perspective",totalDownloads:3802,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Ana Mane Kapaj and Ilir Kapaj",downloadPdfUrl:"/chapter/pdf-download/27050",previewPdfUrl:"/chapter/pdf-preview/27050",authors:[{id:"72167",title:"Dr.",name:"Ana",surname:"Mane-Kapaj",slug:"ana-mane-kapaj",fullName:"Ana Mane-Kapaj"},{id:"83206",title:"Dr.",name:"Ilir",surname:"Kapaj",slug:"ilir-kapaj",fullName:"Ilir Kapaj"}],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},subseries:null,tags:null},relatedBooks:[{type:"book",id:"5286",title:"Products from Olive Tree",subtitle:null,isOpenForSubmission:!1,hash:"b1c4ed3e0237d388a235b51b1b415886",slug:"products-from-olive-tree",bookSignature:"Dimitrios Boskou and Maria Lisa Clodoveo",coverURL:"https://cdn.intechopen.com/books/images_new/5286.jpg",editedByType:"Edited by",editors:[{id:"77212",title:"Dr.",name:"Dimitrios",surname:"Boskou",slug:"dimitrios-boskou",fullName:"Dimitrios Boskou"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1936",title:"Trends in Vital Food and Control Engineering",subtitle:null,isOpenForSubmission:!1,hash:"90c8c82796e6d5ab1ec2239459aff1b9",slug:"trends-in-vital-food-and-control-engineering",bookSignature:"Ayman Hafiz Amer Eissa",coverURL:"https://cdn.intechopen.com/books/images_new/1936.jpg",editedByType:"Edited by",editors:[{id:"32499",title:"Prof.",name:"Ayman",surname:"Amer Eissa",slug:"ayman-amer-eissa",fullName:"Ayman Amer Eissa"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1019",title:"Organic Food and Agriculture",subtitle:"New Trends and Developments in the Social Sciences",isOpenForSubmission:!1,hash:"8cc66b611ecb99e3cef0ba064ef69d0a",slug:"organic-food-and-agriculture-new-trends-and-developments-in-the-social-sciences",bookSignature:"Matthew Reed",coverURL:"https://cdn.intechopen.com/books/images_new/1019.jpg",editedByType:"Edited by",editors:[{id:"68720",title:"Dr.",name:"Matthew",surname:"Reed",slug:"matthew-reed",fullName:"Matthew Reed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1410",title:"Food Quality",subtitle:null,isOpenForSubmission:!1,hash:"88b2411c74bbd98c196628c0624d28b8",slug:"food-quality",bookSignature:"Kostas Kapiris",coverURL:"https://cdn.intechopen.com/books/images_new/1410.jpg",editedByType:"Edited by",editors:[{id:"96405",title:"Dr.",name:"Kostas",surname:"Kapiris",slug:"kostas-kapiris",fullName:"Kostas Kapiris"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5058",title:"Organic Farming",subtitle:"A Promising Way of Food Production",isOpenForSubmission:!1,hash:"2fc4ebe62bfe43276e05ac2021c624ef",slug:"organic-farming-a-promising-way-of-food-production",bookSignature:"Petr Konvalina",coverURL:"https://cdn.intechopen.com/books/images_new/5058.jpg",editedByType:"Edited by",editors:[{id:"77330",title:"Dr.",name:"Petr",surname:"Konvalina",slug:"petr-konvalina",fullName:"Petr Konvalina"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6548",title:"Food Safety",subtitle:"Some Global Trends",isOpenForSubmission:!1,hash:"de67614bdc5a5e48a1cf96f9e34e68a1",slug:"food-safety-some-global-trends",bookSignature:"Yehia El-Samragy",coverURL:"https://cdn.intechopen.com/books/images_new/6548.jpg",editedByType:"Edited by",editors:[{id:"81644",title:"Prof.",name:"Yehia",surname:"El-Samragy",slug:"yehia-el-samragy",fullName:"Yehia El-Samragy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8063",title:"Food Security in Africa",subtitle:null,isOpenForSubmission:!1,hash:"8cbf3d662b104d19db2efc9d59249efc",slug:"food-security-in-africa",bookSignature:"Barakat Mahmoud",coverURL:"https://cdn.intechopen.com/books/images_new/8063.jpg",editedByType:"Edited by",editors:[{id:"92016",title:"Dr.",name:"Barakat",surname:"Mahmoud",slug:"barakat-mahmoud",fullName:"Barakat Mahmoud"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7913",title:"Mycotoxins and Food Safety",subtitle:null,isOpenForSubmission:!1,hash:"d7abe8bb35a0bb913a4aacc7a2c06c1f",slug:"mycotoxins-and-food-safety",bookSignature:"Suna Sabuncuoğlu",coverURL:"https://cdn.intechopen.com/books/images_new/7913.jpg",editedByType:"Edited by",editors:[{id:"270856",title:"Associate Prof.",name:"Suna",surname:"Sabuncuoglu",slug:"suna-sabuncuoglu",fullName:"Suna Sabuncuoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"79789",slug:"corrigendum-graves-disea-1",title:"Corrigendum: Graves’ Disease",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/79789.pdf",downloadPdfUrl:"/chapter/pdf-download/79789",previewPdfUrl:"/chapter/pdf-preview/79789",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/79789",risUrl:"/chapter/ris/79789",chapter:{id:"76577",slug:"autoimmune-mechanism-and-recurrence-risk-in-graves-disease",signatures:"Vasudha Bakshi and Gollapalli Rajeev Kumar",dateSubmitted:"December 8th 2020",dateReviewed:"April 8th 2021",datePrePublished:null,datePublished:"December 1st 2021",book:{id:"10312",title:"Graves' Disease",subtitle:null,fullTitle:"Graves' Disease",slug:"graves-disease",publishedDate:"December 1st 2021",bookSignature:"Robert Gensure",coverURL:"https://cdn.intechopen.com/books/images_new/10312.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"16515",title:"Dr.",name:"Robert",middleName:null,surname:"Gensure",slug:"robert-gensure",fullName:"Robert Gensure"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"291193",title:"Ph.D.",name:"Vasudha",middleName:null,surname:"Bakshi",fullName:"Vasudha Bakshi",slug:"vasudha-bakshi",email:"vasudhapharmacy@cvsr.ac.in",position:null,institution:null},{id:"335131",title:"Dr.",name:"Gollapalli Rajeev",middleName:null,surname:"Kumar",fullName:"Gollapalli Rajeev Kumar",slug:"gollapalli-rajeev-kumar",email:"rajeevpharmacy@cvsr.ac.in",position:null,institution:null}]}},chapter:{id:"76577",slug:"autoimmune-mechanism-and-recurrence-risk-in-graves-disease",signatures:"Vasudha Bakshi and Gollapalli Rajeev Kumar",dateSubmitted:"December 8th 2020",dateReviewed:"April 8th 2021",datePrePublished:null,datePublished:"December 1st 2021",book:{id:"10312",title:"Graves' Disease",subtitle:null,fullTitle:"Graves' Disease",slug:"graves-disease",publishedDate:"December 1st 2021",bookSignature:"Robert Gensure",coverURL:"https://cdn.intechopen.com/books/images_new/10312.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"16515",title:"Dr.",name:"Robert",middleName:null,surname:"Gensure",slug:"robert-gensure",fullName:"Robert Gensure"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"291193",title:"Ph.D.",name:"Vasudha",middleName:null,surname:"Bakshi",fullName:"Vasudha Bakshi",slug:"vasudha-bakshi",email:"vasudhapharmacy@cvsr.ac.in",position:null,institution:null},{id:"335131",title:"Dr.",name:"Gollapalli Rajeev",middleName:null,surname:"Kumar",fullName:"Gollapalli Rajeev Kumar",slug:"gollapalli-rajeev-kumar",email:"rajeevpharmacy@cvsr.ac.in",position:null,institution:null}]},book:{id:"10312",title:"Graves' Disease",subtitle:null,fullTitle:"Graves' Disease",slug:"graves-disease",publishedDate:"December 1st 2021",bookSignature:"Robert Gensure",coverURL:"https://cdn.intechopen.com/books/images_new/10312.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"16515",title:"Dr.",name:"Robert",middleName:null,surname:"Gensure",slug:"robert-gensure",fullName:"Robert Gensure"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"11278",leadTitle:null,title:"Regulatory T Cells",subtitle:null,reviewType:"peer-reviewed",abstract:"
\r\n\tCD4+FOXP3+ regulatory T cells (Treg) have an indispensable role in maintaining immune homeostasis and immune tolerance. They control unwanted immune responses that are involved in the regulation of immune tolerance to self as well as to foreign antigens. Loss-of-function mutation in FOXP3 locus, a gene encoding Treg lineage transcription factor FOXP3, leads to multiorgan autoimmune associated disease including diabetes, thyroiditis, eczema, hyper-IgE syndrome, and cytokine storm. However, FOXP3+ Treg might become unstable especially under certain inflammatory conditions, and might transform into proinflammatory cytokine-producing cells. The issue of heterogeneity and instability of Treg has caused considerable debate in the field and has important implications for Treg-based immunotherapy. Modulation of Treg is proposed as a means of treating autoimmunity and preventing organ transplant rejection. For optimizing these Treg-based therapies, it is vital to get a better understanding of Treg expansion, migration, and suppressive function. Besides, it is essential to consider the metabolic profiles of Treg throughout these capacities. A full understanding of Treg metabolic profile throughout proliferation, migration, and suppressive function, as well as how Treg metabolism could be exploited for tolerance-inducing therapies for autoimmune diseases are a few popular research topics at the current moment.
",isbn:"978-1-80356-057-1",printIsbn:"978-1-80356-056-4",pdfIsbn:"978-1-80356-058-8",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,isSalesforceBook:!1,hash:"d594f0b2443f78fb7e04ceac6403827f",bookSignature:"Dr. Xuehui He",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/11278.jpg",keywords:"Treg Heterogeneity, Thymus, Foxp3, CD25, Autoimmune Diseases, Solid Organ Transplantation, Stem Cell Transplantation, Immune Tolerance, Metabolism, Immune Checkpoint Inhibitors, Cancer, Personalized Medical Care",numberOfDownloads:7,numberOfWosCitations:0,numberOfCrossrefCitations:0,numberOfDimensionsCitations:0,numberOfTotalCitations:0,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"December 2nd 2021",dateEndSecondStepPublish:"March 8th 2022",dateEndThirdStepPublish:"May 7th 2022",dateEndFourthStepPublish:"July 26th 2022",dateEndFifthStepPublish:"September 24th 2022",remainingDaysToSecondStep:"2 months",secondStepPassed:!0,currentStepOfPublishingProcess:4,editedByType:null,kuFlag:!1,biosketch:"A pioneering researcher in the field of immune tolerance induction and immune profile of various immune-related diseases.",coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"284559",title:"Dr.",name:"Xuehui",middleName:null,surname:"He",slug:"xuehui-he",fullName:"Xuehui He",profilePictureURL:"https://mts.intechopen.com/storage/users/284559/images/system/284559.jpg",biography:"Dr. Xuehui He received her PhD at Tuebingen University, Germany, in the field of molecular biology. Thereafter, she moved to Nijmegen, The Netherlands, for continuing the adventure in immunology field. Over the years, the regulation of the immune system especially in relation to autoimmune diseases has been her main topic of research including the basics of T cell activation, the induction of immune tolerance, and the modulatory effect of various immune suppressants. Identification of biomarkers for personalized therapy and using the biomarker profile as a co-diagnostic tool is her recent research focus. Her final aim is to capture disease severity in validated outcome measures and assess side effects of treatments in real clinical practice.",institutionString:"Radboud University Nijmegen Medical Centre",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Radboud University Nijmegen Medical Centre",institutionURL:null,country:{name:"Netherlands"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"16",title:"Medicine",slug:"medicine"}],chapters:[{id:"81691",title:"Function and Therapeutic Intervention of Regulatory T Cells in Immune Regulation",slug:"function-and-therapeutic-intervention-of-regulatory-t-cells-in-immune-regulation",totalDownloads:7,totalCrossrefCites:0,authors:[null]}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"444315",firstName:"Karla",lastName:"Skuliber",middleName:null,title:"Mrs.",imageUrl:"https://mts.intechopen.com/storage/users/444315/images/20013_n.jpg",email:"karla@intechopen.com",biography:"As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"9607",title:"Immunosuppression",subtitle:null,isOpenForSubmission:!1,hash:"9e4a6d6f6a85696f31c1afb3edba3306",slug:"immunosuppression",bookSignature:"Xuehui He",coverURL:"https://cdn.intechopen.com/books/images_new/9607.jpg",editedByType:"Edited by",editors:[{id:"284559",title:"Dr.",name:"Xuehui",surname:"He",slug:"xuehui-he",fullName:"Xuehui He"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6550",title:"Cohort Studies in Health Sciences",subtitle:null,isOpenForSubmission:!1,hash:"01df5aba4fff1a84b37a2fdafa809660",slug:"cohort-studies-in-health-sciences",bookSignature:"R. Mauricio Barría",coverURL:"https://cdn.intechopen.com/books/images_new/6550.jpg",editedByType:"Edited by",editors:[{id:"88861",title:"Dr.",name:"R. Mauricio",surname:"Barría",slug:"r.-mauricio-barria",fullName:"R. Mauricio Barría"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9500",title:"Recent Advances in Bone Tumours and Osteoarthritis",subtitle:null,isOpenForSubmission:!1,hash:"ea4ec0d6ee01b88e264178886e3210ed",slug:"recent-advances-in-bone-tumours-and-osteoarthritis",bookSignature:"Hiran Amarasekera",coverURL:"https://cdn.intechopen.com/books/images_new/9500.jpg",editedByType:"Edited by",editors:[{id:"67634",title:"Dr.",name:"Hiran",surname:"Amarasekera",slug:"hiran-amarasekera",fullName:"Hiran Amarasekera"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"314",title:"Regenerative Medicine and Tissue Engineering",subtitle:"Cells and Biomaterials",isOpenForSubmission:!1,hash:"bb67e80e480c86bb8315458012d65686",slug:"regenerative-medicine-and-tissue-engineering-cells-and-biomaterials",bookSignature:"Daniel Eberli",coverURL:"https://cdn.intechopen.com/books/images_new/314.jpg",editedByType:"Edited by",editors:[{id:"6495",title:"Dr.",name:"Daniel",surname:"Eberli",slug:"daniel-eberli",fullName:"Daniel Eberli"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"76391",title:"Recent Developments in the Crystallization of PLLA-Based Blends, Block Copolymers, and Nanocomposites",doi:"10.5772/intechopen.97088",slug:"recent-developments-in-the-crystallization-of-plla-based-blends-block-copolymers-and-nanocomposites",body:'
1. Introduction
Biobased polymers are gaining great popularity recently due to the increasing environmental concerns associated with conventional polymers. One such polymer is poly(lactic acid)(PLA), which is obtained from 100% natural resources such as corn starch and sugar cane. PLA has a good advantage of mechanical strength and modulus (comparable to PET), however, it has slow crystallization rate, low elongation at break, and processing difficulties due to the low thermal stability which significantly restricts its practical applications. PLA exists in three optical isomeric forms poly(L-lactic acid) (PLLA), poly(D-lactic acid)(PDLA), and poly(D, L-lactic acid) (PDLLA). The PLLA and PDLA both can be partially crystallized with a melting temperature of 170–180 °C. However, a racemic blend (50% L and 50% D) gives an amorphous polymer. Generally, commercial PLA grades are comprised of L-lactic acid in majority with small amount of D moiety. The thermal and mechanical properties of PLLA are significantly affected by the presence of D units in PLLA [1].
The study of crystallization behavior of PLLA is very important to control its thermal, mechanical, and gas-barrier properties. The crystalline structure of PLLA has been studied by many researchers [2, 3, 4, 5]. It has been reported that the crystallization of PLLA leads to several crystal forms (α, α’, β, and γ). The α form is the most stable polymorph which is developed from the melt or solution. The crystalline structure of PLLA α form is pseudo-orthorhombic with dimensions of a = 1.0683 nm, b = 0.617 nm, c (chain axis) = 2.78 nm, where the molecules adopt a 103 helical conformation. Aleman et al. [6] proposed the space group of P212121 as the most plausible packing mode of 103 helices.
In this chapter, we review the recent developments [7, 8, 9, 10, 11, 12, 13, 14, 15] of crystallization of PLLA-based blends, block copolymers and nanocomposites. This chapter contains four sections. The first section deals with the enhancement in the crystallization of PLLA by adding biobased additives. Over the years, there have been several strategies employed by researchers to improve the crystallizability of PLLA [1, 16, 17, 18, 19]. One of the most common and effective method is the addition of a nucleating agent. The nucleating agents are known to provide the sites for nucleation in polymers which results in the enhancement of overall crystallization process. Most of the nucleating agents reported for PLLA (talc, carbon nanotubes, graphene, clay) are inorganic materials that are non-biodegradable in nature [1, 20]. Recently, it is an emerging trend to utilize renewable resources for the improvement of crystallizability of PLLA. In this regard, we used solid-state biobased additives like silk fibroin nanodisc (SFN) and cellulose nanocrystal (CNC) with the aim of improving the crystallization of PLLA. The SFN is a biobased and environmentally benign material which was extracted from the waste of muga silk cocoons, which is composed of 83.8% poly(L-alanine) [21]. The CNC is also a biobased material which was extracted from the waste of marine green algae biomass residue (ABR). Further, we used liquid-state biobased additive, i.e., organic acid monoglyceride (OMG) for the sake of improvement of crystallizability of PLLA. The differential scanning calorimetry (DSC), polarizing optical microscopy (POM), synchrotron small-angle X-ray scattering (SAXS), and wide-angle X-ray scattering (WAXS) measurements were used for the study of crystallization of PLLA. It is worthy to mention here that the time-resolved SWAXS (simultaneous measurements of SAXS and WAXS) technique is one of the most promising technique to detect the initiation of nucleation and follow the change in the structure of growing crystals during the crystallization from the melt.
The second section talks about the stereocomplex crystallization of PLA. When PLLA (left-handed helix) and PDLA (right-handed helix) are mixed, the resultant mixture is known to form a complex so-called “stereocomplex (SC)”. The SC is known to improve the thermal stability of PLA [22, 23]. This is due to the approximately 50°C higher melting temperature of the SC crystals compared to the PLLA or PDLA homopolymer crystal (HC). While pure PLLA and PDLA crystallize in pseudo-orthorhombic form with a 103 helix conformation, the SC has a 31 helix form [24]. The crystalline structure of PLA stereocomplex is triclinic with dimension of a = b = 0.916 nm, c (chain axis) = 0.87 nm, α = β = 109.2°, and γ = 109.8°, in which PLLA and PDLA chains are packed parallel taking 31 helical conformation [25]. The formation of SC is influenced by the molecular weights of PLLA and PDLA. It is very challenging to get SC crystals exclusively in the high molecular weight PLLA/PDLA blend due to the competing formation of SC and HC during the crystallization [26]. In view of this, we added 1% SFN in PLLA/PDLA (50/50) blend, aiming to enhance the SC crystallization.
The third section deals with the blend of PLLA and poly(ethylene glycol), PEG. PEG is a biocompatible polymer which is known for improving the toughness of PLLA [20, 27, 28]. The crystallization study of the PLLA/PEG blend is important from the aspect of the structural development, due to the fact that both the component (PLLA and PEG) are crystallizable having different Tg and Tm. Since PLLA and PEG are known to be miscible with each other, PLLA/PEG blend has attracted many researchers for the studies of structure control. Although there have been extensive research on the crystallization of PLLA part in the dual crystalline PLLA/PEG blend [28, 29, 30, 31, 32], the effect of PLLA spherulites on the PEG crystallization is not well-known. In this regard, we studied the effects of space confinement when the PEG crystallizes from the molten mixed amorphous phase sandwiched by the crystalline lamellae of the PLLA.
The final section of this chapter deals with the block copolymers of PLA (PLLA or PDLA) and poly (ε-caprolactone), PCL. PCL is a biodegradable polymer which is also known for improving the toughness of PLLA [28, 33]. Since it is known that PLA and PCL are immiscible, copolymerization is a better route in comparison with the blending to avoid the macro-phase separation. In view of this, we studied the crystallization behavior of dual crystalline PLLA-b-PCL, PDLA-b-PCL diblock copolymers by changing the block length of PLLA or PDLA, however, the block length of PCL was fixed. Furthermore, the blend of PLLA-b-PCL and PDLA-b-PCL is also studied for the study of formation of SC crystal by changing the block length of PLLA and PDLA components.
The PLLA samples were obtained from NatureWorks and the PDLA was obtained from Purac. The sample characteristics are summarized in Table 1. The specimens preparation method is mentioned in the respective section.
Sample code
Optical purity
Number-average molecular weight (Mn)
Mw/Mn
PLLA 4032D (D1.4)
98.6%
1.66 × 105
2.05
PLLA 2500HP (D0.5)
99.5%
1.74 × 105
2.22
PDLA D130
> 99.5%
1.41 × 105
2.03
Table 1.
Sample characterization.
The DSC measurements for the isothermal crystallization were performed by DSC214 Polyma (NETZSCH, Germany). The specimens were first melted at 200°C (or 260°C) for 5 min and immediately cooled to Tiso with the cooling rate of 300°C/min, and kept isothermally until the completion of the crystallization process. POM observations were conducted by using a Nikon Eclipse Ci-POL polarizing optical microscope equipped with the Linkam THMS600 hot stage (Linkam Scientific, UK). The specimens were sandwiched between two coverslips. Next, the specimens were melted on the hot stage, then quickly cooled (cooling rate = 150°C/min) to the isothermal crystallization temperature, and then kept isothermally until the completion of the crystallization process. The POM images were taken under crossed polarizers with a 530 nm optical retardation plate inserted in the optical path. The time-resolved SWAXS measurements were carried out at the beamline BL-6A of Photon Factory at the KEK (High-Energy Accelerator Research Organization) in Tsukuba, Japan. The wavelength of the incident X-ray beam was 0.150 nm. The T-jump experiments were conducted using a sample holder designed to allow for a quick T-jump (385°C/min). The details of the experimental set-up are reported elsewhere [7].
2. Improvement of PLLA crystallizability by biobased additives
2.1 Solid state additives (nucleation agents)
In this section, we report the effect of solid-state additives (SFN and CNC) on the isothermal crystallization of PLLA from the melt (200°C).
2.1.1 Silk fibroin nanodisc (SFN)
The SFN used in this study was extracted from wastes of the muga silk (Antheraea assama) cocoon [21]. The crystalline portion (the β sheets) of the silk fibroin was isolated by using the acid-hydrolysis method. The obtained extract comprises 83.8% L-alanine, and the well-defined disc-like nano particles were obtained (see Figure 1 for the chemical structure of poly(L-alanine)). Such morphology and dimensions have been reported as the average diameter and thickness of ∼45 nm and ∼ 3 nm, respectively [21]. The detailed information about the preparation of SFN can be found in Ref. [21]. PLLA/ SFN specimens were prepared by the solution-casting method, using dichloromethane (DCM) as a solvent [8]. The specimens are labeled as D1.4/SFN(x) or D0.5/SFN(x), where the numbers after D denote the % of D moiety in PLLA, and x stands for % of SFN inclusion.
Figure 1.
Chemical structures of poly(L-lactic acid) and poly(L-alanine). L-alanine is the main component (83.8%) of the silk fibroin nanodisc.
POM observations were conducted to observe spherulites and to evaluate the growth rate of spherulites and the nucleation density as a function of time. The specimens were melted on the hot stage at 200°C for 3 min, then quickly cooled (cooling rate = 150°C/min) to the isothermal crystallization temperature (Tiso) of 120°C, and then kept isothermally until the completion of the crystallization process. The representative images of the evolution of spherulites for the D1.4 neat and D1.4/SFN(1.0) specimens at 120°C as a function of time are shown in Figure 2(a) and (b). First, negative spherulites were observed for both of the D1.4 neat and D1.4/SFN(1.0) specimens. As shown in Figure 2(d) the total number of spherulites increased ∼4.7 times (from 9 to 42). In addition, the induction period was shortened from 101 to 39 s. However, the growth rate of the spherulites was unchanged (5 μm/min) by the addition of SFN. These results clearly show that SFN can enhance nucleation of PLLA. SFN is considered to provide sites for easy formation of PLLA nuclei.
Figure 2.
POM images as a function of time for isothermal crystallization at 120°C (a) D1.4 neat (b) D1.4/SFN(1.0) specimens. (c) Spherulite diameter and (d) the number of spherulites formed during the isothermal crystallization at 120°C (adapted from reference [8] with a permission).
Figure 3 shows the DSC results of the isothermal crystallization of neat and 1% SFN included specimens at 110°C. the degree of PLLA crystallinity (ϕDSC) as evaluated based on the heat flow results using the following equation.
Figure 3.
(a) Heat flow as a function of time during isothermal crystallization at 110°C and (b) degree of crystallinity (ϕDSC) as a function of time, which was evaluated based on the heat flow result (adapted from reference [8] with a permission).
ϕDSCt=∫0tHtdtΔHmoE1
where t denotes time and ΔHmo is the enthalpy of fusion for the 100% crystal of PLLA. The value of ΔHmo is taken as 93 J/g, following reference [34]. Figure 3(b) clearly indicates that the induction period was reduced and the final degree of crystallinity was increased by the presence of SFN. Maximum achievable crystallinity was found in the case of D0.5/SFN(1.0).
The inverse of crystallization half-time (t0.5) can be used for the discussion of the crystallization rate, which is plotted as a function of the crystallization temperature in Figure 4. The graph shows a parabolic curve thereby producing maximum crystallization rate (1/t0.5,max). As shown in Figure 4, the overall crystallization growth rate was significantly increased by the inclusion of SFN, the maximum crystallization rate, 1/t0.5,max, was observed at 107.2°C. It should be noted that for both specimens D1.4 and D0.5, the crystallization rate showed the same tendency, as the most effective temperature is ∼107°C, although the TmO differs (The TmO values for the D1.4 neat and D0.5 neat specimens were 180.7°C and 193.3°C, respectively [8]). These results indicate that the PLLA crystallization is predominantly governed by the kinetic driving force (T − Tg) rather than the thermodynamic driving force (TmO − T). It is important to note here that the spherulite growth rate does not change in the presence of SFN (Figure 2), while 1/t0.5 is increased. The reason for the enhancement of 1/t0.5 can be attributed to the increased number of nuclei due to the addition of SFN (Figure 2). The enhanced nucleation of PLLA by SFN may be ascribed to the plausible formation of hydrogen bonding between the C=O group in PLLA and the N–H group of poly(L-alanine) (see the chemical structure in Figure 1).
Figure 4.
Inverse of crystallization half time as a function of crystallization temperature, calculated from DSC results (adapted from reference [8] with a permission).
Figure 5(a) and (b) show the time-resolved WAXS profiles for the D1.4 neat and D1.4/SFN(1.0) specimens as a function of time for isothermal crystallization at 110°C. Here, the magnitude of the scattering vector q˜ is defined as, | q˜ | = q = (4π/λ) sin(θ/2) with λ and θ being the wavelength of X-ray and the scattering angle, respectively. As shown in Figure 5(a) and (b), there is no crystalline peak initially, which shows the presence of 100% amorphous phase in the early stage. As time proceeds, a crystalline peak appears at q = 11.96 nm−1 (which has been shown by the red arrow). The induction period (t0) of the crystallization is evaluated from the first detection of the crystalline peak. It was found that loading of 1% SFN decreased the t0 from 90 s to 40 s, which shows that SFN enhanced the nucleation of PLLA.
Figure 5.
Time-resolved (a)-(b) WAXS and (c)-(d) Lorentz-corrected SAXS profiles of D1.4 neat and D1.4/SFN(1.0) specimens. The red arrow indicates the first detection of the peak (adapted from reference [9] with a permission).
The time evolution of the degree of crystallinity was calculated from the WAXS profiles by using the following equation
ϕWAXS=ΣAcΣAc+AaE2
Here, ΣAc is the summation of the peak area of the crystalline peaks, and Aa is the peak area of the amorphous halo. The peak decomposition was conducted, and the degree of crystallinity ϕWAXS was calculated, which is plotted as a function of crystallization time in Figure 6.
Figure 6.
Degree of crystallinity as a function of time for the isothermal crystallization at 110°C (adapted from reference [9] with a permission).
As can be seen in Figure 6, the final degree of the crystallinity has been increased and t0.5 is decreased by the inclusion of 1% SFN, indicating the acceleration of the crystallization rate.
Figure 5(c) and (d) show the changes in the Lorentz-corrected SAXS profiles as a function of time during the isothermal crystallization at 110°C for the D1.4 neat and D1.4/SFN(1.0) specimens. Here, the scattering intensity, I(q), is corrected as q2I(q) by multiplying q2. There was no SAXS peak observed in the early stage of crystallization. As time goes on, a clear scattering peak was observed at t = 180 s for the D1.4 neat or t = 90 s for the D1.4/SFN(1.0) specimen, which indicates the development of the lamellar stacking with sandwiching the amorphous layers. It is significant to observe that the SAXS peak appears later than the WAXS peak (Figure 5) which indicates that single lamellae (without stacking) are generated in the initial state of the PLLA crystallization from the melt.
As seen in Figure 5(c) and (d), the SAXS peak moves towards the higher q as the crystallization proceeds. The long period (D) of the lamellar stacks was evaluated from the peak position (q*) as D = 2π/q*. As shown in Figure 7(a), the D decreases as a function of the crystallization time which seemed to be conflicting to the process of crystallization. To understand this behavior, the average thickness of the crystalline lamella (L) was calculated from the SAXS profile through the correlation function [35]. The correlation function is expressed as:
Figure 7.
SAXS results for isothermal crystallization at 110°C (a) long period (D), (b) average lamellar thickness (L) as a function of (t-t0), where t0 is the induction period (adapted from reference [9] with a permission).
γr=∫0∞Iqq2cosqrdq∫0∞Iqq2dqE3
Here, γ(r) is the correlation function and r is the distance in the real space. γ(r) function was obtained from the comprehensive I(q) from q = 0 to q = ∞ by conducting the extrapolation of SAXS data for q → ∞ according to Porod’s law and for q → 0, Guinier’s law is used. The detailed procedure is reported in Ref. [7]. Figure 7(b) shows thus-evaluated L as a function of time. As a result, the average lamellar thickness, L increases with time, which is reasonable as a crystallization behavior. Therefore, the decreasing behavior of D (as shown in in Figure 7(a)) is also reasonable, as schematically shown in Figure 8. Upon crystallization, shrinkage takes place. Since the lamella thickens with time, this results in the decrease of D (Figure 8(b) and (c)), as the amorphous layer thickness is decreased to a greater extent as compared to the increasing extent of L (lamellar thickness).
Figure 8.
Schematic illustrations showing the change in the nanostructure upon crystallization of PLLA. (a) At the amorphous state before crystallization of the polymer melt, (b) in an early stage of crystallization, (c) lamellar thickening in the subsequent stage of the crystallization (adapted from reference [9] with a permission).
2.1.2 Cellulose nanocrystal (CNC)
In this section, we discuss the enhancement in PLLA crystallizability by the inclusion of marine green algae biomass residue (ABR) based additives, i.e., washed ABR (WABR) and the ABR extracted cellulose nanocrystal (CNC). The CNC was extracted from the waste of ABR by using acid hydrolysis method. The complete extraction and characterization process is reported in Ref. [14]. Apart from effect of CNC on the crystallization behavior of PLLA, we also compare the utility of waste ABR after washing, i.e., WABR (washed algae biomass residue) as a filler for PLLA. As reported in Ref. [14] it was found that WABR had irregular morphology (micron size), while the CNC had needle-like morphology with an average diameter of 30–35 nm, and average length of 520–700 nm. [14]. PLLA/WABR and PLLA/CNC composites were prepared by solution casting method using chloroform as a solvent. The loading amount of the additives were 0.5%, 1%, and 2% by weight. The effects of WABR and CNC on isothermal crystallization of PLLA are discussed by DSC and POM.
Figure 9 shows the degree of crystallinity as a function of time based on DSC results for the isothermal crystallization of neat PLA, PLA/WABR and PLA/CNC nanocomposites at 110°C. The degree of crystallinity (ϕ) was calculated by using Eq. (1). As shown in Figure 9, the addition of WABR, and CNC can improve the crystallizability of PLLA by reducing induction period, crystallization half-time, and by increasing the ultimate degree of crystallinity. It was observed that the CNCs were more effective as a crystallizing agent in comparison to WABR. Based on the DSC measurement in heating scan, it was found that WABR and CNC does not change the Tg and Tm of PLLA [14]. These results are similar to the case of loading SFN which is also a solid state additive [8].
Figure 9.
Degree of crystallinity as a function of time based on DSC results for the isothermal crystallization of neat PLA, PLA/WABR and PLA/CNC nanocomposites at 110°C. the degree of crystallinity (ϕ) was calculated by using Eq.(1) (adapted from reference [14] with a permission).
Figure 10 shows the representative POM images for the isothermal crystallization at 125 °C for the neat PLA, PLA/WABR(1.0), and PLA/CNC(1.0) specimens at t = 12 min. First, negative spherulites were observed for all the specimens which shows that WABR and CNC had no effect on the structure of the PLA spherulites. Furthermore, Figure 11 shows the spherulite diameter, and number of spherulites as a function of time, which were calculated from the POM images. It was observed that the incorporation of WABR, and CNC into the PLA matrix accelerated the rate of nucleation, however, the growth rate of the PLA spherulite was almost unchanged. CNC was found to be more effective than the WABR. The needle-like morphology and high aspect ratio of CNC were mainly accountable for the better effectiveness on improvement in the crystallization of PLA. On the contrary, the larger particle size of WABR might be the possible reason for its less effectiveness.
Figure 10.
The representative POM images for the (a) neat PLA, (b) PLA/WABR(1.0), and (c) PLA/CNC(1.0) specimens for the isothermal crystallization at 125°C for t = 12 min (adapted from reference [14] with a permission). The figure has been slightly modified.
Figure 11.
(a) Spherulite diameter, (b) number of spherulites in the PLA/CNC bio-nanocomposites, and (c) spherulite diameter, (d) number of spherulites in the PLA/WABR bio-composites as a function of time at an isothermally crystallized temperature of 125°C (adapted from reference [14] with a permission).
The results shown in this section suggest that even the low loading amount of solid state additives can enhance the crystallization of PLLA by providing more sites for nucleation without altering Tg, Tm, and spherulite growth during the isothermal crystallization from the melt.
2.2 Liquid state additive (plasticizer)
In this section, we will focus on the enhancement in crystallizability of PLLA by using a special plasticizer (organic acid monoglyceride; OMG). The chemical structure of OMG is shown in Figure 12. OMG is a product of Taiyo Kagaku Co., Ltd. The commercial name of OMG is Chirabazol D, which is a biobased plasticizer. The OMG has a molecular weight of 500 and a melting temperature of Tm = 67°C. PLLA/OMG specimens were prepared by the solution casting method, using chloroform as a solvent. The specimens are labeled as D1.4/OMG(x) or D0.5/OMG(x), where the numbers after D denote the % of D moiety in PLLA, and x stands for % of OMG inclusion.
Figure 12.
Chemical structure of OMG.
Figure 13 shows the effect of OMG on the glass transition temperature (Tg) of PLLA. It is noticeably observed that Tg of PLLA decreases with the OMG content. More rigorously, we compare the result with the estimation by the plasticizing effect. The Tg can be simply estimated as.
Figure 13.
Glass transition temperature (Tg) as evaluated from DSC curves. The lines show estimated Tg (adapted from reference [10] with a permission).
Figure 13 shows the experimental Tg and the estimated Tg (with two straight lines) as a function of OMG content. The data points are almost in accord with the lines up to 1.0%, and then deviated from the lines above the OMG content of 1.0%. These results suggest that the OMG acts as a plasticizer for PLLA when the OMG loading is <1.0%. Figure 14(a) shows the DSC results of the isothermal crystallization of neat and 1% OMG loaded specimens at 110°C. The reduction in t0.5 in Figure 14(b) confirmed the enhancement in crystallization rate. Figure 14(c) shows the apparent degree of crystallinity which was evaluated using Eq. (2), based on the WAXS results as a function of the crystallization time for all specimens. The effect of the OMG is very clear for the acceleration of crystallization.
Figure 14.
(a) DSC results for isothermal crystallization at 110°C (b) crystallization half-time as a function of OMG loading (c) apparent crystallinity based on WAXS results, and (d) d spacing as a function of time (adapted from reference [7] with a permission).
Figure 15(a) shows the change in long period, D as a function of time during the isothermal crystallization at 110°C for neat and 1% OMG loaded specimens. The long period decreases as the crystallization proceeds which can be explained by Figure 8. Furthermore, Figure 15(b) shows changes in the lamellar thickness (calculated from SAXS profile through the correlation function, γ(r)) as a function of time. As time proceeded, the lamellar thickness increased in the early stage and then leveled off in the later stage. These results suggest that the lamellar thickness increased quickly in the early stage of crystallization due to a decrease in the D-content and the addition of OMG. The ultimate lamellar thicknesses (at 3000 s) for all specimens are relatively similar, although the value for the D0.5/OMG is 0.94 times those of the others.
Figure 15.
SAXS results for isothermal crystallization at 110°C (a) long period (D), (b) lamellar thickness (L) as a function of time (adapted from reference [7] with a permission).
The time-resolved Lorentz-corrected SAXS profiles during isothermal crystallization at 100°C form the melt (200°C) for D1.4/OMG and D0.5/OMG specimens are shown in Figure 16. There was no SAXS peak observed in the early stage. As the crystallization proceeds, the SAXS peak appears which gradually shifts towards the higher q range. As can be seen in Figure 16(b), there was observed a clear second peak in the higher q range for the D0.5/OMG(1.0) specimen. However, the position of the new peak is not twice of the position of the first-order peak which means that the new peak is independent of the first-order peak. This result correspond to the newly formed lamellar stacking. There are three possible models to account for the appearance of a new peak in the higher q range. One is the formation of new lamellar stacks in the amorphous region with much shorter long period, as schematically shown in Figure 17(a). The second one is the new lamellar stacks formed perpendicular to the original lamellar stacks, as schematically shown in the Figure 17(b). This model is referred to as the cross-hatched lamellae [36, 37, 38]. The third one is the insertion of a new lamella into the amorphous phase, which is sandwiched by the neighboring two preceding lamellae, as schematically shown in the Figure 17(c). This kind of insertion of a new lamella has been considered by Hama et al. [39]. At present, it is difficult to specify which model is appropriate. Although there was no such peak observed for the D0.5/OMG(2.0) specimen, the shoulders are clearly observed for this specimen (Figure 16(c)). Therefore, even for this specimen the effect of OMG to induce such a new lamellar stack can be recognized.
Figure 16.
Temporal changes in the Lorentz-corrected SAXS profiles upon T-jump from 200 °C to 100 °C for the specimen (a) D0.5 neat, (b) D0.5/OMG(1.0), (c) D0.5/OMG(2.0), (d) D1.4 neat, (e) D1.4/OMG(1.0), and (f) D1.4/OMG(2.0) specimens (adapted from reference [10] with a permission).
Figure 17.
Schematic representation for the formation of a new lamellar stack. (a) Independent stacking, (b) formation of a new stack in the amorphous phase in between the original lamellae with the stacking direction perpendicular to each other (cross-hatched lamellae) and (c) insertion of a new lamella in between the original lamellae (adapted from reference [10] with a permission).
The POM observations were conducted to count the number of the spherulites as a function of time during the isothermal crystallization at 130 °C. Figure 18(a) and (b) show the representative POM images for the isothermal crystallization at 130 °C for the D1.4 neat and D1.4/OMG(1.0) specimens at t = 29 min. Since, the negative spherulites were observed which indicates that there is no effect of OMG on the structure of the spherulites. Figure 18(b) shows enhanced number of spherulites by loading of OMG which indicates that OMG can enhance the nucleation process of PLLA. From Figure 18(c), it can be seen that the OMG enhances the spherulite growth of PLLA which clearly shows the effect of OMG to improve the crystallizability of PLLA. We speculate that the lowering of the activation energy for the PLLA crystallization may be the main effect of the OMG [10].
Figure 18.
(a), (b) POM images for the D1.4 neat and D1.4/OMG(1.0) specimens for the isothermal crystallization at 130°C for t = 29 min. (c) Plots of the radius of spherulite vs. time evaluated from the results of POM (adapted from reference [10] with a permission). The figure has been slightly modified.
3. Enhancement in stereocomplex crystallization of PLLA/PDLA blend
In this section, the PLLA/PDLA (50/50) blends were prepared by solution casting method. Firstly, the PLLA and PDLA solutions were separately prepared with a concentration of 5% (w/v), using dichloromethane (DCM) as a solvent. The SFN was dispersed in DCM by using the ultrasonication method as discussed in the reference [8]. The PLLA, PDLA solutions, and the SFN dispersion, all together were mixed in one glass vessel and stirred for 12 h. The loading of SFN was 1% with the weight ratio of PLLA, PDLA, and SFN as 49.5/49.5/1.0. After the mixing, the solution was poured into a Petri dish for solvent evaporation at RT. After complete evaporation of the solvent, the as-cast films were obtained which were further dried in a vacuum oven at 50°C for 24 h. The specimens are labeled as LD neat and LD/SFN(x), where LD denotes the blend of PLLA/PDLA(50/50), and x denotes the % loading of SFN.
Prior to the study of the effect of SFN on the crystallization of PLLA/PDLA (50/50) blend, we checked the effect of SFN on PDLA crystallization as SFN was known to improve the crystallization of PLLA (see Section 2.1.1). Figure 19 shows the comparison of degree of crystallinity during isothermal crystallization of PLLA neat, PLLA/SFN(1.0), PDLA neat, and PDLA/SFN(1.0) specimens at 110°C. It can be seen from this figure that the ultimate degree of crystallinity (ϕ∞) at the isothermal crystallization temperature of 110°C is increased by adding 1% SFN in PLLA or PDLA specimen. As shown in Figure 19 the induction period, t0 and the crystallization half-time, t0.5 of the PDLA neat specimen are shorter than those of the PLLA neat specimen. This may be because the optical purity of the PDLA sample (D-content >99.5%) is higher than that of PLLA sample (L-content = 99.5%), as we know that the nucleation and crystallization of PLA (PLLA or PDLA) becomes quicker with the increasing optical purity. By adding SFN, the t0 was almost unchanged for the case of the PDLA/SFN(1.0) specimen, while it was significantly decreased for the case of PLLA/SFN(1.0), furthermore, the t0.5 is decreased for both cases. It was much decreased for the case of PLLA than that of PDLA, ensuring the superior SFN effect due to its similarity of the chemical structure to PLLA. These results indicate the enhancement in the crystallizability of PDLA by adding 1% SFN, although SFN is much effective for the improvement of crystallizability of PLLA.
Figure 19.
Degree of crystallinity (ϕDSC) as a function of time, which was evaluated based on the heat flow results (adapted from reference [15] with a permission).
For the isothermal crystallization from melt, we set the melt temperature at 260°C for 5 min and then immediately quench to 110°C or 170°C and hold it isothermally until the crystallization completes. The reason why we selected 110°C is that it was found in Figure 4 that the rate of crystallization of PLLA HC crystal is maximum at ∼110°C. This is the best temperature to achieve the maximum amount of crystallinity of PLLA which is desirable for industrial purposes.
Furthermore, since at 110°C the formation of HC and SC occurs simultaneously so to see the effect of SFN on the formation of SC crystals solely, we conducted the isothermal crystallization at 170°C because at this temperature HC crystals cannot form (Tm,HC = 170 ∼ 180°C) due to the shallow quench depth (ΔT = TmO – Tc).
The effect of SFN on the isothermal crystallization behavior of the PLLA/PDLA blend specimen was investigated at Tiso = 110°C. Figure 20 shows the DSC results of the isothermal crystallization of LD neat and LD/SFN(1.0) specimens at 110°C from the melt (260°C). In Figure 20(a), the heat flow as a function of time at the isothermal crystallization temperature is plotted. Adding 1% SFN, the crystallization exothermic peak shifts to the shorter time, showing an enhancement in the crystallization speed. However, it was not possible to distinguish the evolution of HC and SC phases from the plots of Figure 20(a). To see the crystallites formed in the isothermal crystallization, the subsequent heating is conducted after the complete crystallization at 110°C. Figure 20(b) shows the results of the DSC heating scan. It is seen that by adding 1% SFN the ΔHm,HC and Tm,HC decreased and the ΔHm,SC and Tm,SC increased. These results indicate that the SFN can enhance the formation of SC and can suppress the formation of HC. The change in the melting temperature indicates that the presence of SFN may increase the lamellar thickness of the SC crystals while the lamellar thickness of HC crystals may be decreased due to the suppression of the HC crystallization. The increase in the melting point of SC is helpful to increase the thermal stability of PLA.
Figure 20.
(a) Heat flow as a function of time during the isothermal crystallization at 110°C from the melt (260°C), and (b) the subsequent heating scan from 110–260°C with the rate of 20°C/min. (c) Heat flow curves as a function of time during the isothermal crystallization at 170°C from the melt (260°C), and (d) changes in the degree of crystallinity (ϕDSC) as a function of time at 170°C, (adapted from reference [15] with a permission).
The effect of SFN on the isothermal crystallization behavior of the PLLA/PDLA blend specimen at 170°C was studied by the DSC measurement as shown in Figure 20(c). Since the temperature 170°C is too high for the formation of HC (Tm,HC = 170 ∼ 180°C), only the formation of SC can be considered at this temperature (see later WAXS results in Figure 21(c) and (d)). From Figure 20(c) and (d), it is clearly seen that the ultimate degree of crystallinity at the isothermal crystallization temperature of 170°C is increased by the presence of SFN. The t0 was decreased from 13 min to 7.4 min and the t0.5 was also decreased from 32.3 min to 19.1 min. These results indicate the enhancement in the stereocomplex crystallization of PLLA/PDLA (50/50) blend specimens by adding 1% SFN.
Figure 21.
Time-resolved WAXS profiles after the T-jump from 260–110°C for (a) LD neat (b) LD/SFN(1.0) specimens. (the red arrow indicates the first detection of the peak for the HC). (c) Time-resolved WAXS profiles after the T-jump from 260–170°C for (c) LD neat (d) LD/SFN(1.0) specimens. (the red arrow indicates the first detection of the SC peak) (adapted from reference [15] with a permission).
To clearly distinguish the evolution of HC and SC during the isothermal crystallization, we conducted the time-resolved WAXS measurements at 110°C upon T-jump from 260°C. Figure 21(a) and (b) show the change in WAXS profiles for the LD neat and LD/SFN(1.0) specimens as a function of time at 110°C. The peaks located at q = 8.75, 14.6, and 16.6 nm−1 belong to the SC crystals while the other reflection peaks belong to the HC. As shown in Figure 21(a), even at the very early stage the SC(110) refection peak was observed for both the specimens, while the peak area of SC(110) was much larger for the case of LD/SFN(1.0) specimen. The shorter induction period of SC than HC is due to the fact that the nucleation of SC is faster than that of HC in PLLA/PDLA (50/50) blend by the difference in the thermodynamic driving force of the crystallization. (ΔTSC > ΔTHC where ΔTSC = Tm, SC– T and ΔTHC = Tm, HC– T). As time goes on, the HC peak appears at 125 s. It is noteworthy to observe here that the induction period of HC is unchanged by adding SFN. The time evolution of the degree of crystallinity was calculated from the WAXS profiles which is plotted as a function of time in Figure 22. As can be seen from Figure 22 for the case of LD neat specimen, the HC peak appears later than the SC peak while it keeps on increasing and finally, ϕHC overcomes ϕSC. For the case of LD/SFN(1.0) specimen, the SC crystallization is much accelerated in the very early stage with the almost zero induction period and in the final stage ϕHC < < ϕSC. The fraction of SC (fSC) is increased after loading of 1% SFN while the total degree of crystallinity (ϕHC + ϕSC) is unchanged at 30 min.
Figure 22.
Degree of crystallinity calculated from the results of Figure 21 for (a) LD neat and (b) LD/SFN(1.0) specimens. (c) Total (HC + SC) degree of crystallinity and (d) fraction of SC as a function of time. Plots of average crystallite size as a function of time evaluated by Scherrer’s equation for (e) HC and (f) SC (adapted from reference [15] with a permission).
The average crystallite size (Dhkl) in the direction normal to the (hkl) plane was evaluated by Scherrer’s Equation [40].
Dhkl=Kλβhklcosθ2E5
where K is a constant (0.9) and λ is the wavelength of the incident X-ray. βhkl is a full-width at half maximum (FWHM) in the unit of radian, and θ is the scattering angle. Note here that the raw data were used as the βhkl values without correction for the peak broadening due to the collimation error of the WAXS setup, if any.
As seen in Figure 22(e) and (f), the crystallite size is initially increasing as a function of time and it levels off after 5 min elapsed from the onset of crystallization. The slope of the plots in Figure 22(e) and (f) can be considered as the crystallite growth rate. Then, it can be stated that the growth rate of the HC crystallites is unchanged by the addition of SFN. The final value of the size of the HC crystallite for LD/SFN(1.0) specimens is slightly smaller than that in the LD neat specimen due to the effect of the SFN loading. As can be seen from Figure 22(f), the size of the SC crystallite in the LD/SFN(1.0) specimen is much smaller than those of the LD neat specimen. Furthermore, it is interesting to notice that the initial size of the SC crystallite is the same for both the LD neat and the LD/SFN(1.0) specimens (Figure 22(f)).
To check the effect of SFN loading on the formation of SC crystals solely, we conducted the time-resolved WAXS measurements at 170°C. The changes in the WAXS profile were measured in the isothermal crystallization process at 170°C from the melt (260°C). Figure 21(c) and (d) show the WAXS profile for the LD neat and LD/SFN(1.0) specimens as a function of time. It is also clearly shown that there is no peak for HC crystals which is due to such a high temperature, i.e. 170°C. It can be said that at 170°C only SC crystal formation takes place.
Figure 23(a) and (b) show the changes in Lorentz corrected SAXS profiles as a function of time during isothermal crystallization at 110°C for the LD neat and LD/SFN(1.0) specimens. The SAXS profiles in Figure 23(a) and (b) show the scattering from both the HC and SC crystal (as evidenced by WAXS results in Figure 21). To distinguish the contribution of HC and SC crystal, we conducted the peak decomposition of the SAXS profiles. The detailed procedure about the peak decomposition is mentioned in Ref. [15]. For t < 6 min, the SAXS profiles are symmetric which belong to SC crystals. As time goes on, after t = 6 min, the second peak appears which shows the scattering from HC crystals. From the peak position (q*), the long period (D) of the lamellar stacks was evaluated as D = 2π/q*. Figure 24(a) shows the plot of D as a function of time for the LD neat and LD/SFN(1.0) specimens which show the contribution of HC and SC separately. As seen in Figure 24(a), D decreases as a function of time for HC crystals in the LD neat specimen. After loading 1% SFN, a similar trend was observed while the value of D of the HC lamellar stack was smaller than that of the LD neat specimen. The D of the SC lamellar stack in the LD neat specimen first increases up to t = 6 min and then decreases after t > 6 min. Considering Figure 22(a), t = 6 min can be taken as t0.5 (crystallization half-time). Then, the crystallization was quick in the stage t < t0.5. Namely, D increased with time during the rapid crystallization while D decreased with time during the subsequent slow crystallization. Figure 22(f), also suggests that the lateral size of SC lamellae was very rapidly increased for t < 6 min. Therefore, it can be considered that the SC lamellae grow in their lateral direction by folding the polymer chains in the amorphous region outside of the lamellar stacks. In the meantime, thickening of the lamellae can be considered during this stage (t < t0.5). Namely, the lamellar thickening may be considered to take place by including the amorphous chains from outside of the lamellar stack. This situation quite differs from Figure 8, for which D is explained to be decreasing with time because of shrinkage in volume upon crystallization. As for the current case, no change in the amorphous layer with increasing of the thickness of the crystalline lamellae result in increasing the long period, D. For the LD/SFN(1.0) specimen D of the SC lamellar stack decreases from the beginning however the decreasing tendency became more evident for t > 6 min.
Figure 23.
Changes in the Lorentz-corrected SAXS profiles as a function of time for LD neat and LD/SFN(1.0) specimens during the isothermal crystallization at (a)-(b) 110° C and (c)-(d) 170°C from the melt (260°C) (adapted from reference [15] with a permission).
Figure 24.
Plots of long period (D) as a function of time during the isothermal crystallization at (a) 110°C and (b) 170°C from the melt (260°C) (adapted from reference [15] with a permission).
Figure 23(c) and (d) show the changes in Lorentz corrected SAXS profiles as a function of time during isothermal crystallization at 170°C for the LD neat and LD/SFN(1.0) specimens. The intensity of the peak observed at q = 0.29 nm−1 increases as a function of time. As seen in Figure 23(c) and (d), the SAXS peak moves towards the higher q as the crystallization proceeds. Increase in q suggests the decrease in D as shown in Figure 24(b). It can be seen that the long period, D decreases by the loading of SFN.
POM observations were conducted to evaluate the spherulite growth rate and the nucleation density as a function of time. The POM images of the evolution of spherulites for the LD neat and LD/SFN(1.0) specimens at 170°C as a function of time are shown in Figure 25(a) and (b). First, negative spherulites were observed with the typical Maltese-cross patterns for both of the LD neat and LD/SFN(1.0) specimens. The number of spherulites and the spherulite diameter as a function of time are plotted in Figure 25(c) and (d). As shown in Figure 25(c) the number of spherulites increases as a function of time for the LD neat specimen below 4 min, suggesting homogeneous nucleation. In contrast, for the case of LD/SFN(1.0), the number of spherulites significantly increases and kept constant as a function of time (Figure 25(d)), suggesting heterogeneous nucleation due to the nucleation effect of SFN. The final number of spherulites increased approximately 3.6 times (from 21 to 73) upon the addition of SFN. Based on these results, SFN is considered as a nucleation agent for SC nuclei. The induction period calculated from Figure 25(c) looks unchanged. Furthermore, as seen in Figure 25(d) the growth rate (8.6 μm/min) of the spherulites in the LD/SFN(1.0) specimen is smaller than that of the spherulites in the LD neat specimen (10.7 μm/min). Although the growth rate of the SC crystals is decreased by the loading of SFN, the ultimate degree of crystallinity at 170°C (see Figure 20(d)) is increased by the loading of SFN. The slower growth of SC spherulites by adding SFN seems conflicting with the larger nucleation effects of SFN. These two conflicting results (as shown in Figure 25(c) and (d)) induced by the SFN loading are worthy of future research.
Figure 25.
POM images as a function of time for the isothermal crystallization at 170°C for (a) LD neat (b) LD/SFN(1.0) specimens. (c) Changes in the number of spherulites as a function of time, (d) the plots of spherulite diameter as a function of time during isothermal crystallization at 170°C, evaluated from the POM images (adapted from reference [15] with a permission).
4. Confined crystallization of PEG inside the preformed PLLA spherulite
In this section, we focus on the confined crystallization of PEG inside the preformed PLLA spherulite. The PLLA sample used in this study is the product of NatureWorks (code 4032D, D-content = 1.4%). The PEG sample was purchased from Wako Pure Chemical Industries, Ltd., of which Mw is 20,000. The PLLA/PEG (50/50) blend specimen was prepared by the solution casting method, using DCM as a solvent to obtain a solution with ca. 5 wt% of the total polymer concentration. The polymer solution was then poured into a Petri dish for complete evaporation of DCM.
The PLLA/PEG (50/50) blend specimen was heated up to 180.0°C and kept at this temperature for 5 min to obtain complete melt without liquid–liquid phase separation. Then, a two-step temperature-jump was conducted as 180.0°C → 127.0°C → 45.0°C. The isothermal crystallization time at 127.0 °C was controlled as 0, 5, 10, and 15 min where the PLLA spherulite grew. After that, the specimen was quenched to 45.0 °C and kept at this temperature for 40 min to induce the crystallization of PEG, as shown in Figure 26.
Figure 26.
Temperature protocol for the POM observations and the DSC measurements for the PLLA/PEG (50/50) blend specimens isothermally crystallized by the two-step T-jump (adapted from reference [13] with a permission).
As can be seen from the POM micrographs in Figure 27(a), PEG does not crystallize at 45.0 °C upon the direct quench from melt at 180.0 °C, however at 41°C PEG crystallization was clearly observed. This is due to the freezing temperature (Tf) depression of PEG in the mixture of the PLLA/PEG (50/50) blend specimen by noting that Tf for the neat PEG specimen is 52.0 °C. It should be noted that here we prefer to use the terminology “freezing temperature” instead of “crystallization temperature” to avoid any confusion with the “isothermal crystallization temperature” at which the isothermal crystallization experiment was conducted. Furthermore, the Tg of the PLLA/PEG (50/50) blend is approximately estimated as −8.2 °C by using the Fox equation with Tg,PEG = − 53.0 °C [41] and Tg,PLLA = 59.6 °C [8]. Therefore, the homogeneous mixture of PLLA and PEG is in the rubbery state at 41°C. However, PLLA crystallization was not observed at 41°C which may be due to the worse crystallizability of PLLA as compared to that of PEG.
Figure 27.
POM micrographs showing the crystallization processes of PLLA/PEG (50/50) blend specimens at 45.0 °C (40 min) after the temperature jump from 127.0 °C, where PLLA was allowed to crystallize for (a) 0, (b) 5, (c) 10, and (d) 15 min. Subsequently, the specimens were subjected to reheating with 50°C min−1 up to 67.0°C. POM images shown in the right column were taken after 10 s of the temperature equilibration at 67.0°C (adapted from reference [13] with a permission).
The direct evidence of the confined crystallization of PEG inside the preformed PLLA spherulite was observed by the bright-field optical microscopic observation which is shown in Figure 28. Actually, polarizer and analyzer plates were removed after first-step of T-jump at 127.0°C for 600 s. Afterwards, the specimen was quenched to 45.0°C. Around 484–486 s elapsed at 45.0°C, the dark spokes were observed inside the PLLA spherulite which were disappeared when temperature was increased up to 67.0°C. Thus, the confined crystallization of PEG in the preformed PLLA spherulite was evident. Upon further quenching from 67.0°C to 45.0°C, the confined crystallization of PEG again occured inside the PLLA spherulite, as shown in the bottom row of Figure 28. It is interesting to observe that the crystallization of PEG did not start from the center of the preformed PLLA spherulite. It rather seems that the initiation of the PEG crystallization was at random. Also, interesting to note no memory effect, i.e., the trajectories of the second-time PEG crystallization were completely different from the first-time ones. Furthermore, there observed a bridging PEG crystalline region which continuously strides over two-neighboring PLLA spherulites being contacted to each other with a straight boundary.
Figure 28.
POM image obtained at 127.0°C (600 s isothermal crystallization; shown at the top-left corner) and bright-field micrographs showing the confined crystallization of PEG in the PLLA spherulites for the PLLA/PEG (50/50) blend specimen. The specimen was quickly cooled from the melt state (180.0°C) to the crystallization state of PLLA at 127.0°C. after 600 s elapsed (isothermal crystallization for 600 s at 127.0°C), the specimen was again quenched to 45.0°C for the isothermal crystallization of PEG. Then, the specimen was subjected to reheating up to 67.0°C to melt the PEG crystalline phase. Subsequently (after 6 s elapsed), the specimen was quenched to 45.0°C for the isothermal crystallization at 45.0°C for the second time by keeping the same PLLA spherulites in which the confined crystallization of PEG took place again (adapted from reference [13] with a permission).
Figure 29(a) shows the change in the WAXS profiles during the isothermal crystallization at 45.0°C after the PLLA crystallization for 15 min at 127.0°C. Initially at t = 315 s, only the PLLA crystalline reflection peaks at q = 11.95, 13.43, and 15.45 nm−1 were observed. As time goes on, the PEG crystalline reflection peaks also appear at q = 13.56, 15.94, 16.12, 16.30 nm−1 with increasing their intensity. Figure 29(b). shows the plots of peak area as a function of time. The peak area for the PLLA crystalline peak was unchanged with the time however, that of PEG peaks showed the increasing tendency and then leveled off. The onset time of the peak evolution can be considered as the induction period which was about 5 min for this particular case. Although the peak positions of the PEG reflections in the second-step of T-jump of the blend specimen are the same as those for the neat PEG, it is specific to recognize the tremendous suppression of the (124¯)/(1¯24) reflection peak for the blend specimen as compared to that for the neat PEG [13]. This may indicate the effect of the space confinement that the direction of the PEG crystal growth was suppressed, which is the [124¯]/[1¯24] direction almost parallel to the c-axis, in turn, the polymer chain direction. On the other hand, the (120) reflection peak was not suppressed, indicating that the PEG crystal growth in the direction perpendicular to the polymer chains was not affected. Assuming the folded-chain crystal of the PEG crystalline lamella, these results suggest the suppression of the lamellar thickening due to the space confinement in the amorphous phase sandwiched by the preformed PLLA crystalline lamellae. This further suggests the orientation of the PEG lamellae parallel to those of PLLA. The parallel orientation of the PEG lamellae (parallel to the preformed PLLA crystalline lamellae) as a consequence of the space confinement can be explained by the previous work of Huang et al. [42].
Figure 29.
(a) Time-resolved 1 d-WAXS profiles along the PEG crystallization at 45.0°C in the PLLA/PEG (50/50) blend specimen after PLLA crystallized at 127.0°C for 15 min. (b) Plots of the area of crystallization peaks as a function of time, which was evaluated from WAXS results shown in Figure 29(a) after the peak decomposition (adapted from reference [13] with a permission).
Such a space confinement effect results in the formation of extraordinarily thin PEG lamellae, in turn the lowering of the melting temperature according to the Gibbs–Thomson equation. To check this speculation, the DSC measurements were conducted. The specimens were first quenched from 180.0°C to 127.0°C to allow isothermal crystallization of PLLA for X min (X = 5, 10, 15, and 20) in prior to the second-step T-jump to 45.0°C to allow isothermal PEG crystallization at 45.0°C for 30 min. After the isothermal PEG crystallization at 45.0°C for 30 min, the specimen was then heated with the rate of 10°C/min where the DSC measurement was conducted. Figure 30 shows the change in Tm of PEG as a function of the PLLA crystallization time at 127.0°C. It is clear that the Tm′s of PEG in PLLA/PEG(50/50) blend are much lower than that for the neat PEG crystallized, suggesting the formation of thinner PEG lamellae in case of the confined crystallization. It is noteworthy to observe that Tm of PEG is monotonically increased with an increase of the PLLA crystallization time, which might imply that the space confinement effect becomes lesser with the growth of the PLLA spherulite and eventually reaching no space confinement effect for the PLLA crystallization time larger than 20 min. Although this tendency seems to be reasonable, it should be noted that thickening of the PLLA lamellae with an increase in the PLLA crystallization time results in more significant confinement to the PEG crystallization taking place in the amorphous region sandwiched by two PLLA crystalline lamellae. Therefore, the result shown in Figure 30 rather implies the effect of the increase in the weight fraction of PEG (wPEG) in the amorphous region comprising the homogeneous mixture of PEG and PLLA. Furthermore, there might be still a weaker confinement, as the density of crystalline PLLA (1.29 g/cm3) [43] is higher compared to that of amorphous PLLA (1.25 g/cm3) [43]. Consequently, at the same time as PLLA lamellae grow in size, the amorphous phase will deplete in PLLA and due to the difference in densities there might be an overall gain in space, which enhances the growth of the PEG lamellae. As this effect becomes larger with the progress in the PLLA crystallization, the PEG lamellae can grow more so that the Tm of PEG increases with an increase in the PLLA crystallization time at 127°C, as shown in Figure 30. Thus, the DSC confirmation of the above-mentioned speculation of the formation of the PEG lamellae oriented parallel to the preformed PLLA lamellae is not satisfactory. We will report results of detailed DSC experiments using several PEG/PLLA blend specimens with different wPEG in our future publication.
Figure 30.
Tm of PEG as a function of the PLLA crystallization time at 127.0°C (adapted from reference [13] with a permission).
Furthermore, the Tf of PEG in the melt mixture of PEG and PLLA amorphous phase were determined by conducting the DSC measurements. Here, it is important to avoid crystallization of PLLA. Therefore, the specimens were quickly cooled from 180°C to 80.0°C and then cooled to 10°C with cooling rate 1,2 5 and 10°C/min. We conducted cooling-rate dependencies to correct for the cooling-rate effect on this temperature and to evaluate Tf of PEG by the extrapolation of the onset temperature of the exothermic peak to the zero-cooling rate [13]. Thus-evaluated Tf of PEG is plotted as a function of wPEG for the PLLA/PEG blend specimens in Figure 31(a). It can be seen that Tf is increased when wPEG is increased. Based on this plot, the mechanism of the confined crystallization in the preformed PLLA spherulites is considered. Upon the crystallization of PLLA from the melt of the PLLA/PEG amorphous phase, the PEG content in the amorphous region inside the PLLA spherulite is increased so that Tf is increased from its original one (Tf = 45.3°C) at wPEG = 0.5. The fact that no PEG crystallization at 45.0°C (Figure 27(a)) was observed for this blend specimen with wPEG = 0.5 seems to conflict with the fact of Tf = 45.3°C. Since this value (Tf = 45.3°C) was estimated by the extrapolation of the onset temperature of the PEG crystallization to the zero-cooling rate, the PEG crystallization at 45.0°C would take infinitely long time for this blend specimen (PLLA/PEG (50/50)). Figure 27(a) showing no PEG crystallization at 45.0°C implies that the PEG crystallization would take place more than 40 min. Consequently, it can be considered that when the PLLA crystallization time at 127.0°C is longer, the PEG content in the amorphous region becomes higher so that the PEG crystallizability becomes more sufficient. The experimental results definitely supported this speculation.
Figure 31.
(a) Dependence of the freezing temperature of PEG (Tf) on the weight fraction of PEG (wPEG) in the PLLA/PEG blend specimens. (b) Dependence of Tf of PEG on the PLLA crystallization time at 127.0°C (adapted from reference [13] with a permission).
Next, the PEG fraction in the amorphous phase in the preformed PLLA spherulite was estimated by DSC measurements. The PLLA/PEG (50/50) blend specimens were annealed at 180.0°C for 5 min, and then quenched first to 127.0°C for 10 min to form the PLLA spherulites. Afterward, the specimens were quenched to 60.0°C and then cooled gradually down to room temperature and DSC scans were observed [13]. Thus-evaluated Tf of PEG are plotted as a function of the crystallization time of PLLA at 127.0°C in Figure 31(b). Based on the result shown in Figure 31(b) combined with Figure 31(a) it was possible to estimate wPEG, which is increased from wPEG = 0.5 with increasing of PLLA crystallization time at 127.0°C. Figure 32 shows the ∆wPEG (= wPEG – 0.5) behavior as a function of the PLLA crystallization time. It is clearly observed that wPEG is increased with increasing of PLLA crystallization time at 127.0°C, which supports the above-mentioned discussion that wPEG in the amorphous region inside the larger PLLA spherulite is larger than that inside the smaller PLLA spherulite because of the progress in the PLLA crystallization. It is noteworthy that it leveled off around 20 min, suggesting completeness of the PLLA crystallization at 127.0°C around 20 min.
Figure 32.
Plot of wPEG as a function of the PLLA crystallization time at 127.0°C (adapted from reference [13] with a permission).
5. Confined crystallization of PCL in the block copolymer of PLA and PCL
In this section, we focus on block copolymers of PLA with PCL, namely, PLLA-PCL diblock copolymers and PLLA-PCL-PDLA triblock copolymers with respect to the confined crystallization within the microphase-separated domain of PCL which is sandwiched by the glassy PLLA microphase. In this study, PLLA, PDLA, PCL and their block copolymers were synthesized. The polymer synthesis method is described in Ref. [12]. The molecular weight information is reported in Table 2. The diblock copolymers are represented by XCL-YL and XCL-YD where X and Y denote the block length or the number-average molecular weights (Mn) in kDa of the component PCL (CL), PLLA (L), and PDLA (D) blocks. Whereas, the tri-stereoblock (trisb) copolymers are represented by XCL-YL-ZD where X, Y, and Z denote the block lengths or Mn values in kDa of its following block sequences shown by the abbreviated symbols. Further, the synthesized diblock copolymers were blended with their corresponding enantiomers, which are abbreviated as B_X-Y where X and Y denote the block length. For example, B_10–10 shows the blend of 10CL-10 L and 10CL-10D. Furthermore, all the prepared specimens were hot-pressed followed by quenching in ice-water, to obtain polymer films.
Specimen
Mn
Mw
Mw / Mn
10CL-10D
48.6
71.8
1.47
10CL-10 L
45.5
69.8
1.53
10CL-10 L-10D
59.0
100.6
1.70
10CL-20D
64.0
107.2
1.67
10CL-30D
69.8
160.5
2.30
Table 2.
Molecular weight of the synthesized block copolymers (analyzed by GPC).
The DSC thermograms of the block copolymers compared with that of neat PCL and neat PDLA are shown in Figure 33. The enthalpy of melting (ΔHm) of PCL decreases from 42.4 to 20.2 J/g with increasing the block length of PDLA, whereas the ΔHm of PDLA is increased from 36.8 to 43.4 J/g. These changes in enthalpy correspond to the decreasing content of PCL and increasing content of PDLA in the copolymer system. Furthermore, different melting peaks of PCL and PDLA confirms separate crystallization of PCL and PDLA blocks of varying length. Figure 33(b) shows the DSC results of the enantiomeric diblock copolymer blends and the trisb copolymer in the heating scan (10°C/min). As can be seen in the figure, the specimen B_10–10 form perfect SC crystal upon blending, without generating the HC. This is because of the low molecular weight of the PDLA/PLLA blocks. Furthermore, double melting peaks were observed for SC crystal at 221.8°C and 235.4°C which may be due to the formation of relatively thinner and thicker lamellae of SC crystal. It should be noted that more formation of HC in B_10–20 and B_10_30 specimen is due to the increasing molecular weight of PLLA/PDLA blocks. Therefore, it can be concluded that the higher molecular weight of the block sequences increases the formation of HC instead of SC.
Figure 33.
DSC thermograms of (a) neat PCL, neat PDLA, and PCL-PDLA diblock copolymers and (b) enantiomeric diblock copolymer blends and trisb copolymer (adapted from reference [12] with a permission).
The stress–strain (SS) curves of the polymer films of the block copolymers and their enantiomeric blends as well as that of the trisb copolymer are shown in Figure 34. As can be seen that the elongation of 30PCL specimen is higher than that of 30D specimen. The higher elongation of PCL is due to its soft and flexible nature as the stress–strain test is performed at 25°C (rubbery region of PCL) while PDLA is in glassy state. The tensile strength, modulus, and the toughness of the diblock copolymers are enhanced with increasing the block length of PDLA. The highest elongation at break was found for the specimen 10CL-30D. To understand such an unusual increase in elongation at break for 10CL-30D, it is important to consider the structure at the amorphous state at higher temperature. Here, it is noted that PCL/PLLA polymer blends exhibit LCST (lower critical solution temperature) phase behavior [44] so that PCL-PLLA blends are subjected to microphase separation at higher temperature. As a matter of fact, the SAXS results (Figure 35) indicated the microphase separation at higher temperature (210°C) for the PCL-PDLA diblock copolymers. The judgment of morphology was uncertain due to the presence of only a first order peak. For the 10CL-30D specimen, there may be the possibility of the formation of PCL lamellar or cylindrical microdomains due to the PCL fraction being 25%. It may be perceived that upon rapid quenching from 210 to 0°C, the PDLA matrix is vitrified due to which the PCL block chains would only crystallize in the interior of the cylindrical microdomains surrounded by the glassy matrix. Because of the confined crystallization, the crystallite may be considered as tiny and dispersed in the interior of PCL microdomains. In such a situation, the crack propagation of glassy PDLA matrix is terminated at the PCL microdomains when the specimen is drawn which could be attributed to amorphous PCL phase (rubbery domain) at room temperature. Also, the PCL block chains are much easier to be unfolded from the tiny crystalline lamellae as compared to larger (thicker) lamellae in other specimens. Therefore, the 10CL-30D specimen is found to exhibit the most stretchable character which may be ascribed to its structural origin.
Figure 34.
Representative data for stress vs. (%) Strain of (a) homopolymers and diblock copolymers; (b) diblock blends and trisb copolymer (adapted from reference [12] with a permission).
Figure 35.
Lorentz-corrected scattering intensity vs. q of (a) homopolymers and diblock copolymers and (b) enantiomeric diblock copolymer blends and trisb copolymer (adapted from reference [12] with a permission).
6. Conclusions
The crystallization of PLLA is one of the key factor for analyzing structure–property relationships of PLLA-based blend, block copolymer and nanocomposites. The presence of solid state additives (SFN and CNC) increased the nucleation of PLLA, thus influences the whole crystallization process, however the spherulite growth of PLLA was not significantly changed by loading SFN or CNC. For the case of liquid-state additive i.e. OMG, nucleation and spherulite growth rate both were found to be increased which improves the crystallizability of PLLA. The presence of SFN enhanced the SC crystallization while it suppressed the HC crystallization. It is noteworthy for this particular case that the spherulite growth rate was suppressed by the addition of 1% SFN whereas the nucleation density was much increased by SFN. For the case of PLLA/PEG(50/50) blend, a two-step temperature-jump was conducted as 180.0°C → 127.0°C → 45.0°C. For this particular condition, it was found that PEG can crystallize only in the preformed spherulites of PLLA. The confined crystallization of PEG can be accounted for as follows. Upon the PLLA crystallization at 127.0°C, the PEG content in the amorphous region inside the PLLA spherulite is increased because of the formation of the pure solid phase of PLLA (crystalline phase). Then, Tf of PEG increases so that PEG can crystallize but this crystallization is only allowed inside the PLLA spherulite. The direct evidence of the PEG crystallization was obtained by the bright-field optical microscopic observation and WAXS measurements. For the case of PLA and PCL block copolymers, the poor mechanical property of PDLA (which is poor elongation at break) was reported to be much improved by the presence of extensible PCL block component even in case of a short PCL chain in the block copolymer, which may be ascribed to the confined crystallization of PCL in the microdomain structure. Furthermore, the formation of SC crystal in the enantiomeric blend of PLLA-b-PCL and PDLA-b-PCL have been examined by changing the block length of PLLA and PDLA components.
\n',keywords:"Crystallization, poly(lactic acid), stereocomplex crystallization, poly(ethylene glycol), poly(caprolactone), biobased additives, improvement of crystallizability, X-ray scattering, crystalline block copolymer, crystalline polymer blend, confined crystallization",chapterPDFUrl:"https://cdn.intechopen.com/pdfs/76391.pdf",chapterXML:"https://mts.intechopen.com/source/xml/76391.xml",downloadPdfUrl:"/chapter/pdf-download/76391",previewPdfUrl:"/chapter/pdf-preview/76391",totalDownloads:163,totalViews:0,totalCrossrefCites:0,totalDimensionsCites:1,totalAltmetricsMentions:0,impactScore:0,impactScorePercentile:44,impactScoreQuartile:2,hasAltmetrics:0,dateSubmitted:null,dateReviewed:"March 8th 2021",datePrePublished:"May 3rd 2021",datePublished:"March 30th 2022",dateFinished:"April 22nd 2021",readingETA:"0",abstract:"Despite the extensive studies of poly(L-lactic acid)(PLLA), the crystallization of PLLA-based materials is still not completely understood. This chapter presents recent developments of crystallization of PLLA-based blends, block copolymers and nanocomposites. The first section of the chapter discusses the acceleration of PLLA crystallization by the inclusion of biobased (solid and liquid state) additives. It was found that the solid state additives work as a nucleating agent while the liquid-state additive works as a plasticizer. Both type of the additives can significantly enhance the crystallization of PLLA, as indicated by crystallization half-time (t0.5) values. Such composites are of great interest as they are 100% based on renewable resources. The second section talks about the enhanced formation of stereocomplex (SC) crystals in the PLLA/PDLA (50/50) blends by adding 1% SFN. It was found that the loading of SFN enhances the formation of SC crystals and it suppresses the formation of HC (homocrystal). The third section deals with confined crystallization of poly(ethylene glycol) (PEG) in a PLLA/PEG blend. The PLLA/PEG (50/50) blend specimen was heated up to 180.0°C and kept at this temperature for 5 min. Then, a two-step temperature-jump was conducted as 180.0°C → 127.0°C → 45.0°C. For this particular condition, it was found that PEG can crystallize only in the preformed spherulites of PLLA, as no crystallization of PEG was found in the matrix of the mixed PLLA/PEG amorphous phase. The last section describes the confined crystallization of PCL in the diblock and triblock copolymers of PLA-PCL. Furthermore, enantiomeric blends of PLLA-PCL and PDLA-PCL or PLLA-PCL-PLLA and PDLA-PCL-PDLA have been examined for the purpose of the improvement of the poor mechanical property of PLLA to which the SC formation of PLLA with PDLA components are relevant.",reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/76391",risUrl:"/chapter/ris/76391",book:{id:"10504",slug:"crystallization-and-applications"},signatures:"Amit Kumar Pandey and Shinichi Sakurai",authors:[{id:"186430",title:"Dr.",name:"Shinichi",middleName:null,surname:"Sakurai",fullName:"Shinichi Sakurai",slug:"shinichi-sakurai",email:"shin@kit.ac.jp",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:null},{id:"341133",title:"Dr.",name:"Amit Kumar",middleName:null,surname:"Pandey",fullName:"Amit Kumar Pandey",slug:"amit-kumar-pandey",email:"amitpandey886@gmail.com",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Indian Institute of Technology Guwahati",institutionURL:null,country:{name:"India"}}}],sections:[{id:"sec_1",title:"1. Introduction",level:"1"},{id:"sec_2",title:"2. Improvement of PLLA crystallizability by biobased additives",level:"1"},{id:"sec_2_2",title:"2.1 Solid state additives (nucleation agents)",level:"2"},{id:"sec_2_3",title:"2.1.1 Silk fibroin nanodisc (SFN)",level:"3"},{id:"sec_3_3",title:"2.1.2 Cellulose nanocrystal (CNC)",level:"3"},{id:"sec_5_2",title:"2.2 Liquid state additive (plasticizer)",level:"2"},{id:"sec_7",title:"3. Enhancement in stereocomplex crystallization of PLLA/PDLA blend",level:"1"},{id:"sec_8",title:"4. Confined crystallization of PEG inside the preformed PLLA spherulite",level:"1"},{id:"sec_9",title:"5. Confined crystallization of PCL in the block copolymer of PLA and PCL",level:"1"},{id:"sec_10",title:"6. Conclusions",level:"1"}],chapterReferences:[{id:"B1",body:'Saeidlou, S.; Huneault, M.A.; Li, H.; Park, C.B. Poly(lactic acid) crystallization. Prog. Polym. Sci.2012, 37, 1657–1677.'},{id:"B2",body:'Wasanasuk, K.; Tashiro, K.; Hanesaka, M.; Ohhara, T.; Kurihara, K.; Kuroki, R.; Tamada, T.; Ozeki, T.; Kanamoto, T. Crystal structure analysis of poly(l-lactic acid) α form on the basis of the 2-dimensional wide-angle synchrotron X-ray and neutron diffraction measurements. Macromolecules 2011, 44, 6441–6452.'},{id:"B3",body:'Wasanasuk, K.; Tashiro, K. Structural regularization in the crystallization process from the glass or melt of poly(l-lactic acid) viewed from the temperature-dependent and time-resolved measurements of FTIR and wide-angle/small-angle X-ray scatterings. Macromolecules2011, 44, 9650–9660.'},{id:"B4",body:'Zhang, J.; Tashiro, K.; Tsuji, H.; Domb, A.J. Disorder-to-order phase transition and multiple melting behavior of poly(L-lactide) investigated by simultaneous measurements of WAXD and DSC. Macromolecules2008, 41, 1352–1357.'},{id:"B5",body:'Zhang, J.; Tashiro, K.; Domb, A.J.; Tsuji, H. Confirmation of disorder α form of poly(L-lactic acid) by the X-ray fiber pattern and polarized IR/Raman spectra measured for uniaxially-oriented samples. Macromol. Symp.2006, 242, 274–278.'},{id:"B6",body:'Aleman, C.; Lotz, B.; Puiggali, J. Crystal Structure of the α-Form of Poly (L-lactide). Macromolecules2001, 34, 4795–4801.'},{id:"B7",body:'Thi Ngoc Diep, P.; Mochizuki, M.; Doi, M.; Takagi, H.; Shimizu, N.; Igarashi, N.; Sasaki, S.; Sakurai, S. Effects of a special diluent as an agent of improving the crystallizability of poly(L-lactic acid). Polym. J.2019, 51, 283–294.'},{id:"B8",body:'Pandey, A.K.; Katiyar, V.; Sasaki, S.; Sakurai, S. Accelerated crystallization of poly(l-lactic acid) by silk fibroin nanodisc. Polym. J.2019.'},{id:"B9",body:'Pandey, A.K.; Katiyar, V.; Takagi, H.; Shimizu, N.; Igarashi, N.; Sasaki, S.; Sakurai, S. Structural Evolution in Isothermal Crystallization Process of Poly(L-lactic acid) Enhanced by Silk Fibroin Nano-Disc. Materials.2019, 12, 1872.'},{id:"B10",body:'Thi Ngoc Diep, P.; Takagi, H.; Shimizu, N.; Igarashi, N.; Sasaki, S.; Sakurai, S. Effects of Loading Amount of Plasticizers on Improved Crystallization of Poly (L-lactic acid). J. Fiber Sci. Technol.2019, 75, 99–111.'},{id:"B11",body:'Pandey, A.K.; Diep, P.T.N.; Patwa, R.; Katiyar, V.; Sasaki, S.; Sakurai, S. DSC and SWAXS Studies on the Effects of Silk Nanocrystals on Crystallization of Poly(l-Lactic Acid). In Advances in Sustainable Polymers; Springer, 2020; pp. 321–339.'},{id:"B12",body:'Mulchandani, N.; Gupta, A.; Masutani, K.; Kumar, S.; Sakurai, S.; Kimura, Y.; Katiyar, V. Effect of Block Length and Stereocomplexation on the Thermally Processable Poly (ε-caprolactone) and Poly (Lactic acid) Block Copolymers for Biomedical Applications. ACS Appl. Polym. Mater.2019, 1, 3354–3365.'},{id:"B13",body:'BANPEAN, A.; SAKURAI, S. Confined Crystallization of Poly (ethylene glycol) in Spherulites of Poly (L-lactic acid) in a PLLA/PEG Blend. Polymer.2021, 123370.'},{id:"B14",body:'Mondal, K.; Sakurai, S.; Okahisa, Y.; Goud, V. V.; Katiyar, V. Effect of cellulose nanocrystals derived from Dunaliella tertiolecta marine green algae residue on crystallization behaviour of poly(lactic acid). Submitted to Carbohydr. Polym.2020.'},{id:"B15",body:'Pandey, A.K.; Takagi, H.; Igarashi, N.; Shimizu, N.; Sakurai, S. Exclusive Formation of Stereocomplex Crystallites in Poly(L-lactic acid)/Poly(D-lactic acid) Blends Promoted by Silk Fibroin Nanodisc. Submitted to Macromolecules2021.'},{id:"B16",body:'Li, H.; Huneault, M.A. Effect of nucleation and plasticization on the crystallization of poly (lactic acid). Polymer.2007, 48, 6855–6866.'},{id:"B17",body:'Carbone, M.J.; Vanhalle, M.; Goderis, B.; Puyvelde, P. Van Amino acids and poly ( amino acids ) as nucleating agents for poly ( lactic acid ). 2015, 35, 169–180.'},{id:"B18",body:'Kawamoto, N.; Sakai, A.; Horikoshi, T.; Urushihara, T.; Tobita, E. Nucleating agent for poly(L-lactic acid) - An optimization of chemical structure of hydrazide compound for advanced nucleation ability. J. Appl. Polym. Sci.2007, 103, 198–203.'},{id:"B19",body:'Ouchiar, S.; Stoclet, G.; Cabaret, C.; Gloaguen, V. Influence of the Filler Nature on the Crystalline Structure of Polylactide-Based Nanocomposites: New Insights into the Nucleating Effect. Macromolecules2016, 49, 2782–2790.'},{id:"B20",body:'Müller, A.J.; Ávila, M.; Saenz, G.; Salazar, J. CHAPTER 3. Crystallization of PLA-based Materials; 2015; ISBN 9781782624806.'},{id:"B21",body:'Patwa, R.; Soundararajan, N.; Mulchandani, N.; Bhasney, S.M.; Shah, M.; Kumar, S.; Kumar, A.; Katiyar, V. Silk nano-discs: A natural material for cancer therapy. Biopolymers2018, 109, 23231.'},{id:"B22",body:'Tsuji, H. Poly(lactic acid) stereocomplexes: A decade of progress. Adv. Drug Deliv. Rev.2016, 107, 97–135.'},{id:"B23",body:'Tan, B.H.; Muiruri, J.K.; Li, Z.; He, C. Recent Progress in Using Stereocomplexation for Enhancement of Thermal and Mechanical Property of Polylactide. ACS Sustain. Chem. Eng.2016, 4, 5370–5391.'},{id:"B24",body:'Tsuji, H.; Ikada, Y. Stereocomplex Formation between Enantiomeric Poly(lactic acid)s. 9. Stereocomplexation from the Melt. Macromolecules1993, 26, 6918–6926.'},{id:"B25",body:'Okihara, T.; Tsuji, M.; Kawaguchi, A.; Katayama, K.I.; Tsuji, H.; Hyon, S.H.; Ikada, Y. Crystal Structure of Stereocomplex of Poly(L-lactide) and Poly(D-lactide). J. Macromol. Sci. Part B1991, 30, 119–140.'},{id:"B26",body:'Tsuji, H.; Fukui, I. Enhanced thermal stability of poly(lactide)s in the melt by enantiomeric polymer blending. Polymer.2003, 44, 2891–2896.'},{id:"B27",body:'Long, H.; Wu, Z.; Dong, Q.; Shen, Y.; Zhou, W.; Luo, Y.; Zhang, C.; Dong, X. Effect of polyethylene glycol on mechanical properties of bamboo fiber-reinforced polylactic acid composites. J. Appl. Polym. Sci.2019, 136, 47709.'},{id:"B28",body:'Liu, H.; Zhang, J. Research progress in toughening modification of poly (lactic acid). J. Polym. Sci. part B Polym. Phys.2011, 49, 1051–1083.'},{id:"B29",body:'Lai, W.-C.; Liau, W.-B.; Lin, T.-T. The effect of end groups of PEG on the crystallization behaviors of binary crystalline polymer blends PEG/PLLA. Polymer.2004, 45, 3073–3080.'},{id:"B30",body:'Li, Y.; Li, X.; Xiang, F.; Huang, T.; Wang, Y.; Wu, J.; Zhou, Z. Crystallization, rheological, and mechanical properties of PLLA/PEG blend with multiwalled carbon nanotubes. Polym. Adv. Technol.2011, 22, 1959–1970.'},{id:"B31",body:'Kulinski, bZ; Piorkowska, E. Crystallization, structure and properties of plasticized poly (L-lactide). Polymer.2005, 46, 10290–10300.'},{id:"B32",body:'Piorkowska, E.; Kulinski, Z.; Galeski, A.; Masirek, R. Plasticization of semicrystalline poly (L-lactide) with poly (propylene glycol). Polymer.2006, 47, 7178–7188.'},{id:"B33",body:'Zhao, X.; Hu, H.; Wang, X.; Yu, X.; Zhou, W.; Peng, S. Super tough poly (lactic acid) blends: a comprehensive review. RSC Adv.2020, 10, 13316–13368.'},{id:"B34",body:'Tsuji, H.; Ikada, Y. Properties and morphologies of poly (L-lactide): 1. Annealing condition effects on properties and morphologies of poly (L-lactide). Polymer.1995, 36, 2709–2716.'},{id:"B35",body:'Strobl, G.R.; Strobl, G.R. The physics of polymers; Springer, 1997; Vol. 2;.'},{id:"B36",body:'Padden Jr, F.J.; Keith, H.D. Mechanism for lamellar branching in isotactic polypropylene. J. Appl. Phys.1973, 44, 1217–1223.'},{id:"B37",body:'Yamada, K.; Matsumoto, S.; Tagashira, K.; Hikosaka, M. Isotacticity dependence of spherulitic morphology of isotactic polypropylene. Polymer.1998, 39, 5327–5333.'},{id:"B38",body:'Uchida, K.; Mita, K.; Higaki, Y.; Kojio, K.; Takahara, A. Lamellar orientation in isotactic polypropylene thin films: a complement study via grazing incidence X-ray diffraction and surface/cross-sectional imaging. Polym. J.2019, 51, 183–188.'},{id:"B39",body:'Hama, H.; Tashiro, K. Structural changes in isothermal crystallization process of polyoxymethylene investigated by time-resolved FTIR, SAXS and WAXS measurements. Polymer.2003, 44, 6973–6988.'},{id:"B40",body:'Patterson, A.L. The scherrer formula for X-ray particle size determination. Phys. Rev.1939, 56, 978–982.'},{id:"B41",body:'Faucher, J.A.; Koleske, J. V; Santee Jr, E.R.; Stratta, J.J.; Wilson Iii, C.W. Glass transitions of ethylene oxide polymers. J. Appl. Phys.1966, 37, 3962–3964.'},{id:"B42",body:'Huang, P.; Zhu, L.; Guo, Y.; Ge, Q.; Jing, A.J.; Chen, W.Y.; Quirk, R.P.; Cheng, S.Z.D.; Thomas, E.L.; Lotz, B. Confinement size effect on crystal orientation changes of poly (ethylene oxide) blocks in poly (ethylene oxide)-b-polystyrene diblock copolymers. Macromolecules2004, 37, 3689–3698.'},{id:"B43",body:'E.W. Fischer, H.J. Sterzel, and G. Wegner, Investigation of the structure of solution grown crystals of lactide copolymers by means of chemical reactions. Kolloid-Z.Z. Polym.1973, 251(11), 980–990.'},{id:"B44",body:'Meredith, J.C.; J. Amis, E. LCST phase separation in biodegradable polymer blends: poly (D, L-lactide) and poly (ϵ-caprolactone). Macromol. Chem. Phys.2000, 201, 733–739.'}],footnotes:[],contributors:[{corresp:null,contributorFullName:"Amit Kumar Pandey",address:null,affiliation:'
Department of Biobased Materials Science, Kyoto Institute of Technology, Japan
Department of Biobased Materials Science, Kyoto Institute of Technology, Japan
Indian Institute of Technology Guwahati, India
'}],corrections:null},book:{id:"10504",type:"book",title:"Crystallization and Applications",subtitle:null,fullTitle:"Crystallization and Applications",slug:"crystallization-and-applications",publishedDate:"March 30th 2022",bookSignature:"Youssef Ben Smida and Riadh Marzouki",coverURL:"https://cdn.intechopen.com/books/images_new/10504.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",isbn:"978-1-83969-317-5",printIsbn:"978-1-83969-316-8",pdfIsbn:"978-1-83969-318-2",reviewType:"peer-reviewed",numberOfWosCitations:0,isAvailableForWebshopOrdering:!0,editors:[{id:"311698",title:"Dr.",name:"Youssef",middleName:null,surname:"Ben Smida",slug:"youssef-ben-smida",fullName:"Youssef Ben Smida"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:{id:"290142",title:"Dr.",name:"Riadh",middleName:null,surname:"Marzouki",slug:"riadh-marzouki",fullName:"Riadh Marzouki"},coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"1169"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"76095",type:"chapter",title:"Polycrystalline Powder Synthesis Methods",slug:"polycrystalline-powder-synthesis-methods",totalDownloads:215,totalCrossrefCites:0,signatures:"Mosbah Jemmali, Basma Marzougui, Youssef Ben Smida, Riadh Marzouki and Mohamed Triki",reviewType:"peer-reviewed",authors:[{id:"311698",title:"Dr.",name:"Youssef",middleName:null,surname:"Ben Smida",fullName:"Youssef Ben Smida",slug:"youssef-ben-smida"},{id:"290142",title:"Dr.",name:"Riadh",middleName:null,surname:"Marzouki",fullName:"Riadh Marzouki",slug:"riadh-marzouki"},{id:"339980",title:"Dr.",name:"Mosbah",middleName:null,surname:"Jemmali",fullName:"Mosbah Jemmali",slug:"mosbah-jemmali"},{id:"347889",title:"Dr.Ing.",name:"Basma",middleName:null,surname:"Marzougui",fullName:"Basma Marzougui",slug:"basma-marzougui"},{id:"347890",title:"Prof.",name:"Mohamed",middleName:null,surname:"Triki",fullName:"Mohamed Triki",slug:"mohamed-triki"}]},{id:"73922",type:"chapter",title:"Effect of Operating Parameters and Foreign Ions on the Crystal Growth of Calcium Carbonate during Scale Formation: An Overview",slug:"effect-of-operating-parameters-and-foreign-ions-on-the-crystal-growth-of-calcium-carbonate-during-sc",totalDownloads:254,totalCrossrefCites:0,signatures:"Atef Korchef",reviewType:"peer-reviewed",authors:[{id:"327261",title:"Associate Prof.",name:"Atef",middleName:null,surname:"Korchef",fullName:"Atef Korchef",slug:"atef-korchef"}]},{id:"75752",type:"chapter",title:"Cadmium Contents in Biodegradable Films Made from Cassava",slug:"cadmium-contents-in-biodegradable-films-made-from-cassava",totalDownloads:157,totalCrossrefCites:0,signatures:"Maite Rada-Mendoza, José Luis Arciniegas Herrera and Patricia Vélez Varela",reviewType:"peer-reviewed",authors:[{id:"330797",title:"Dr.",name:"Maite",middleName:"Del Pilar",surname:"Rada-Mendoza",fullName:"Maite Rada-Mendoza",slug:"maite-rada-mendoza"},{id:"346659",title:"Dr.",name:"José Luis",middleName:null,surname:"Arciniegas Herrera",fullName:"José Luis Arciniegas Herrera",slug:"jose-luis-arciniegas-herrera"},{id:"346848",title:"Dr.",name:"Patricia",middleName:null,surname:"Vélez Varela",fullName:"Patricia Vélez Varela",slug:"patricia-velez-varela"}]},{id:"78554",type:"chapter",title:"Simultaneously Recovery of Phosphorus and Potassium Using Bubble Column Reactor as Struvite-K and Implementation on Crop Growth",slug:"simultaneously-recovery-of-phosphorus-and-potassium-using-bubble-column-reactor-as-struvite-k-and-im",totalDownloads:120,totalCrossrefCites:0,signatures:"Endar Hidayat and Hiroyuki Harada",reviewType:"peer-reviewed",authors:[{id:"339828",title:"Ph.D. Student",name:"Endar",middleName:null,surname:"Hidayat",fullName:"Endar Hidayat",slug:"endar-hidayat"},{id:"435339",title:"Dr.",name:"Hiroyuki",middleName:null,surname:"Harada",fullName:"Hiroyuki Harada",slug:"hiroyuki-harada"}]},{id:"76391",type:"chapter",title:"Recent Developments in the Crystallization of PLLA-Based Blends, Block Copolymers, and Nanocomposites",slug:"recent-developments-in-the-crystallization-of-plla-based-blends-block-copolymers-and-nanocomposites",totalDownloads:163,totalCrossrefCites:0,signatures:"Amit Kumar Pandey and Shinichi Sakurai",reviewType:"peer-reviewed",authors:[{id:"186430",title:"Dr.",name:"Shinichi",middleName:null,surname:"Sakurai",fullName:"Shinichi Sakurai",slug:"shinichi-sakurai"},{id:"341133",title:"Dr.",name:"Amit Kumar",middleName:null,surname:"Pandey",fullName:"Amit Kumar Pandey",slug:"amit-kumar-pandey"}]},{id:"76025",type:"chapter",title:"Polymorphism and Supramolecular Isomerism: The Impasse of Coordination Polymers",slug:"polymorphism-and-supramolecular-isomerism-the-impasse-of-coordination-polymers",totalDownloads:203,totalCrossrefCites:1,signatures:"Francisco Sánchez-Férez and Josefina Pons",reviewType:"peer-reviewed",authors:[{id:"344057",title:"Dr.",name:"Josefina",middleName:null,surname:"Pons",fullName:"Josefina Pons",slug:"josefina-pons"},{id:"344064",title:"Mr.",name:"Francisco",middleName:null,surname:"Sánchez-Férez",fullName:"Francisco Sánchez-Férez",slug:"francisco-sanchez-ferez"}]},{id:"80113",type:"chapter",title:"Brushite: Synthesis, Properties, and Biomedical Applications",slug:"brushite-synthesis-properties-and-biomedical-applications",totalDownloads:105,totalCrossrefCites:0,signatures:"Khalil Issa, Abdulaziz Alanazi, Khalid A. Aldhafeeri, Ola Alamer and Mazen Alshaaer",reviewType:"peer-reviewed",authors:[{id:"315119",title:"Dr.",name:"Mazen",middleName:null,surname:"Alshaaer",fullName:"Mazen Alshaaer",slug:"mazen-alshaaer"}]},{id:"76140",type:"chapter",title:"Advanced Biocrystallogenesis",slug:"advanced-biocrystallogenesis",totalDownloads:174,totalCrossrefCites:0,signatures:"Ivana Kuta Smatanova, Petra Havlickova, Barbora Kascakova and Tatyana Prudnikova",reviewType:"peer-reviewed",authors:[{id:"82667",title:"Prof.",name:"Ivana",middleName:null,surname:"Kuta Smatanova",fullName:"Ivana Kuta Smatanova",slug:"ivana-kuta-smatanova"},{id:"343944",title:"MSc.",name:"Barbora",middleName:null,surname:"Kascakova",fullName:"Barbora Kascakova",slug:"barbora-kascakova"},{id:"343945",title:"MSc.",name:"Petra",middleName:null,surname:"Havlickova",fullName:"Petra Havlickova",slug:"petra-havlickova"},{id:"343946",title:"Dr.",name:"Tatyana",middleName:null,surname:"Prudnikova",fullName:"Tatyana Prudnikova",slug:"tatyana-prudnikova"}]}]},relatedBooks:[{type:"book",id:"3621",title:"Silver Nanoparticles",subtitle:null,isOpenForSubmission:!1,hash:null,slug:"silver-nanoparticles",bookSignature:"David Pozo Perez",coverURL:"https://cdn.intechopen.com/books/images_new/3621.jpg",editedByType:"Edited by",editors:[{id:"6667",title:"Dr.",name:"David",surname:"Pozo",slug:"david-pozo",fullName:"David Pozo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"9729",title:"Thermodynamic Properties of Nano-Silver and Alloy Particles",slug:"thermodynamic-properties-of-nano-silver-and-alloy-particles",signatures:"Wangyu Hu, Shifang Xiao, Huiqiu Deng, Wenhua Luo and Lei Deng",authors:[null]},{id:"9731",title:"Linear and Nonlinear Optical Properties of Aligned Elongated Silver Nanoparticles Embedded in Silica",slug:"linear-and-nonlinear-optical-properties-of-aligned-elongated-silver-nanoparticles-embedded-in-silica",signatures:"Raul Rangel-Rojo, J.A. Reyes-Esqueda, C. Torres-Torres, A. Oliver, L. Rodriguez-Fernandez, A. Crespo-Sosa, J.C. Cheang-Wong, J. McCarthy, H.T. Bookey and A.K. Kar",authors:[null]},{id:"9724",title:"The Applicability of Global and Surface Sensitive Techniques to Characterization of Silver Nanoparticles for Ink-Jet Printing Technology",slug:"the-applicability-of-global-and-surface-sensitive-techniques-to-characterization-of-silver-nanoparti",signatures:"M. Puchalski, P.J. Kowalczyk, Z. Klusek and W. Olejniczak",authors:[null]},{id:"9721",title:"In Situ Photochemically assisted Synthesis of Silver Nanoparticles in Polymer Matrixes",slug:"in-situ-photochemically-assisted-synthesis-of-silver-nanoparticles-in-polymer-matrixes",signatures:"Lavinia Balan, Jean-Pierre Malval and Daniel-Joseph Lougnot",authors:[null]},{id:"9732",title:"Linear and Nonlinear Optical Properties of Silver Nanoparticles Synthesized in Dielectrics by Ion Implantation and Laser Annealing",slug:"linear-and-nonlinear-optical-properties-of-silver-nanoparticles-synthesized-in-dielectrics-by-ion-im",signatures:"Andrey L. Stepanov",authors:[null]},{id:"9719",title:"Synthesis of Silver Nanoparticles with Laser Assistance",slug:"synthesis-of-silver-nanoparticles-with-laser-assistance",signatures:"A. Pyatenko",authors:[null]},{id:"9735",title:"Synthesis of Ag Nanoparticles by Through Thin Film Ablation",slug:"synthesis-of-ag-nanoparticles-by-through-thin-film-ablation",signatures:"P. Terrence Murray and Eunsung Shin",authors:[null]},{id:"9720",title:"O-Phenylenediamine Encapsulated Silver Nanoparticles and Their Applications for Organic Light-Emitting Devices",slug:"o-phenylenediamine-encapsulated-silver-nanoparticles-and-their-applications-for-organic-light-emitti",signatures:"Chang-Sik Ha, Jin-Woo Park and Habib Ullah",authors:[null]},{id:"9722",title:"High Surface Clay-Supported Silver Nanohybrids",slug:"high-surface-clay-supported-silver-nanohybrids",signatures:"Jiang-Jen Lin, Rui-Xuan Dong and Wei-Cheng Tsai",authors:[null]},{id:"9723",title:"Silver Nanoparticles in Oxide Glasses: Technologies and Properties",slug:"silver-nanoparticles-in-oxide-glasses-technologies-and-properties",signatures:"N.V. Nikonorov, Sidorov A.I. and Tsekhomskii V.A.",authors:[null]},{id:"9730",title:"Silver Nanoparticles: Sensing and Imaging Applications",slug:"silver-nanoparticles-sensing-and-imaging-applications",signatures:"Carlos Caro, Paula M. Castillo, Rebecca Klippstein, David Pozo and Ana P. Zaderenko",authors:[null]},{id:"9734",title:"Silver Nanoparticles as Optical Sensors",slug:"silver-nanoparticles-as-optical-sensors",signatures:"Chien Wang, Marta Luconi, Adriana Masi and Liliana Fernandez",authors:[null]},{id:"9725",title:"Biosynthesis and Application of Silver and Gold Nanoparticles",slug:"biosynthesis-and-application-of-silver-and-gold-nanoparticles",signatures:"Zygmunt Sadowski",authors:[null]},{id:"9733",title:"On-Paper Synthesis of Silver Nanoparticles for Antibacterial Applications",slug:"on-paper-synthesis-of-silver-nanoparticles-for-antibacterial-applications",signatures:"Hirotaka Koga and Takuya Kitaoka",authors:[null]},{id:"9727",title:"The Silver Nanoparticle (Nano-Ag): a New Model for Antifungal Agents",slug:"the-silver-nanoparticle-nano-ag-a-new-model-for-antifungal-agents",signatures:"Juneyoung Lee, Keuk-Jun Kim, Woo Sang Sung, Jong Guk Kim and Dong Gun Lee",authors:[null]},{id:"9728",title:"Silver Nanoparticles Interactions with the Immune System: Implications for Health and Disease",slug:"silver-nanoparticles-interactions-with-the-immune-system-implications-for-health-and-disease",signatures:"Rebecca Klippstein, Rafael Fernandez-Montesinos, Paula M. Castillo, Ana P. Zaderenko and David Pozo",authors:[null]},{id:"9726",title:"Potential Use of Silver Nanoparticles as an Additive in Animal Feeding",slug:"potential-use-of-silver-nanoparticles-as-an-additive-in-animal-feeding",signatures:"Manuel Fondevila",authors:[null]}]}],publishedBooks:[{type:"book",id:"1504",title:"Fingerprints in the Optical and Transport Properties of Quantum Dots",subtitle:null,isOpenForSubmission:!1,hash:"426663a84c1bdc6d7af7042655bda8a0",slug:"fingerprints-in-the-optical-and-transport-properties-of-quantum-dots",bookSignature:"Ameenah Al-Ahmadi",coverURL:"https://cdn.intechopen.com/books/images_new/1504.jpg",editedByType:"Edited by",editors:[{id:"25229",title:"Dr.",name:"Ameenah",surname:"Al-Ahmadi",slug:"ameenah-al-ahmadi",fullName:"Ameenah Al-Ahmadi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8823",title:"On the Properties of Novel Superconductors",subtitle:null,isOpenForSubmission:!1,hash:"7ac9708760da3a91f84d9183feb90be2",slug:"on-the-properties-of-novel-superconductors",bookSignature:"Heshmatollah Yavari",coverURL:"https://cdn.intechopen.com/books/images_new/8823.jpg",editedByType:"Edited by",editors:[{id:"24773",title:"Dr.",name:"Heshmatollah",surname:"Yavari",slug:"heshmatollah-yavari",fullName:"Heshmatollah Yavari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2257",title:"Quantum Dots",subtitle:"A Variety of New Applications",isOpenForSubmission:!1,hash:"607ff61d3333a88f4c315273e91926b7",slug:"quantum-dots-a-variety-of-new-applications",bookSignature:"Ameenah Al-Ahmadi",coverURL:"https://cdn.intechopen.com/books/images_new/2257.jpg",editedByType:"Edited by",editors:[{id:"25229",title:"Dr.",name:"Ameenah",surname:"Al-Ahmadi",slug:"ameenah-al-ahmadi",fullName:"Ameenah Al-Ahmadi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9215",title:"Progress in Fine Particle Plasmas",subtitle:null,isOpenForSubmission:!1,hash:"42c9a3b34a54b24180ac3b1fe5c544b3",slug:"progress-in-fine-particle-plasmas",bookSignature:"Tetsu Mieno, Yasuaki Hayashi and Kun Xue",coverURL:"https://cdn.intechopen.com/books/images_new/9215.jpg",editedByType:"Edited by",editors:[{id:"209593",title:"Dr.",name:"Tetsu",surname:"Mieno",slug:"tetsu-mieno",fullName:"Tetsu Mieno"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3057",title:"New Progress on Graphene Research",subtitle:null,isOpenForSubmission:!1,hash:"93498540bbb77f6316f5aae8cd11721e",slug:"new-progress-on-graphene-research",bookSignature:"Jian Ru Gong",coverURL:"https://cdn.intechopen.com/books/images_new/3057.jpg",editedByType:"Edited by",editors:[{id:"61172",title:"Prof.",name:"Jian Ru",surname:"Gong",slug:"jian-ru-gong",fullName:"Jian Ru Gong"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],publishedBooksByAuthor:[{type:"book",id:"5371",title:"X-ray Scattering",subtitle:null,isOpenForSubmission:!1,hash:"af21d4ead14637fcfa5f919430ec45f5",slug:"x-ray-scattering",bookSignature:"Alicia Esther Ares",coverURL:"https://cdn.intechopen.com/books/images_new/5371.jpg",editedByType:"Edited by",editors:[{id:"91095",title:"Dr.",name:"Alicia Esther",surname:"Ares",slug:"alicia-esther-ares",fullName:"Alicia Esther Ares"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10504",title:"Crystallization and Applications",subtitle:null,isOpenForSubmission:!1,hash:"3478d05926950f475f4ad2825d340963",slug:"crystallization-and-applications",bookSignature:"Youssef Ben Smida and Riadh Marzouki",coverURL:"https://cdn.intechopen.com/books/images_new/10504.jpg",editedByType:"Edited by",editors:[{id:"311698",title:"Dr.",name:"Youssef",surname:"Ben Smida",slug:"youssef-ben-smida",fullName:"Youssef Ben Smida"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},onlineFirst:{chapter:{type:"chapter",id:"72259",title:"Cell Cycle and Factors Involved in Inhibition or Progression of Breast Cancer",doi:"10.5772/intechopen.92576",slug:"cell-cycle-and-factors-involved-in-inhibition-or-progression-of-breast-cancer",body:'
1. Introduction
Deregulation in cell cycle is a remarkable feature of tumor cells [1, 2]. Cell cycle helps to maintain homeostasis of normal cell growth and viability in a compact process. Cell cycle occurs in four phases as follows:
preparation for cell division in G1 phase;
process of DNA synthesis in S phase;
G2 phase for cell growth and enzyme production; and
mitosis: M phase, which is regulated by several controlled events, directs the replication of DNA and cell division [3].
The transitions between G1 to S and G2 to M phase are governed by changes in the kinase activity of CDKs [4]: Cdk1, Cdk2, Cdk4, Cdk6, and cyclins. Cyclins are the regulatory units, and CDKs contain the catalytic subunit of an activated heterodimer. The cyclin binds to CDKs and gets activated by forming CDK/cyclin complex by phosphorylation leading the dividing cell into next phase of cell cycle. During G1 phase, the predominant cyclin-CDK complexes are cyclin D-Cdk4, 6, cyclin E-Cdk2, cyclin A-Cdk2 during S phase, cyclin A-Cdk1, and cyclin B-Cdk1 during G2/mitotic phases. The control of the G2/M transition is important in all cancers resulting in chromosomal aberrations, but the G1/S transition involves many of the important cell-cycle events that may be altered in breast cancer. G1/S transition involves functions of the oncogenes/tumor suppressors cyclin E, cyclin D1, and p27 [5]. The oncogenic processes do occur by targeting the regulators of G1 phase progression [6]. During the G phase, cells respond to extracellular signals by either going into next division or withdraw from the cycle and thus are arrested in a state (Go). G1 progression is dependent on stimulation by mitogens or growth factors and can be blocked by anti-proliferative cytokines, but cancer cells do not obey these controls. Cancer cells remain in a continuous cycle of cell division by halting maturation and terminal differentiation. Once the cells pass a restriction point late in G1, they do not respond to extracellular growth regulatory signals and commit themselves to the independent program that causes cell division. The cells, which pass through the restriction point G1 and enter into S phase, which is controlled by cyclin-dependent protein kinases (CDKs) that are regulated by cyclins D, E, and A, are committed to divide.
Cyclin D acts as growth factor regulator in response to extracellular signals in the cell cycle. The activity of Cyclin D depends on mitogenic stimulation upon binding with CDK4 and CDK6. Once bound, the catalytic activity of this complex is maximum in G1-S phase transition, but withdrawal of mitogen causes stoppage of cyclin D synthesis, and thus, the D cyclins holoenzyme activities decay rapidly, and the cells exit the cycle [7]. So, if cyclin DI-dependent kinase activity is lost before the restriction point, it prevents cells from entering S phase [8]. To pass through first check point – G1 phase that occurs in normal cell cycle, cyclin D-dependent kinases should phosphorylate protein retinoblastoma tumor suppressor protein (RB) [9]. As the hyper-phosphorylated RB gets dissociated from E2f, DP1, RB complex will result in the activation of E2F genes and leads to transcription of several genes such as cyclin E, cyclin A, and DNA polymerase. RB and other RB-like proteins (pI30, P107), which regulate gene expression which in turn are regulated by a family of heterodimeric transcriptional regulator E2Fs [10], which can transactivate genes and are required for S phase entry [11]. INK4 proteins inhibit (inhibitors of CDK4 and CDK6 INK4 proteins can directly block cyclin D-dependent kinase activity and cause G1 phase arrest) cyclin D-dependent kinases that phosphorylate RB. RB pathway does not functioning normal, which is feature of cancer cells [12]. The RB is inactivated by phosphorylation or by DNA damage; RB gene causes shrinking of G1 phase, and cell size is decreased. The mitogens and other signals required for cell are still present [13]. As the RB negative cells have few requirements for growth factors, these factors in addition to RB phosphorylation work for restriction point control [14]. As the cell cycle proceeds, the cyclin A- and cyclin B-dependent kinases keep RB in its hyper-phosphorylated state. RB is not dephosphorylated until mitosis is completed and again renters the GI phase or Go. The activity of cyclin A synthesis occurs later in GI and is important for the G1-S transition, as blockage of cyclin A function in cells can also block S phase entry. For cell cycle progression, the inactivation of cyclin E and E2F is important when the cell enters S phase [15]. Cyclin B, B-cdc2 complex leads to stimulation of nuclear envelope and initiation of prophase, but its deactivation leads the cell to exit mitosis [16].
2. Drug resistance
Hindrance in treating cancer patient mainly occurs by drug resistance [17]. Targeted therapies on breast cancer depend on the type of receptor being implicated by the expression of estrogen receptor (ER), progesterone receptor (PR), and overexpression of Her2/neu [17]. The therapeutic agents given in such cases, which eventually develop resistance as an acquired drug resistance, are clinically bigger challenge to treat. Thus, patient’s resistant to chemotherapy has poor prognosis and overall poor survival [18].
2.1 Cell cycle regulation in tamoxifen-resistant breast cancers
The main drug given to patients expressing estrogen receptor is tamoxifen, which is the first therapeutic agent for the estrogen or progesterone receptor expressing breast cancers, mostly in premenopausal women with or without conventional chemotherapeutic agents [19]. The estrogen receptor (ER) induction occurs during G0/G1 phase in MCF-7 cells and breast cancer cells [19]. In the late S-phase, a rapid increase in ER has been reported [19]. A tamoxifen-resistant phenotype was developed by long-term exposure of MCF-7 xenografts to tamoxifen resulted in an altered expression of ER during the G0/G1 phase [19]. It has been shown that tamoxifen-resistant MCF-7 cells express higher levels of cell cycle regulators cyclin E1 and CDK2 than parental cells [20]. It has been shown that cyclins E1 and E2 were overexpressed in the tamoxifen-resistant cells when compared with parental MCF-7 cells [20]. TAMR cells may be dependent on cyclin E more than MCF-7C, which indicates that CDK2 is inhibited and is a potential therapeutic marker in endocrine-resistant breast cancer [20]. Cyclin E2 downregulation is required for anti-estrogen inhibition of cell proliferation; cyclin E2 overexpression is associated with endocrine resistance in breast cancer providing reason for deregulation of the cell cycle in endocrine resistance [21, 22, 23, 24].
3. Genes associated with breast cancer development and its progression
There are various genes associated with breast cancer, and how these respond to different treatments are mentioned as follows:
3.1 EGFR
Epidermal growth factor receptor EGFR (ERBB1 or HER1) is from ERBB family of cell-surface receptor tyrosine kinases including HER2, also known as NEU or ERBB2 [25, 26]. The epidermal growth factor receptor family consists of four cell surface receptors; EGF receptor also called as HER1, HER2 or neu, HER3, and HER4. Epithelial growth factor binds to the receptor and stimulates homo/hetero dimerization of receptor with other ERBB member like HER2, receptor phosphorylation, which makes binding sites available for cytosolic proteins containing src homology 2 (SH2) domains [27]. EGFR growth factors cause activation of downstream effectors such as RAS-RAF-MEK-ERK-MAPK and PI3K-AKT-mTOR pathway. PI3K-AKT-mTOR sources irreversible entry of the cell in S phase of cell cycle resulting in cell proliferation [28]. There are various EGFR ligands such as transforming growth factor-α (TGF-α), amphiregulin, epigen, betacellulin, heparin-binding EGF, and epiregulin [29]. EGFR has an important involvement in cellular differentiation, motility, survival, and tissue development [30]. There are many copies of the EGFR gene in some of the breast cancer cells termed as EGFR amplification, which effects on behavior and response of cancer cell. There are other EGFR-positive cancers like colon cancer, which respond to medicines that target EGFR-positive cancers [31]. In a clinical study, there was an increase in EGFR gene copy number in about 6% of breast cancers and protein overexpression in 7% of breast cancers [32]. The study also showed that increased EGFR gene copy number changes, and protein overexpression was seen mostly in ER negative, PR negative, and HER2 negative (triple negative) cases with three exceptions that are HER2-positive cases in total of 175 cases (reference). The study was similar to that of gene expression profiling studies, which have identified EGFR expression mainly in basal-like breast carcinomas (reference). There was another subtype of breast carcinoma that showed an increase in EGFR copy number, or EGFR protein expression is the heterogeneous category of metaplastic carcinoma. These tumors are subtypes called as basal-like breast carcinomas [33] and were seen in 47 metaplastic breast carcinomas in which EGFR protein overexpression was in 32 cases, but gene amplification (as >5 EGFR gene copy number) was seen only in 11 of these 32 (34%) cases [33]. There are other studies that have shown that EGFR gene amplification and EGFR protein overexpression in various organ systems have found similarity in approximately 50% cases [34]. EGFR protein expression is the result of multiple genomic processes of which EGFR gene amplification is only one of them [34]. EGFR protein expression is seen in breast carcinoma, which is mostly triple negative, and there exists a relation between EGFR gene copy number and protein expression, but relation is not as strong as seen with HER2 [34]. The therapeutic use of EGFR as a responsive marker in breast carcinoma is being studied and needs to identify breast cancer patients that will respond to EGFR-related therapies. A new mechanism-based inhibitors and combination therapies are being worked to overcome therapeutic resistance in tumors [34, 35, 36].
3.2 HER2
HER2 gene is amplified in breast cancers by about 20% categorized as HER2-positive breast cancers [37], the extra HER2 protein leads to increase in activation of signal pathway, which results in uncontrolled growth and occurrence of cancer. Breast tumors having HER2 overexpressed proteins are more aggressive than other breast tumors [37]. This results in poorer prognosis in patients and decreased survival rate compared with patients whose tumors do not overexpress HER2 [37]. The inhibition of HER2 signaling will provide a tool to reduce breast cancer. Monoclonal antibodies like lapatinib are used to inhibit the signaling [37]. Herceptin (trastuzumab) is also a monoclonal antibody binding to HER2 [37]. This stops receptor from activating the signaling pathways, which is responsible for proliferation and survival of breast cancer cells [37]. Herceptin also causes inhibition of cancer cell growth by activating an immune response, which will damage nearby cells [37]. It is used to treat breast cancer only in tumor overexpressing HER2 with at least one high risk like estrogen receptor or progesterone receptor negative, pathologic tumor size greater than 2 cm, Grades 2–3, age less than 35 years [37]. Herceptin is used in combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer [37].
And as a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease [33, 37, 38].
3.3 HSP27
Heat shock protein 27 (HSP27) is the small molecular weight heat shock protein (HSP) family (12–43 kDa). HSP27 and different members of small HSP family possess a conserved c-terminal domain, the α-crystallin domain, which is similar to the vertebrate eye lens α-crystallin [39]. HSP27 was originally characterized in response to heat shock as a protein chaperone making proper refolding of damaged proteins [40]. It has been seen that HSP27 protein also responds to cellular stress such as oxidative stress and chemical stress. HSP27 is a protein, which functions as a protein chaperone, as an antioxidant helps in inhibition of apoptosis and actin cytoskeletal remodeling, regulation of cell development, cell differentiation, and signal transduction [41]. The oligomerization state of HSP27 is due to chaperone activity as the aggregates of large oligomers have high chaperone activity, whereas dimers have no chaperone activity. Large aggregates are formed under heat shock [40]. Hsp27 occurs in all cell types, mostly of muscle cells. It is located mainly not only in the cytosol but also in the perinuclear region, endoplasmic reticulum, and nucleus. It is overexpressed during cell differentiation and development. It has an essential role in the differentiation of tissues [41].
HSP27 functions as an antioxidant during oxidative stress, which lowers the levels of reactive oxygen species (ROS) by increasing the levels of intracellular glutathione and lowering the levels of intracellular iron [40, 42]. During chemical stress, protein acts as an anti-apoptotic agent through mitochondrial-dependent and -independent pathways of apoptosis [43]. During Fas-FasL-mediated apoptosis, HSP27 binds DAXX and stops the binding of Ask1 by DAXX [43]. HSP27 also interplays with Bax and cytochrome c stopping mitochondrial-dependent apoptosis [43]. HSP27 is mostly useful in protection from programmed cell death by inhibition of caspase-dependent apoptosis [43]. The anti-apoptotic properties of HSP27, which occur due to chemical stress, have been useful in chemotherapies such as doxorubicin and gemcitabine [44, 45]. HSP27 regulates actin cytoskeletal dynamics during heat shock and stress conditions, promotes both actin polymerization, and concerts as an actin capping protein. The upregulation of HSP27 is a biomarker acting in some of the disease subsequently, a cell safeguards itself from death or reduces oxidative stress by the help of HSP27 [46].
In vitro studies have shown that HSP27 acts as an ATP-independent chaperone by inhibiting protein aggregation and stabilizing partially denatured proteins, which ensures refolding by the Hsp70-complex [46]. It also preserves the focal contacts fixed at the cell membrane [46]. The main function of Hsp27 is to provide thermo tolerance in vivo, cytoprotection, and support of cell survival under stress conditions [46]. Another function of Hsp27 is the activation of the proteasome. It speeds up the degradation of irreversibly denatured proteins and junk proteins by binding to ubiquitinated proteins and to the 26S proteasome [46]. Hsp27 enhances the activation of the NF-κB pathway that controls a lot of processes, such as cell growth and inflammatory and stress responses [47]. Various reports have confirmed that cytoprotective properties of Hsp27 have been attributed to its ability to modulate reactive oxygen species production and to raise glutathione levels [47]. Hsp27 is known to play a role in the process of cell differentiation [47].
Hsp27 expression is varied in several cells such as Ehrlich ascites cells, embryonic stem cells, normal B cells, B-lymphoma cells, osteoblasts, keratinocytes, and neurons [47]. The upregulation of Hsp27 relates with the rate of phosphorylation and with an increase in large oligomers [48]. It is possible that Hsp27 plays a crucial role in the termination of growth [40].
3.4 HSP27 in breast cancer
Tumor cells show an increase in transcription of heat shock proteins (HSPs) due to loss of p53 functions and increased expression of proto-oncogenes such as HER and c-Myc, which is important for tumorigenesis [49]. Cellular protection and protein folding being the entailed function of HSPs are operative during oncogenesis [49]. Since tumor cell growth and survival are enabled by the increased expression of HSPs. HSP27 is mostly the important heat shock protein involved in protection from programmed cell death by inhibiting caspase-dependent apoptosis [45]. Since HSP27 has been associated with poor prognosis in many types of cancers such as gastric, liver, and prostate carcinoma, osteosarcoma, rectal, lung, and breast cancer [45]. HSP27 has been reported to play an important drug resistance in breast cancer, and some other cancers, HSPs, are involved in immune tolerance by cancer cells and are important targets for cancer therapy process [50]. A study done by Langer et al. in 2008 found that the protein expression profiles in patients with esophageal adenocarcinomas from two groups have shown as responsive and nonresponsive to neo-adjuvant platin and 5-fluorouracil based chemotherapy. The study showed that low HSP27 expression has a correlation with nonresponsiveness to the chemotherapy application [49]. It shows that low levels of HSP27 expression are associated with a negative outcome in cancer. HSP27 levels were studied in patients having colon or rectal cancer [49]. It showed that high HSP27 expression level results in incomplete resection margins in rectal cancer and poor survival.
HSP27 expression was not having any role in survival of colon cancer group but was related to poor survival in the rectal cancer group [49]. The metastatic breast cancer cell lines, which overexpress Her2 and are resistant to Herceptin (SK-BR3 HR), also overexpress HSP27 [49]. The downregulation of HSP27 protein levels was shown by transfecting with siRNA, where Herceptin resistance was also reduced in SK-BR3-HR cells [49]. HSP27 could form a complex with Her2, resulting in a potential mechanism by which the protein potentiates [51]. Her2 overexpressing breast cancer tumors have showed increased expression of phosphorylated HSP27, particularly at serine 78 [51, 52].
3.5 H2AX (H2A histone family, member X)
Histone H2A is programmed by a gene H2AFX (H2A histone family, member X), as H2A is one of the four core histones of DNA in humans and eukaryotes [53]. H2AX helps in nucleosome formation and in the structure of DNA. DNA known as the most stable material present, whose damage occurs due to ionizing radiation, hypoxia, reactive oxygen species, chemicals, and replication or transcriptional errors, which causes activation of DNA repair pathway [53]. Different materials can cause different types of damage in DNA-like double stranded breaks (DSBs), where both DNA strands have been cleaved [53]. If the damage occurred is not repaired, DSBs are lethal for the cell. DNA damage leads to an activation of the DNA damage repair pathway, phosphorylation of histone H2AX on serine 139. Activation of downstream pathway is done by the kinases of the PI3 family (ataxia telangiectasia mutated, ATR, and DNA-PKcs), which are responsible for this phosphorylation, especially ATM. γ-H2AX enrolls other factors, for example, 53BP1, BRCA1, MDC1, and the MRE11-RAD50-NBS1 (MRN) complex to sites of damage [53]. The DSBs, which are not repaired due to irradiation induced γ-H2AX foci, have been used in tumors as a biomarker for sensitivity to radiotherapy [54]. Endogenous γ-H2AX foci are present in normal primary human cells and tissues [54]. In tumor cells, phosphorylated H2AX exists in different levels in the absence of exogenously DSBs [54]. Instability of chromosomes occurs in cells having more endogenous foci [41]. The colocalization of these endogenous foci in association with other DNA repair factors, for example, 53BP1, MRN complex shows that DNA repair occurs at these sites [54]. The endogenous expression of γ-H2AX is present not only in tumor cell lines but also in cancer tissues and in their precursor lesions, which gives an insight into activated DNA damage repair in tumorigenesis [55]. The endogenous expression of DNA damage response factors is also due to damaged, shortened telomeres and hypoxia [56, 57].
Constitutive γ-H2AX expression is higher in triple negative and in BRCA1 and p53-mutated breast cancer cell lines, which makes a relation between endogenous γ-H2AX expression and 53BP1 expression in breast cancer tissue [55]. Other studies have also supported that triple negative breast cancers are having more endogenous γ-H2AX expression and have higher chances of carrying errors in components of the DNA damage repair pathway [55, 57]. Higher occurrence of γ-H2AX positive is present in basal like and triple negative tumors that are BRCA1 mutation carriers. So, the breast cancer patients having high endogenous γ-H2AX or 53BP1 expression showed a subset of triple negative tumors with poor prognosis. The expression of endogenous γ-H2AX in cancers is due to telomeres (protective structures that form the chromosome ends in eukaryotes) [57].
Cell having DNA damaged after duplication of DNA results in shortened telomeres after every cell cycle, so in precancerous event, there occurs shortening of telomeres and activation of telomerase, an enzyme necessary for telomere lengthening [58]. Telomere shortening in normal process is an action for replication arrest and replicative senescence, but in the absence of a telomeric structure, chromosome ends are not stable and are likely either to undergo degradation, combining with other chromosomes resulting in genomic instability or having DNA double-stranded breaks [58]. A good number of endogenous γ-H2AX foci present, which do not have actual double-stranded breaks, are in fact uncapped telomeres, but the DNA damage and phosphorylation of H2AX at these sites occur due to nonfunctioning of telomere [58]. Telomere-associated chromosomal rearrangements may lead to a tumor phenotype with the associated immortality and replicative potential without any barrier [58, 59].
4. PARP poly ADP ribose polymerase
4.1 PARP in normal cells
PARP1 (protein) repairs single-strand breaks of DNA in a normal cell when it is damaged or mutated, and the cell survives when its DNA repaired, but sometimes when the DNA repair mechanism fails, the cell undergoes suicidal apoptotic process, subsequently that the damaged DNA is not passed to progeny cells [60]. When DNA is damaged or requires repair, one of the proteins, which is involved in repairing damaged DNA, is poly (ADP ribose) polymerase 1, or PARP1 moves at the site of damage, gets activated, and enables various DNA repair proteins to repair the broken strand of DNA, but if the breaks in DNA are not repaired until DNA replication occurs, then the replication itself causes double-strand breaks to form [60]. Inhibition of PARP1 is done by number of drugs, which causes double-strand breaks. Tumors having BRCA1, BRCA2, or PALB2 mutations where repair is not done, the double-strand breaks cannot be repaired causing death of cells [61]. In normal cells, DNA replication is not as frequent as in cancer cells, and they also do not have mutated BRCA1 or BRCA2 but have homologous repair mechanism, which makes them to survive the inhibition of PARP [61]. There are cancer cells that lack the tumor suppressor PTEN and maybe sensitive to PARP inhibitors because of downregulation of Rad51, a critical homologous recombination component [33]. A study has shown that PARP inhibitors may also be effective against PTEN-defective tumors like prostate cancers. Most of the tumors are sensitive to PARP inhibitors [61].
4.2 PARP in breast cancer cells
DNA damage in dividing cells or tumor cells is caused mainly by the chemotherapeutic drugs and radiation therapy, but if PARP repairs the damage caused by these agents, the tumor cells survive and grow.
4.3 Inhibiting PARP: mechanism of action
The preclinical studies have shown that standard therapies alone are not as effective as in combination with PARP inhibitors; they are used in cancer cells, which make protein unable to function during chemotherapy, which results in apoptosis of the cell where DNA is unrepaired [61]. In inherent DNA repair defects, such as breast tumors with mutations in the DNA repair proteins BRCA1 or BRCA2, PARP inhibitors are effective as single agents, and they undergo an arrest of the cell cycle and apoptosis on exposure to PARP inhibitors, whereas cells with normal BRCA proteins survive and continue to grow [61]. It has also been predicted that cancer cells with BRCA1 or BRCA mutations are more sensitive to PARP inhibitors to undergo growth arrest and apoptosis than cells with normal BRCA1 or BRCA2 [61]. This occurs due to combination of PARP and loss of BRCA1 or BRCA2 function causing inactivation of two major forms of DNA repair [61], and the damaged cells are not able to maintain the integrity of their genome and become more prone to apoptosis [37, 38, 62].
Function of PARP inhibitors is to block PARP enzyme activity, which stops the repair of DNA damage and causes the cell death [62]. In one of a clinical study that has shown the PARP inhibitors localize PARP proteins near the site of DNA damage, which suggests its role in antitumor activity [62]. The PARP inhibitors are able to trap PARP proteins on damaged DNA, and this function varies among inhibitors, for example, PARP family of proteins in humans includes PARP1 and PARP2, which are used in binding of DNA and protein repair action [63]. DNA damage causes activation of these proteins; they recruit other proteins that are actually involved in repairing DNA [63]. In normal condition, PARP1 and PARP2 are released from DNA when the repair mechanism is in process [64]. The study shows that when they are attached to PARP inhibitors, PARP1 and PARP2 become trapped on DNA [38]. The trapped PARP-DNA complexes are more harmful to cells than the single-strand DNA breaks, which are not repaired that accumulate in the absence of PARP activity resulting in harmful action of PARP inhibitors [38, 62]. There may be two classes of PARP inhibitors, catalytic inhibitors that block PARP enzyme activity and do not trap PARP proteins on DNA and dual inhibitors that both inhibit PARP enzyme activity and act as PARP poison [38, 63, 64]. Various PARP inhibitors are used in clinical trials as shown in Table 1.
A number of studies have been done to see the toxicity with PARP inhibitors as monotherapy in tumors with homologous recombination defects and have been compared with chemotherapy [68]. Moreover, in some studies, combination of PARP inhibitors is used in combination with chemotherapy. PARP inhibitors as known can act as chemo sensitizing agents [68]. The resistance to chemotherapy drugs occurs when PARP repairs the DNA damage caused by these agents, for example, temozolomide is an alkylating agent, which causes DNA damage in which PARP inhibitors act as potential anticancer agents [68].
4.5 PARP in combination with radiotherapy
Radiotherapy causes DNA strand breaks leading to DNA damage and cell death; however, it kills all of the targeted cells, having side effects [68]. Combining radiation therapy with PARP inhibitors has been used to overcome the side effects as these inhibitors form double-strand breaks from the single-strand breaks generated by the radiotherapy in tumor tissue with BRCA1 or BRCA2 mutations. In such cases, the combinatorial therapy leads to better and efficient response with less dose of radiation [68].
5. ROS
Reactive oxygen species (ROS) are reactive molecules containing oxygen [69]. These molecules are formed when a chemical reaction takes place, for example, between oxygen ions and peroxides [69]. ROS plays an important role in cell signaling and homeostasis, due to environmental stress like UV or heat exposure, and ROS levels are increased, which damage cell structure and its function [69].
5.1 ROS in cancer
ROS being secondary messengers in cell signaling are required for various biological processes in normal cells; any dysfunction in redox balance results in human cancers [27]. ROS are increased mostly in cancer cells when oncogenes are activated, and there is lack of blood supply, which initiates progression and metastasis of cancer [27]. ROS levels decide the difference between tumor and nontumor cells [27]. Generation and elimination of ROS at the same time in the system are the expenditure to operate regulatory pathways in a normal physiological condition of cell, and this process is balanced by scavenging system [27]. When oxidative stress occurs, ROS are generated more, which cause carboxylation of cellular proteins, peroxidation of lipids, and DNA damage leading to dysfunction of cell resulting in carcinogenesis, while in cancer cells, ROS stress causes increased metabolism and mitochondrial dysfunction [27]. Consequently, ROS have dual function, on one side, it helps in survival of cancer cell, as cell cycle progression, which is regulated by growth factors via receptor tyrosine kinase activation and chronic inflammation, is regulated by ROS [62]. On an altered side, an increase in ROS level suppresses tumor growth by activating cell cycle inhibitors, which induces cell death and senescence by damaging macromolecules [62]. This dual mechanism helps in chemotherapy and radiotherapy, where cancer cells are killed by ROS stress. The cancer cells are able to differentiate between ROS as survival or apoptotic signal because of the dosage, duration, type, and site of ROS production [66]. ROS is used for survival of cancer cells in moderate level and kills cancer cells in excessive level [66]. Effects of ROS are maintained by cell metabolism by producing antioxidant molecules such as reduced glutathione (GSH) and thioredoxin (TRX), which depend on the reducing power of NADPH to maintain their function (reference) [27]. Sometimes tumor cells overproduce ROS because the NADPH oxidase is regulated by the GTPase Rac1, which is a downstream of proto-oncogene Ras [27]. ROS when associated with cancer activate various transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B cells—NF-κB, activator protein-1—AP-1, hypoxia-inducible factor-1α, and signal transducer and activator of transcription 3—STAT3, which cause protein expression for inflammation, cell transformation, tumor cell survival and proliferation and invasion, angiogenesis, and metastasis (reference). ROS also control the expression of different tumor suppressor genes such as p53, retinoblastoma gene (Rb), and phosphatase and tensin homolog (PTEN) [70, 71, 72, 73].
The several causes for oxidative stress in breast cancer cells are as follows:
Thymidine phosphorylase induction in cancer cells is caused by oxidative stress, an enzyme that is overexpressed in breast cancer. Thymidine phosphorylase catabolizes thymidine to thymine and 2-deoxy-D-ribose-1-phosphate, which is a very powerful reducing sugar that rapidly glycates proteins, generating oxygen radicals within the cancer cell [74].
Glucose deprivation and hypoxia is caused by continuously usage of blood supply which causes increased cellular oxidative stress in MCF-7 breast cancer cell line but does not increase in nontransformed cell line, reason being glucose deprivation depletes intracellular pyruvate in breast cancer cell, which prevents the decomposition of endogenous oxygen radicals [75]. Study done [76] supports that breast tumor increases its blood supply, leading to glucose deprivation and hypoxia thus causing glucose deprivation, which rapidly induces cellular oxidative stress within the MCF-7 breast carcinoma cell line, although it does not cause oxidative stress in nontransformed cell lines [75]. Cancer cells like breast cancer cells cause increase in blood vessel development (angiogenesis process), where blood flow causes hypoxia followed by reperfusion, which leads to myocardial infarction leading to generation of ROS which leads to oxidative stress in breast cancer [75].
Breast tumors are accompanied by macrophage population [75]. Oxygen radicals are produced by macrophages; it causes oxidative stress in murine mammary tumor cells. Also, tumor necrosis factor is secreted by macrophages, which also cause cellular oxidative stress [67, 77].
5.2 Effects of ROS in breast cancer
Increase in mutation rate and tumor progression is caused mainly by ROS in which oxygen radicals cause DNA damage, which result in strand breaks, alterations in guanine and thymine bases, and sister chromatid exchanges [78]. ROS lead to inactivation of tumor suppressor genes in tumor cells and increase expression of proto-oncogenes; thus, genetic instability due to persistent oxidative stress in cancer cell will increase malignancy of the tumor [79]. In vitro ROS cause initiation of growth sensing signaling pathways due to cell proliferation in response to hydrogen peroxide because of activation of mitogen-activated protein kinases (MAPKs), like HeLa cells when treated with hydrogen peroxide lead to activation of all three MAPK pathways, extracellular signal-related protein kinase, c-Jun amino-terminal kinase, and stress-activated protein kinase and p38 [79]. Hyper-phosphorylation of c-Jun by oxidative stress activates activator protein-1 in MCF-7 breast cancer cells, which stimulates proliferation [80]. Multidrug-resistant human breast carcinoma cells lead to activation of extracellular signal-related protein kinase-2 when stressed by glucose deprivation [76]. ROS may also cause stimulation of mitosis by MAPK-independent mechanisms. Oncogenic Ras causes ROS production by activating Rac1 and NADPH-oxidase. It has been also seen that in Ras-transformed human fibroblasts, ROS control cell cycle progression without the activation of MAPK pathways [81, 82].
5.3 Resistance to therapy
Apoptosis is caused by oxidative stress, which is induced depending on p53 in both mouse and human cells [83]. Resistance to apoptosis is caused by persistent oxidative stress [84], whereas the resistant to cytolysis by hydrogen peroxide may be explained by an upregulation of anti-ROS mechanism in cancer cells. Hydrogen peroxide activates anti-apoptotic Akt (protein kinase B) leading response to chronic oxidative stress that can be used for anticancer therapy though in radiotherapy, photodynamic therapy, and other chemotherapies generating oxygen radicals showing antitumor activity [85]. This is due to the induction of tumor cell apoptosis in response to oxidative stress and oxygen radical prompted DNA damage [85]. This results in persistent oxidative stress within carcinoma cells causes resistance to therapy that is further increased by oxygen radicals leading to an increasing carcinoma cell expression of P-glycoprotein, the multidrug-resistance efflux pump [86].
Angiogenesis, which may be one of the reasons for oxidative stress, leads to tumor growth in blood borne metastasis of breast tumor, where oxygen radicals cause tumor migration causing increased risk of invasion and metastasis by activation of p38 MAPK and subsequent phosphorylation of heat shock protein-27 by p38 MAPK causing changes in actin dynamics [46, 79]. Studies have shown that phosphorylated heat shock protein-27 promotes the migration of MDA-MB-231 breast cancer cells on laminin-5 in vitro [41]. Oxidative stress in breast tumors causes invasion and metastasis by activating MMPs as well as by inhibiting antiproteases. MMP-2 as gelatinase has a major role in breast cancer invasion and metastasis; once its levels are high, there is a poor prognosis in breast cancer patients [87]. Subsequently, MMP-2 is seen more in malignant than in benign breast tumors; therefore, it is ROS, which also activate MMP-2 due to reaction of oxygen radicals with thiol groups within MMP-2 [88]. Oxygen radicals inactivate protease inhibitors, such as α1-proteinase inhibitor and plasminogen activator by oxidation of methionine residues at their active sites [65], leading to protease activation, which increase invasion and metastasis processes, for example, plasminogen activator causes metastasis [65].
Cancer cells synthesizing ROS at a higher level in vitro and tumors in vivo are under persistent oxidative stress, as oxygen radicals lead to a poorer prognosis, antioxidants can be used for therapeutic role in breast cancer [89]. Various research studies have shown that human melanoma cells were transfected with cDNA encoding the antioxidant enzyme manganese superoxide dismutase leading to suppression of malignancy; cells not only lost their ability to form colonies on soft agar but also no longer formed tumors in nude mice [89]. Various anticancer therapies are there, which add to the oxidative stress within breast cancer such as chemotherapeutic agent’s doxorubicin, mitomycin C, etoposide, and cisplatin, which are superoxide generating agents [85], radiotherapy, and photodynamic therapy, which generate oxygen radicals within the carcinoma cell, and anti-estrogen tamoxifen used in breast cancer therapy also induces oxidative stress within cancer cells in vitro [90]. Conversion of breast tumors to a tamoxifen-resistant phenotype that has been seen is associated with a progressive shift toward a pro-oxidant environment of cells as a result of oxidative stress [90].
6. P53
P53 protein, a tumor protein present in humans, which is encoded by the TP53 gene (tumor suppressor gene), functions to inhibit proliferation of cells and regulates cell cycle, thereby preventing cancer, also called as the guardian of the genome as it maintains the stability in a cellular process preventing genetic mutation, under normal cellular phenomenon the p53 signaling pathway is in static mode, whereas its activation occurs when there is a cellular stresses like DNA damage or oncogene activation [91, 92]. Post-translational modifications activate P53 protein for DNA binding, transactivating downstream effector genes whose activation depends on the nature of stress and its extent. After oxidative stress transcriptional coactivators, for example, apoptosis stimulating protein of p53 and BRCA1 promotes various cellular processes like apoptosis, other components of signaling pathway which are targeted for genetic and epigenetic changes in breast cancer, for example, activation of MDM2 which acts as a negative feedback regulator of the pathway by promoting the degradation of p53 [93].
6.1 P53 mutations in breast cancer
p53 being activator of apoptosis or cell cycle arrest is generated upon DNA damage, or cellular stress has a major role in cancer as it stimulates genomic stability and anti-angiogenic effects, manages tumor inflammation and immune response, and represses metastases [94]. TP53 is mutated mostly in 50% of all human cancers and in 20–30% of breast cancers with more than 15,000 different mutations, which makes P53 as a potential biomarker for breast cancer [94].
In one of a clinical study, it was studied that in premenopausal women, p53 mutation is associated with ER and PR tumors, but in postmenopausal women having breast cancer, the presence of a p53 mutation is associated with higher body mass index (BMI), higher-grade, and poorly differentiated tumors, so women having tumors as well as p53 mutations had a 2.4-fold increased risk of dying from their disease [53]. In an additional clinical study, it has been shown that TP53 mutated noninflammatory locally advanced breast carcinomas respond to doxorubicin-cyclophosphamide chemotherapy unlike TP53 wild-type tumors, due to senescence in TP53 wild-type tumor cell and in MMTV-Wnt1 mammary tumors, growth arrest and senescent phenotype were stimulated in TP53 WT tumors following doxorubicin treatment, and there was no apoptosis while the absence of arrest in mutant tumors caused aberrant mitosis, cell death, and a better clinical response [53, 95]. In ER-positive breast tumors, ER represses the p53-mediated apoptotic response induced by DNA damage, but in ER-negative TP53 mutated breast cancers, accumulation of genetic abnormalities may lead to mitotic catastrophe and better response [95].
6.2 P53 and chemotherapy
Previous clinical studies done on breast cancer patients [96] have seen that ER (+) tumors (mostly TP53 wild type) are mostly resistant to chemotherapy, while ER (−) tumors (mostly a TP53 mutated) are more chemo sensitive, but in another study, it was found that there was no association shown in sensitivity to classical doses of taxane-based therapy and mutated TP53 in breast tumor [97]. TP53 wild-type tumor cells in human breast xenograft models have the presence of senescence in breast cancers in response to the treatment [95] senescence induction and cell cycle arrest in TP53 wild type tumors showed tumor proliferation after the end of treatment while genetic abnormalities and mitotic catastrophe would occur with further response to treatment in TP53 mutated tumors, which was also seen in MMTV-Wnt1 mammary tumors [95]. It has also been seen that growth arrest and senescent phenotype and no apoptosis were induced in TP53 wild-type tumors following doxorubicin treatment, while lack of arrest in R-172-H mutant tumors resulted in aberrant mitoses, cell death, and a better clinical response; wild-type tumors or mutant tumors, which were having a wild-type TP53 allele, did not show apoptosis and did not lose any volume as did TP53 mutant tumors [98]. In ER (+) breast cancers, it was shown that there is a functional interplay between p53 and ER on a genome wide scale and that ER represses the p53-mediated apoptotic response induced by DNA damage, and distinct TP53 gene signatures are also needed to evaluate prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers [74].
Thus, these clinical findings provide a way how to study p53-mediated response to dose-dense doxorubicin-cyclophosphamide chemotherapy in breast carcinomas in ER (+) TP53 wild-type breast tumors and that ER-induced inhibition of p53 apoptotic response would result in tumor cell senescence and resistance to treatment. However, in ER (−) TP53 mutated breast carcinomas, mostly in those having lost both TP53 alleles, there is an increase in genetic abnormalities that lead to mitotic catastrophe and better response [74].
6.3 P53 and ROS signaling
p53, a tumor suppressor protein being redox active transcription factor, organizes and directs cell function during various stresses that lead to genomic instability, on the other hand, reactive oxygen species (ROS) are products or byproducts generated by cells, which function either as signaling molecules or as cell toxicants (reference). Cellular concentration and distribution of p53 have a different cellular function as ROS act as both up-stream signal that causes p53 activation and downstream factor that results in apoptosis [99], subsequently if ROS level is increased due to oxidative stress in cancer cell, then p53 level may be increased to maintain its stability in the environment [99]. A balance is maintained in cellular concentration between oxidant and antioxidant molecules in normal cells, but when the oxidant part increases or when a disruption of redox signaling occurs, oxidative stress is caused in a redox reaction in the system, which results in damage to DNA, proteins, and lipids through oxidative modification resulting in number of diseases and chemotherapeutic cytotoxicity [15].
The genomic stability is maintained by tumor suppressor protein p53, but when there is a cellular stress like disruption of redox signals, which leads to damage DNA, proteins, and lipids. This tumor suppressor gene maintains transcription of various genes and directs cell for cell cycle arrest, senescence or apoptosis through various activation of target genes, many effector molecules like proteins, noncoding RNAs, for example, myc, Hcas or CSE1L, Hzf and miR-34 which help in selecting transactivation of p53 target genes leading to various cellular responses comes into play [85]. Thus, this oxidative stress is associated with p53-dependent cell cycle arrest, DNA repair, and apoptosis, but a clear understanding of the mechanisms of the interactions between ROS and p53 is still elusive [100].
In unstressed cell or normal cell, P53 has a small half-life and is present in low levels by continuous ubiquitination by Mdm2 COP1 (constitutively photomorphogenic 1) and Pirh2 (p53-induced protein with a RING-H2 domain) and derogation by 26S proteasome, where the physiological levels of p53 have different effects on cellular redox potential either it regulates the pro-oxidant and antioxidant genes or it modulates the cellular metabolism [86, 101].
6.4 Levels of p53 and ROS
Overexpression of p53 transactivates a series of p53-induced genes (PIGs) in which many of these PIGs encode redox active proteins including two ROS-generating enzymes, NQO1-quinone oxido-reductase, PIG3, and proline oxidase (POX, PIG6). The upregulation of these pro-oxidant enzymes will lead to oxidative stress and apoptosis [102, 103]. The pro-oxidant genes, which are upregulated, are BAX, PUMA, and p66shc in which BAX and PUMA stimulate uncoupling of mitochondria, which result in ROS generation from a less efficient electron transport chain, and P66shc is a downstream target of p53, which is present in cytoplasm and is translocated into mitochondria by prolyl isomerase 1 (Pin1) and mitochondrial heat shock protein (mtHsp 70), and pro-apoptotic stimulation of p66shc oxidizes cytochrome c, which produces H2O2 and opens mitochondrial permeability transition pore initiating apoptosis, and upregulation of these pro-oxidant enzymes leads to oxidative stress and consequently to apoptosis [102, 103]. More genes have been added to the list of p53-induced pro-oxidant genes, which include BAX, PUMA, and p66Shc of which BAX and PUMA can induce uncoupling of mitochondria, resulting in ROS being generated from a less efficient electron transport chain (ETC) [74, 104]. P53 has a downstream target known as p66Shc, which predominantly exists in cytoplasm and is translocated into mitochondria with the help of prolyl isomerase 1 (Pin1) and mitochondrial heat shock protein 70 (mtHsp 70) [105, 106].
Oxidative stress is caused by suppression of antioxidant genes by p53, which increases cellular ROS, for example, MnSOD (manganese superoxide dismutase) is suppressed at the promoter level by p53 activation or overexpression [107].
6.5 Redox regulation of p53
The oxidative stress caused by ROS is related to various p53-mediated cell processes like cell cycle arrest, DNA repair, and apoptosis like increase in generation of ROS in mitochondria when treated with chemotherapeutic agent’s results in apoptosis, while oxidative stress in the nucleus causes cells to p53-dependent DNA repair [86, 92]. A number of pathways operating to induce redox and p53 signaling select various p53 target genes that decide the final fate of the cell have been found significant in studies going on cisplatin and ginkgo bilobalide resulted in chemotherapeutics-induced ROS increase C-myc [108]. As soon as C-myc levels increase, it causes suppression of p53 transactivation of p21Cip1 blocking cell cycle arrest but does not affect p53-transactivation of the pro-apoptosis gene PUMA leading to apoptosis [108]. The mechanism acts in a same manner as in pathogenic bacterium Pseudomonas aeruginosa induced cell death having azurin, a copper-containing redox protein excreted by Pseudomonas aeruginosa that binds to p53 and transactivates pro-apoptosis protein Bax resulting in apoptosis [108].
6.6 Redox modification
p53-mediated ROS generation is the most important cellular concentration and subcellular localization function as P53 is a redox sensitive protein, which undergoes redox modification and decides the cell fate on the basis of p53 target genes, and the other factors such as cell type, stress, and intensity of stimuli give an insight into the interaction between ROS and p53 [92, 95].
7. P38-MAP kinase
Response to extracellular stimuli is managed and regulated by intracellular signaling pathways by mitogen-activated protein (MAP) kinase pathways whose members are responsible for signaling cascades, mammalian p38s responses, inflammatory cytokines (TNF-& IL-1), growth factors (CSF-1), ultraviolet irradiation, heat shock, osmotic shock, function in cell differentiation, apoptosis, and autophagy [109]. In general, there are four MAP kinase family subgroups, namely extracellular signal-regulated kinases (ERKs), c-jun N-terminal or stress-activated protein kinases (JNK/SAPK), ERK/big MAP kinase 1 (BMK1), and the p38 group of protein kinases [110]. p38 (p38), a 38-kDa protein when phosphorylated by tyrosine as a responsive protein to LPS stimulation (Han et al. 1993) and its kinases are divided by Thr-Gly-Tyr (TGY) dual phosphorylation motif residues in a TXY (where X is Glu, Pro and Gly in ERKs, JNKs and p38 MAPKs) activation motif by a dual specificity, activation of p38 is not only due to responsive nature on stimulus, but on cell type as well., Insulin signaling is reported to activate p38 in 3T3-L1 adipocytes but downregulates p38 in chick forebrain neuron cells [110].
7.1 p38 in the cell cycle
p38 has been studied in G1, G2, and M phases of the cell cycle [30]. p38 MAPK controls both the G2/M and G1/S cell cycle checkpoint in retort to cellular stress corresponding to DNA damage [30]. It facilitates the cell survival processes and initiation/maintenance of cell cycle checkpoints in retort to particular stimuli [30].
7.2 p38 in senescence and tumor suppression
A number of studies have provided evidence of p38 role in tumorigenesis and senescence [28], when there is a loss of senescence in tumor cells, it has been found that its activation may be decreased in tumors and that its pathway units such as MKK3 and MKK6 are lost resulting in increased proliferation [111].
7.3 p38 role in breast cancer
p38 MAPK in survival of tumor cells functions independently of DNA damage and supplements to metastasis, but this effect is indirectly regulated by p38 MAPK through the mediation of factors responsible for survival or migration of cells, for example, basal stimulation of p38 MAPK in B-cell chronic lymphocytic leukemia (B-CLL) is required for the MMP-9 metalloprotease for survival of these cells grown in the presence of stroma cells [112]. However, in vivo studies found that the decreased basal as well as TGFβ1-induced MMP-9 activity in breast cancer cells cause inhibition of p38 MAPK pathway by genetic regulators and pharmacological compounds causing decreased bone metastases [113].
In cell division and cell survival, p38 is studied at checkpoint control [113]. Role of p38 in invasiveness in cultured cell has been seen, which shows that phospho-p38 level is increased in cultured invasive breast cancer cells [95, 114]; increased expression of P38 MAPK in breast cancer has been found in relation to poor prognosis and in invasiveness and metastasis [115]. Overexpression of phosphorylated-P38 MAPK has been seen in ~20% of primary breast carcinomas or in relation to HER2 amplification and tamoxifen resistance and is a potential prognostic marker in breast cancer [116]. Therefore, the role of P38 MAPK in breast cancer cell proliferation remains a subject of study as it has dual function in survival and proliferation depending on the expression of mutant TP53 being present in most ER-breast tumors to develop P38 MAPK inhibitors for the treatment of TP53-mutated, ER-breast cancers, it is expressed at a higher level in ER+ in comparison with ER tumors without post-transductional activation as there was no change in the phosphorylation rate of P38 MAPK [116].
8. Role of tamoxifen resistance in breast cancer
A number of studies have reported the role of P38 MAPK in the resistance of ER+ breast tumors to endocrine therapy [117] and its relation between activated P38 MAPK levels and tamoxifen resistance [114, 118]. It has been reported that P38 MAPK leads to increased ER agonist activity through increased phosphorylation of ER and increased ER signaling through coactivator regulation [76]. There is switch in estrogen receptor signaling from its classical pathway to the AP1-dependent nonclassical pathway upon activation of MAPK by anti-estrogens apart from ER being their main target; thus, the activation of P38 MAPK can reduce the cellular response to endocrine therapy, which has been reported as a biomarker for resistance to endocrine therapy, and its detailed study of expression and its activation in breast tumors may provide a new approach to the resistance of breast cancer to endocrine therapy; also it has been reported that increased phospho-p38 levels have been associated with high expression of EGFR and ErbB2 in tamoxifen-resistant xenografts, where it acts to support nuclear functions of ER [76]. In matched primary and recurrent tamoxifen-resistant tumors (and a parallel study of a mouse xenograft in tamoxifen resistance), a link between phospho-p38 and increased ErbB2 with tamoxifen resistance was found [64, 69, 119, 120]. The graphic illustration of the pathway is displayed in Figure 1.
Figure 1.
Signalling pathway affecting estrogen receptor (ER) causing increase in EGFR level leading to cell proliferation during tamoxifen resistivity. P53 is increased during resistance and controls p21 function as well. ROS level is increased causing cell proliferation which in turn decreases Hsp27 and MAPK-P38 activity during stress lead by tamoxifen resistance.
Acknowledgments
The authors acknowledge Sheri Kashmir Institute of Medical Sciences for academic support.
Conflict of interest
The authors declare no conflict of interest.
\n',keywords:"cell cycle, breast cancer, drug resistance, tumor suppressor genes, oncogenes",chapterPDFUrl:"https://cdn.intechopen.com/pdfs/72259.pdf",chapterXML:"https://mts.intechopen.com/source/xml/72259.xml",downloadPdfUrl:"/chapter/pdf-download/72259",previewPdfUrl:"/chapter/pdf-preview/72259",totalDownloads:688,totalViews:0,totalCrossrefCites:0,dateSubmitted:"January 8th 2020",dateReviewed:"April 16th 2020",datePrePublished:"May 20th 2020",datePublished:"July 8th 2020",dateFinished:"May 20th 2020",readingETA:"0",abstract:"Cell cycle progression is driven by the sequential activation of a family of cyclin-dependent kinases (CDKs), which phosphorylate and activate proteins that execute events critical to cell cycle progression. Cell cycle checkpoints are scrutiny points that display the order, integrity, and fidelity of the major proceedings of the cell cycle. These comprise development to the correct cell size, the replication, integrity of the chromosomes, and their precise separation at mitosis. Many of these mechanisms are prehistoric in origin and highly preserved and hence have been deeply well versed by studies in model organisms such as the yeasts as well as in higher organisms. These molecular mechanisms switch alternative cell fates with substantial impact on tumor suppression. In the present study, we have explained different checkpoint pathways and the consequences of their dysfunction on cell fate in cancer.",reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/72259",risUrl:"/chapter/ris/72259",signatures:"Shazia Ali, Mohd Ishaq Dar, Rafiq A. Rather and Dil Afroze",book:{id:"8207",type:"book",title:"Breast Cancer Biology",subtitle:null,fullTitle:"Breast Cancer Biology",slug:"breast-cancer-biology",publishedDate:"July 8th 2020",bookSignature:"Dil Afroze, Bilal Rah, Shazia Ali, Faheem Shehjar, Mohd Ishaq Dar, Shailender S. Chauhan and Natasha Thakur",coverURL:"https://cdn.intechopen.com/books/images_new/8207.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",isbn:"978-1-78923-962-1",printIsbn:"978-1-78923-961-4",pdfIsbn:"978-1-78985-883-9",isAvailableForWebshopOrdering:!0,editors:[{id:"244441",title:"Prof.",name:"Dil",middleName:null,surname:"Afroze",slug:"dil-afroze",fullName:"Dil Afroze"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"244441",title:"Prof.",name:"Dil",middleName:null,surname:"Afroze",fullName:"Dil Afroze",slug:"dil-afroze",email:"afrozedil@gmail.com",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/244441/images/system/244441.jpeg",institution:{name:"Sher-i-Kashmir Institute of Medical Sciences",institutionURL:null,country:{name:"India"}}},{id:"249300",title:"Dr.",name:"Shazia",middleName:null,surname:"Ali",fullName:"Shazia Ali",slug:"shazia-ali",email:"w.shazia@gmail.com",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/249300/images/system/249300.jpg",institution:null}],sections:[{id:"sec_1",title:"1. Introduction",level:"1"},{id:"sec_2",title:"2. Drug resistance",level:"1"},{id:"sec_2_2",title:"2.1 Cell cycle regulation in tamoxifen-resistant breast cancers",level:"2"},{id:"sec_4",title:"3. Genes associated with breast cancer development and its progression",level:"1"},{id:"sec_4_2",title:"3.1 EGFR",level:"2"},{id:"sec_5_2",title:"3.2 HER2",level:"2"},{id:"sec_6_2",title:"3.3 HSP27",level:"2"},{id:"sec_7_2",title:"3.4 HSP27 in breast cancer",level:"2"},{id:"sec_8_2",title:"3.5 H2AX (H2A histone family, member X)",level:"2"},{id:"sec_10",title:"4. PARP poly ADP ribose polymerase",level:"1"},{id:"sec_10_2",title:"4.1 PARP in normal cells",level:"2"},{id:"sec_11_2",title:"4.2 PARP in breast cancer cells",level:"2"},{id:"sec_12_2",title:"4.3 Inhibiting PARP: mechanism of action",level:"2"},{id:"sec_13_2",title:"4.4 PARP in combination with chemotherapy",level:"2"},{id:"sec_14_2",title:"4.5 PARP in combination with radiotherapy",level:"2"},{id:"sec_16",title:"5. ROS",level:"1"},{id:"sec_16_2",title:"5.1 ROS in cancer",level:"2"},{id:"sec_17_2",title:"5.2 Effects of ROS in breast cancer",level:"2"},{id:"sec_18_2",title:"5.3 Resistance to therapy",level:"2"},{id:"sec_20",title:"6. P53",level:"1"},{id:"sec_20_2",title:"6.1 P53 mutations in breast cancer",level:"2"},{id:"sec_21_2",title:"6.2 P53 and chemotherapy",level:"2"},{id:"sec_22_2",title:"6.3 P53 and ROS signaling",level:"2"},{id:"sec_23_2",title:"6.4 Levels of p53 and ROS",level:"2"},{id:"sec_24_2",title:"6.5 Redox regulation of p53",level:"2"},{id:"sec_25_2",title:"6.6 Redox modification",level:"2"},{id:"sec_27",title:"7. P38-MAP kinase",level:"1"},{id:"sec_27_2",title:"7.1 p38 in the cell cycle",level:"2"},{id:"sec_28_2",title:"7.2 p38 in senescence and tumor suppression",level:"2"},{id:"sec_29_2",title:"7.3 p38 role in breast cancer",level:"2"},{id:"sec_31",title:"8. Role of tamoxifen resistance in breast cancer",level:"1"},{id:"sec_32",title:"Acknowledgments",level:"1"},{id:"sec_35",title:"Conflict of interest",level:"1"}],chapterReferences:[{id:"B1",body:'Qin C et al. Estrogen up-regulation of p53Gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of a nuclear factor ΰB/CCAAT-binding transcription factor-1 complex. Molecular Endocrinology. 2002;16(8):1793-1809'},{id:"B2",body:'Mendoza-Carrera F et al. Influence of CRP, IL6, and TNFA gene polymorphisms on circulating levels of C-reactive protein in Mexican adolescents. Archives of Medical Research;41(6):472-477'},{id:"B3",body:'Tonetti DA et al. Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 2003;87(1):47-55'},{id:"B4",body:'Alexis RB, Heldt FS, Zhang T, Bakal C, Bela Nova K, et al. Cell Systems. 2016;2:27-37'},{id:"B5",body:'Marcos MPI, González-Sarmiento R, Laso FJ. Common polymorphisms in interleukin genes (IL4, IL6, IL8 and IL12) are not associated with alcoholic liver disease or alcoholism in Spanish men. Cytokine. 2009;45:158-161'},{id:"B6",body:'Hall JM. The estrogen receptor Â-isoform (ERÂ) of the human estrogen receptor modulates ER transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology. 1999;140(12):5566-5578'},{id:"B7",body:'Sherr JC. G1 phase progression: Cycling on cue. Cell. 1994;79(4):551-555'},{id:"B8",body:'Baldin VLJ, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes & Development. 1993;7(5):812-821'},{id:"B9",body:'Heinrich PC et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical Journal. 2003;374(1):1-20'},{id:"B10",body:'JR N. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science. 1992;258(5081):422-429'},{id:"B11",body:'Mardo Kõivomägi EV, Venta R, Iofik A, Lepiku M, Morgan DO, Loog M. Dynamics of Cdk1 substrate specificity during the cell cycle. Molecular Cell. 2011;42(5-4):610-623'},{id:"B12",body:'Neuhold Barbara Wold L. HLH forced dimers: Tethering MyoD to E47 generates a dominant positive myogenic factor insulated from negative regulation by Id. Cell. 1993;74(6):1033-1042'},{id:"B13",body:'Clarke R et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003;22(47):7316-7339'},{id:"B14",body:'Novak BTJ, Gyorffy B, Csikasz-Nagy A. Irreversible cell-cycle transitions are due to systems-level feedback. 2007;9(7):724-728'},{id:"B15",body:'Ali F, Hindley C, McDowell G, Deibler R, Jones A, Kirschner M, et al. Cell cycle-regulated multi-site phosphorylation of Neurogenin 2 coordinates cell cycling with differentiation during neurogenesis. 2011;138(9):4267-4277'},{id:"B16",body:'Aster VKAANFJ. Robbins and Cotran Pathologic Basis of Disease, Professional Edition. 8th ed. 2009'},{id:"B17",body:'Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: An overview. Cancers (Basel). 2014;6(3):1769-1792'},{id:"B18",body:'Pernas S, Sara M. Tolaney HER2-positive breast cancer: New therapeutic frontiers and overcoming resistance. Therapeutic Advances in Medical Oncology. 2019;11:1758835919833519'},{id:"B19",body:'Caponero CHBCSJVR. What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Annals of Oncology. 2009;20(7)'},{id:"B20",body:'Stuart Johnson DNG, Louie TJ, Ruiz NM, Gorbach SL. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea. Antimicrobial Agents and Chemotherapy. 2012;56(8):4043-4045'},{id:"B21",body:'Archer SG et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. British Journal of Cancer. 1995;72(5):1259-1266'},{id:"B22",body:'Varma H, Conrad SE. Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain. Oncogene. 2000;19(41):4746-4753'},{id:"B23",body:'Prall OWJ et al. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. Journal of Biological Chemistry. 1997;272(16):10882-10894'},{id:"B24",body:'Manna S, Holz MK. Tamoxifen action in ER-negative breast cancer. Signal Transduction Insights. 2016;5:1-7'},{id:"B25",body:'Ghayad SE et al. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. International Journal of Cancer;126(2):545-562'},{id:"B26",body:'Fan P et al. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor  out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Research. 2007;67(3):1352-1360'},{id:"B27",body:'Becker KA et al. Estrogen and progesterone regulate radiation-induced p53 activity in mammary epithelium through TGF-Î2-dependent pathways. Oncogene. 2005;24(42):6345-6353'},{id:"B28",body:'Ciardiello FTG. EGFR antagonists in cancer treatment. The New England Journal of Medicine. 2008;358(11):1160-1174'},{id:"B29",body:'Mitsudomi TMS, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. The Lancet Oncology. 2010;11(2):121-128'},{id:"B30",body:'Wang Z et al. Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66. Biochemical and Biophysical Research Communications. 2005;336(4):1023-1027'},{id:"B31",body:'Predicting response to endocrine therapy in breast cancer. Pharma. 1975;12(1):11'},{id:"B32",body:'Fernandez DCBR, Hewitt SM, Levin IW. Infrared spectroscopic imaging for histopathologic recognition. Nature Biotechnology. 2005;23(4):469-474'},{id:"B33",body:'Kaufman B et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. Journal of Clinical Oncology. 2009;27(33):5529-5537'},{id:"B34",body:'Hewitt SC, Couse JF, Korach KS. Estrogen receptor transcription and transactivation estrogen receptor knockout mice: What their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Research. 2000;2(5)'},{id:"B35",body:'Zakaria Z, Zulkifle MF, Hasan WANW, Azhari AK, Raub SHA, Eswaran J, et al. Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort. OncoTargets and Therapy. 2019;12:7749-7756'},{id:"B36",body:'Wang E, Jiang Z, Ben-David Y, et al. Molecular stratification within triple-negative breast cancer subtypes. Scientific Reports. 2019;9:19107'},{id:"B37",body:'Bergh J et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Medicine. 1995;1(10):1029-1034'},{id:"B38",body:'Keung MYT, Wu Y, Vadgam JV. PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers. Journal of Clinical Medicine. 2019;8(4):435'},{id:"B39",body:'Agostini L et al. NALP3 forms an IL-1Î-processing inflammasome with increased activity in muckle-Wells autoinflammatory disorder. Immunity. 2004;20(3):319-325'},{id:"B40",body:'Rogalla T et al. Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor α by phosphorylation. Journal of Biological Chemistry. 1999;274(27):18947-18956'},{id:"B41",body:'Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): Biomarker of disease and therapeutic target. Fibrogenesis & Tissue Repair. 2012;5:7'},{id:"B42",body:'Rust W et al. Heat shock protein 27 plays two distinct roles in controlling human breast cancer cell migration on Laminin-5. Molecular Cell Biology Research Communications. 1999;1(3):196-202'},{id:"B43",body:'Mehlen P et al. Large unphosphorylated aggregates as the active form of hsp27 which controls intracellular reactive oxygen species and glutathione levels and generates a protection against TNFα in NIH-3T3-ras cells. Biochemical and Biophysical Research Communications. 1997;241(1):187-192'},{id:"B44",body:'Charette SJ, Landry J. The interaction of HSP27 with Daxx identifies a potential regulatory role of HSP27 in Fas-induced apoptosis. Annals of the New York Academy of Sciences. 2006;926(1):126-131'},{id:"B45",body:'Cai D et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-Î2 and NF-ΰB. Nature Medicine. 2005;11(2):183-190'},{id:"B46",body:'Landry J, Huot J. 6. Regulation of actin dynamics by stress-activated protein kinase 2 (SAPK2)-dependent phosphorylation of heat-shock protein of 27 kDa (Hsp27). In: Cellular Responses to Stress. Princeton University Press'},{id:"B47",body:'Parcellier A et al. Small heat shock proteins HSP27 and αB-Crystallin: Cytoprotective and oncogenic functions. Antioxidants & Redox Signaling. 2005;7(3-4):404-413'},{id:"B48",body:'Abisambra JF, Jinwal UK, Jones JR, Blair LJ, Koren J, Dickey CA. Exploiting the diversity of the heat-shock protein family for primary and secondary tauopathy therapeutics. Current Neuropharmacology. 2011;9(4):623-631'},{id:"B49",body:'Ciocca DR, Calderwood SK. Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress & Chaperones. 2005;10(2):86'},{id:"B50",body:'Mallerstram E et al. Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray. BMC Cancer;10(1)'},{id:"B51",body:'Zhang D, Wong L, Koay ESC. Phosphorylation of Ser78 of Hsp27 correlated with HER-2/neu status and lymph node positivity in breast cancer. Molecular Cancer. 2007;6(1):52'},{id:"B52",body:'Chatterjee S, Burns TF. Targeting heat shock proteins in cancer: A promising therapeutic approach. International Journal of Molecular Sciences. 2017;18(9):1978'},{id:"B53",body:'Author index to volume 6. Current Molecular Medicine. 2007;7(1):1-4'},{id:"B54",body:'Day CP, James OFW. Steatohepatitis: A tale of two “hits”? Gastroenterology. 1998;114(4):842-845'},{id:"B55",body:'Bartkova JHZ, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;14(434):864-870'},{id:"B56",body:'Shibata AMD, Arvai AS, Perry J, Harding SM, Genois MM, Maity R, et al. DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities. Molecular Cell. 2014;9(53):7-18'},{id:"B57",body:'Nagelkerke KA, van Kuijk SJA, Sweep FCGJ, Nagtegaal ID, Hoogerbrugge N, Martens JWM, et al. Constitutive expression of γ-H2AX has prognostic relevance in triple negative. Breast Cancer. 2011;101(1):39-45'},{id:"B58",body:'Fagerholm RHB, Tommiska J, Aaltonen K, Vrtel R, Syrjäkoski K, Kallioniemi A, et al. NAD(P)H:quinone oxidoreductase 1 NQO1 2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nature Genetics. 2008;40(7):844-853'},{id:"B59",body:'Fardoun MM, Nassif J, Issa K, Baydoun E, Eid AH, A.i.A.n.C.a.L.i. Disclaimer, Raynaud’s phenomenon: A brief review of the underlying mechanisms. Frontiers in Pharmacology. 2016;7:438'},{id:"B60",body:'McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, et al. The quality of health care delivered to adults in the United States. The New England Journal of Medicine. 2003;348:2635-2645'},{id:"B61",body:'Buisson RDCA, Coulombe Y, Launay H, Cai H, Stasiak AZ, Stasiak A, et al. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nature Structural & Molecular Biology. 2010;17(10):1247-1254'},{id:"B62",body:'Murai JHS, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Research. 2012;1(72):5588-5599'},{id:"B63",body:'Gerratanaa L, Basilea D, et al. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treatment Reviews. 2018;68:102-110'},{id:"B64",body:'Wu N, Zhang J, Zhao J, Mu K, Zhang J, Jin Z, et al. The overview of breast cancer: Related signaling pathways, therapeutic targets precision medicine based on tumorigenic signaling pathways for triple negative breast cancer. 2018:4984-4996'},{id:"B65",body:'Swaim MW, Pizzo SV. Review: Methionine sulfoxide and the oxidative regulation of plasma proteinase inhibitors. Journal of Leukocyte Biology. 1988;43(4):365-379'},{id:"B66",body:'MG. PARP inhibitors stumble in breast cancer. Nature Biotechnology. 2011;29(5):373'},{id:"B67",body:'Claire Y, Wenham J, Claire PGC, Wenham YJ. The role of synovitis in osteoarthritis. Therapeutic Advances in Musculoskeletal Disease. 2001;6(10)'},{id:"B68",body:'Reilly NM, Novara L, Di Nicolantonio F, Bardelli A. Exploiting DNA repair defects in colorectal cancer. 2019;03'},{id:"B69",body:'Yu Z, Song YB, Cui Y, Fu AQ. Effects of AIF-1 inflammatory factors on the regulation of proliferation of breast cancer cells. Journal of Biological Regulators and Homeostatic Agents. 2019;33(4):1085-1095'},{id:"B70",body:'Takahashi KYS. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676'},{id:"B71",body:'Meyers CASJ, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial. Journal of Clinical Oncology. 2004;1(22):157-165'},{id:"B72",body:'Gupta SCPS, Aggarwal BB. Therapeutic roles of curcumin: Lessons learned from clinical trials. The AAPS Journal. 2013;15(1):195-218'},{id:"B73",body:'Aubrey BJ, Strasser A, Kelly GL. Tumor suppressor functions of the TP53 pathway. Cold Spring Harbor Perspectives in Medicine. 2016;6(5):a026062'},{id:"B74",body:'Bailey ST et al. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proceedings of the National Academy of Sciences;109(44):18060-18065'},{id:"B75",body:'Spitz DRSJ, Ridnour LA, Galoforo SS, Lee YJ. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? Annals of the New York Academy of Sciences. 2000;899:349-362'},{id:"B76",body:'Commentaire du Travail, de Lee YJ, et al. Endoscopy;47(11):1065'},{id:"B77",body:'Fraser-Brace V, County SJ, et al. International Law Reports. Cambridge University Press. pp. 217-233'},{id:"B78",body:'Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. Biochemical Journal. 1996;313(1):17-29'},{id:"B79",body:'Bose S et al. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene. 1998;17(1):123-127'},{id:"B80",body:'Schiff R. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clinical Cancer Research. 2004;10(1):331S-3336S'},{id:"B81",body:'Irani K et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 1997;275(5306):1649-1652'},{id:"B82",body:'Sarmiento-Salinas FL, Delgado-Magallón A, Montes-Alvarado JB, Ramírez-Ramírez D, Flores-Alonso JC, Cortés-Hernández P, et al. Breast cancer subtypes present a differential production of reactive oxygen species (ROS) and susceptibility to antioxidant treatment. Frontiers in Oncology. 2019;9:480'},{id:"B83",body:'Berger CE et al. p53, a target of estrogen receptor (ER), modulates DNA damage-induced growth suppression in ER-positive breast cancer cells. Journal of Biological Chemistry;287(36):30117-30127'},{id:"B84",body:'Casado P et al. Vincristine regulates the phosphorylation of the antiapoptotic protein HSP27 in breast cancer cells. Cancer Letters. 2007;247(2):273-282'},{id:"B85",body:'Kawahara N et al. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Hepatology Research. 1997;7(1):71-71'},{id:"B86",body:'Ziemann C et al. Reactive oxygen species participate in mdr1b mRNA and P-glycoprotein overexpression in primary rat hepatocyte cultures. Carcinogenesis. 1999;20(3):407-414'},{id:"B87",body:'Duffy MJ et al. Breast Cancer Research. 2000;2(4)'},{id:"B88",body:'Rajagopalan S et al. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. Journal of Clinical Investigation. 1996;98(11):2572-2579'},{id:"B89",body:'Church SL et al. Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proceedings of the National Academy of Sciences. 1993;90(7):3113-3117'},{id:"B90",body:'Ferlini C et al. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. British Journal of Cancer. 1998;79(2):257-263'},{id:"B91",body:'Ciribilli Y et al. The coordinated P53 and estrogen receptor cis-regulation at an FLT1 promoter SNP is specific to genotoxic stress and estrogenic compound. PLoS One;5(4):e10236'},{id:"B92",body:'Al-Madhoun AS et al. The interaction and cellular localization of HSP27 and ERÎ2 are modulated by 17Î2-estradiol and HSP27 phosphorylation. Molecular and Cellular Endocrinology. 2007;270(1-2):33-42'},{id:"B93",body:'Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cell. Cell Differentiation. 2019;26:199-212'},{id:"B94",body:'Petitjean A et al. Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Human Mutation. 2007;28(6):622-629'},{id:"B95",body:'Bertheau P et al. p53 in breast cancer subtypes and new insights into response to chemotherapy. The Breast;22:S27-S29'},{id:"B96",body:'Bunz FHP, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agent. The Journal of Clinical Investigation. 1999;104(3):263s-269s'},{id:"B97",body:'Lonning P et al. Breast cancer prognostication and prediction in the postgenomic era. Annals of Oncology. 2007;18(8):1293-1306'},{id:"B98",body:'Jackson TA et al. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Molecular Endocrinology. 1997;11(6):693-705'},{id:"B99",body:'Liu W et al. Disruption of estrogen receptor 1-p53 interaction in breast tumors: A novel mechanism underlying the anti-tumor effect of radiation therapy. Breast Cancer Research and Treatment. 2008;115(1):43-50'},{id:"B100",body:'Kanagasabai R et al. Forced expression of heat shock protein 27 (HSP27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in adriamycin-resistant human breast cancer cells. Journal of Biological Chemistry;286(38):33289-33300'},{id:"B101",body:'Dornan DWI, Shimizu H, Arnott D, Frantz GD, Dowd P, O’Rourke K, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature. 2004;6(429):86-92'},{id:"B102",body:'Polyak. Mathematical Programming. 1997;76:265'},{id:"B103",body:'Rivera A. Groundwater news. Natural Resources Canada/ESS/Scientific and Technical Publishing Services. 2005'},{id:"B104",body:'Sablina AA et al. The antioxidant function of the p53 tumor suppressor. Nature Medicine. 2005;11(12):1306-1313'},{id:"B105",body:'Trinei M et al. A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis. Oncogene. 2002;21(24):3872-3878'},{id:"B106",body:'Pinton P, Rizzuto R. p66Shc, oxidative stress and aging: Importing a lifespan determinant into mitochondria. Cell Cycle. 2008;7(3):304-308'},{id:"B107",body:'Drane P et al. Reciprocal down-regulation of p53 and SOD2 gene expression-implication in p53 mediated apoptosis. Oncogene. 2001;20(4):430-439'},{id:"B108",body:'Zhou R et al. A role for mitochondria in NLRP3 inflammasome activation. Nature;469(7329):221-225'},{id:"B109",body:'Banin S. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 1998;281(5383):1674-1677'},{id:"B110",body:'Tyler Zarubin QJ, New L, Han J. Identification of eight genes that are potentially involved in tamoxifensensitivity in breast cancer cells. Cell Research. 2005;15(6):439-446'},{id:"B111",body:'Brancho DTN, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, Kyuuma M, et al. Mechanism of p38 MAP kinase activation in vivo. Genes & Development. 2003;17(16):1969-1978'},{id:"B112",body:'White CPAE. Does control of mutant p53 by Mdm2 complicate cancer therapy. Genes & Development. 2008;22(10):1259-1264'},{id:"B113",body:'Wheeler TMSK, Lueck JD, Osborne RJ, Lin X, Dirksen RT, Thornton CA. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat R. Science. 2009;325(5938):336-339'},{id:"B114",body:'Massarweh S et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Research. 2008;68(3):826-833'},{id:"B115",body:'Smith LM et al. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999;18(44):6063-6070'},{id:"B116",body:'Cancello RHC, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes. 2005;54(8):2277-2286'},{id:"B117",body:'Martin ECES, Rhodes LV, Antoon JW, Fewell C, Zhu Y, Driver JL, et al. Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells. Molecular Carcinogenesis. 2014;53(1):38-48'},{id:"B118",body:'Gregory M, Gutierrez M, Chow JW, Tillman MD, McCoy SC, Castellano MV, et al. Resistance training improves gait kinematics in personswith multiple sclerosis. Archives of Physical Medicine and Rehabilitation. 2005;86'},{id:"B119",body:'Hommes DW, Peppelenbosch MP, van Deventer SJH. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut. 2003;52(1):144-151'},{id:"B120",body:'Soni S, Anand P, Padwad YS. PMAPKINAS E MAPKAPK2: The master regulator of RNA-binding proteins modulates transcript stability and tumor progression. Journal of Experimental & Clinical Cancer Research. 2019;38:121'}],footnotes:[],contributors:[{corresp:null,contributorFullName:"Shazia Ali",address:null,affiliation:'
Advanced Center for Human Genetics, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
Advanced Center for Human Genetics, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
'}],corrections:null},book:{id:"8207",type:"book",title:"Breast Cancer Biology",subtitle:null,fullTitle:"Breast Cancer Biology",slug:"breast-cancer-biology",publishedDate:"July 8th 2020",bookSignature:"Dil Afroze, Bilal Rah, Shazia Ali, Faheem Shehjar, Mohd Ishaq Dar, Shailender S. Chauhan and Natasha Thakur",coverURL:"https://cdn.intechopen.com/books/images_new/8207.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",isbn:"978-1-78923-962-1",printIsbn:"978-1-78923-961-4",pdfIsbn:"978-1-78985-883-9",isAvailableForWebshopOrdering:!0,editors:[{id:"244441",title:"Prof.",name:"Dil",middleName:null,surname:"Afroze",slug:"dil-afroze",fullName:"Dil Afroze"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},profile:{item:{id:"176861",title:"Dr.",name:"Anton",middleName:null,surname:"Nikiforov",email:"anton.nikiforov@ugent.be",fullName:"Anton Nikiforov",slug:"anton-nikiforov",position:null,biography:"Dr. Anton Nikiforov received the PhD degree in 2004 in the field of Physical Chemistry from the Russian Academy of Sciences. From year 2009 he works in Ghent University, the Department of Applied Physics, Research Unit of Plasma Technology (RUPT). Main research activity of Dr. A. Nikiforov is essentially experimental work that focuses on the physics, engineering and applications of non-equilibrium (“cold”) atmospheric pressure plasmas. On-going physical studies bear on plasma-surface interactions, on plasmas in liquids and on the advanced diagnostics in non-equilibrium discharges. His current research interests include plasma diagnostics and laser spectroscopy; plasma engineering of biomaterials and plasma-surface interactions.",institutionString:"University of Gent",profilePictureURL:"https://mts.intechopen.com/storage/users/176861/images/system/176861.png",totalCites:0,totalChapterViews:"0",outsideEditionCount:0,totalAuthoredChapters:"2",totalEditedBooks:"1",personalWebsiteURL:null,twitterURL:null,linkedinURL:null,institution:{name:"Ghent University",institutionURL:null,country:{name:"Belgium"}}},booksEdited:[{id:"7393",type:"book",slug:"atmospheric-pressure-plasma-from-diagnostics-to-applications",title:"Atmospheric Pressure Plasma",subtitle:"from Diagnostics to Applications",coverURL:"https://cdn.intechopen.com/books/images_new/7393.jpg",abstract:"Plasma as the fourth state of matter is an ionized gas consisting of both negative and positive ions, electrons, neutral atoms, radicals, and photons. In the last few decades, atmospheric-pressure plasmas have started to attract increasing attention from both scientists and industry due to a variety of potential applications. Because of increasing interest in the topic, the focus of this book is on providing engineers and scientists with a fundamental understanding of the physical and chemical properties of different atmospheric-pressure plasmas via plasma diagnostic techniques and their applications. The book has been organized into two parts. Part I focuses on the latest achievements in advanced diagnostics of different atmospheric-pressure plasmas. Part II deals with applications of different atmospheric-pressure plasmas.",editors:[{id:"176861",title:"Dr.",name:"Anton",surname:"Nikiforov",slug:"anton-nikiforov",fullName:"Anton Nikiforov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",title:"Edited Volume"}}],chaptersAuthored:[{id:"49655",title:"Electrical Discharge in Water Treatment Technology for Micropollutant Decomposition",slug:"electrical-discharge-in-water-treatment-technology-for-micropollutant-decomposition",abstract:"Hazardous micropollutants are increasingly detected worldwide in wastewater treatment plant effluent. As this indicates, their removal is insufficient by means of conventional modern water treatment techniques. In the search for a cost-effective solution, advanced oxidation processes have recently gained more attention since they are the most effective available techniques to decompose biorecalcitrant organics. As a main drawback, however, their energy costs are high up to now, preventing their implementation on large scale. For the specific case of water treatment by means of electrical discharge, further optimization is a complex task due to the wide variety in reactor design and materials, discharge types, and operational parameters. In this chapter, an extended overview is given on plasma reactor types, based on their design and materials. Influence of design and materials on energy efficiency is investigated, as well as the influence of operational parameters. The collected data can be used for the optimization of existing reactor types and for development of novel reactors.",signatures:"Patrick Vanraes, Anton Y. Nikiforov and Christophe Leys",authors:[{id:"49112",title:"Prof.",name:"Christophe",surname:"Leys",fullName:"Christophe Leys",slug:"christophe-leys",email:"christophe.leys@ugent.be"},{id:"176861",title:"Dr.",name:"Anton",surname:"Nikiforov",fullName:"Anton Nikiforov",slug:"anton-nikiforov",email:"anton.nikiforov@ugent.be"},{id:"176862",title:"Mr.",name:"Patrick",surname:"Vanraes",fullName:"Patrick Vanraes",slug:"patrick-vanraes",email:"Patrick.Vanraes@UGent.be"}],book:{id:"5093",title:"Plasma Science and Technology",slug:"plasma-science-and-technology-progress-in-physical-states-and-chemical-reactions",productType:{id:"1",title:"Edited Volume"}}},{id:"60920",title:"A Test Facility to Investigate Sheath Effects during Ion Cyclotron Resonance Heating",slug:"a-test-facility-to-investigate-sheath-effects-during-ion-cyclotron-resonance-heating",abstract:"Nuclear fusion is a promising candidate to supply energy for future generations. At the high temperatures needed for the nuclei to fuse, ions and electrons are no longer bound into atoms. Magnetic fields confine the resulting plasma. One of the heating methods is the ion cyclotron resonant absorption of waves emitted by an external Ion Cyclotron Radio Frequency (ICRF) antenna. The efficiency of ICRF heating is strongly affected by rectified RF electric fields at antenna and other in-vessel components (so-called ‘sheath effects’). The chapter presents an overview of ICRF principles. Attention is given to characterising the detrimental sheath effects through experiments on a dedicated test facility (IShTAR: Ion cyclotron Sheath Test ARrangement). IShTAR has a linear magnetic configuration and is equipped with an independent helicon plasma source. The configuration and capabilities of the test-bed and its diagnostics are described, as well as an analysis of the plasmas.",signatures:"Kristel Crombe, Rodolphe D’ Inca, Eric Faudot, Helmut Faugel, Ana\nKostic, Mariia Usoltceva, Jean-Marie Noterdaeme, Anton Nikiforov,\nHelmut Fuenfgelder, Stephane Heuraux, Jonathan Jacquot, Fabrice\nLouche, Roman Ochoukov, Ilya Shesterikov and Dirk Van Eester",authors:[{id:"176861",title:"Dr.",name:"Anton",surname:"Nikiforov",fullName:"Anton Nikiforov",slug:"anton-nikiforov",email:"anton.nikiforov@ugent.be"},{id:"237886",title:"Dr.",name:"Kristel",surname:"Crombe",fullName:"Kristel Crombe",slug:"kristel-crombe",email:"Kristel.Crombe@ugent.be"},{id:"248149",title:"Dr.",name:"R.",surname:"D' Inca",fullName:"R. D' Inca",slug:"r.-d'-inca",email:"anton-nik@ya.ru"},{id:"248150",title:"Dr.",name:"E.",surname:"Faudot",fullName:"E. Faudot",slug:"e.-faudot",email:"anton-nik@yandex.ru"},{id:"248152",title:"Dr.",name:"H.",surname:"Faugel",fullName:"H. Faugel",slug:"h.-faugel",email:"helmut.faugel@ipp.mpg.de"},{id:"248153",title:"Ms.",name:"A.",surname:"Kostic",fullName:"A. Kostic",slug:"a.-kostic",email:"Ana.Kostic@UGent.be"},{id:"248154",title:"Ms.",name:"M.",surname:"Usoltceva",fullName:"M. Usoltceva",slug:"m.-usoltceva",email:"Mariia.Usoltceva@UGent.be"},{id:"248155",title:"Prof.",name:"J.-M.",surname:"Noterdaeme",fullName:"J.-M. Noterdaeme",slug:"j.-m.-noterdaeme",email:"noterdaeme@ipp.mpg.de"},{id:"248750",title:"Dr.Ing.",name:"Helmut",surname:"Fuenfgelder",fullName:"Helmut Fuenfgelder",slug:"helmut-fuenfgelder",email:"helmut.fuenfgelder@ipp.mpg.de"},{id:"248751",title:"Prof.",name:"Stephane",surname:"Heuraux",fullName:"Stephane Heuraux",slug:"stephane-heuraux",email:"stephane.heuraux@univ-lorraine.fr"},{id:"248752",title:"Dr.",name:"Jonathan",surname:"Jacquot",fullName:"Jonathan Jacquot",slug:"jonathan-jacquot",email:"jonathan.jacquot@ipp.mpg.de"},{id:"248754",title:"Dr.",name:"Fabrice",surname:"Louche",fullName:"Fabrice Louche",slug:"fabrice-louche",email:"fabrice.louche@rma.ac.be"},{id:"248755",title:"Dr.",name:"Roman",surname:"Ochoukov",fullName:"Roman Ochoukov",slug:"roman-ochoukov",email:"Roman.Ochoukov@ipp.mpg.de"},{id:"248756",title:"Dr.",name:"Ilya",surname:"Shesterikov",fullName:"Ilya Shesterikov",slug:"ilya-shesterikov",email:"ilys@ipp.mpg.de"},{id:"248757",title:"Dr.",name:"Dirk",surname:"Van Eester",fullName:"Dirk Van Eester",slug:"dirk-van-eester",email:"d.van.eester@fz-juelich.de"}],book:{id:"6735",title:"Plasma Science and Technology",slug:"plasma-science-and-technology-basic-fundamentals-and-modern-applications",productType:{id:"1",title:"Edited Volume"}}}],collaborators:[{id:"48930",title:"Dr.",name:"Barbara",surname:"Nebe",slug:"barbara-nebe",fullName:"Barbara Nebe",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"176684",title:"Dr.",name:"Kashif Tufail",surname:"Chaudhary",slug:"kashif-tufail-chaudhary",fullName:"Kashif Tufail Chaudhary",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Technology Malaysia",institutionURL:null,country:{name:"Malaysia"}}},{id:"176687",title:"Dr.",name:"Fatemeh",surname:"Rezaei",slug:"fatemeh-rezaei",fullName:"Fatemeh Rezaei",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"K.N.Toosi University of Technology",institutionURL:null,country:{name:"Iran"}}},{id:"176702",title:"Prof.",name:"Yoshihiro",surname:"Deguchi",slug:"yoshihiro-deguchi",fullName:"Yoshihiro Deguchi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Tokushima",institutionURL:null,country:{name:"Japan"}}},{id:"176806",title:"Dr.",name:"Christoph",surname:"Gerhard",slug:"christoph-gerhard",fullName:"Christoph Gerhard",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Applied Sciences and Arts",institutionURL:null,country:{name:"Germany"}}},{id:"176867",title:"Dr.",name:"Syed Zuhaib",surname:"Haider Rizivi",slug:"syed-zuhaib-haider-rizivi",fullName:"Syed Zuhaib Haider Rizivi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"176868",title:"Prof.",name:"Jalil",surname:"Ali",slug:"jalil-ali",fullName:"Jalil Ali",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"176892",title:"Dr.",name:"Zhenzhen",surname:"Wang",slug:"zhenzhen-wang",fullName:"Zhenzhen Wang",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"177773",title:"Prof.",name:"Wolfgang",surname:"Viöl",slug:"wolfgang-viol",fullName:"Wolfgang Viöl",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"177774",title:"Prof.",name:"Stephan",surname:"Wieneke",slug:"stephan-wieneke",fullName:"Stephan Wieneke",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null}]},generic:{page:{slug:"our-story",title:"Our story",intro:"
The company was founded in Vienna in 2004 by Alex Lazinica and Vedran Kordic, two PhD students researching robotics. While completing our PhDs, we found it difficult to access the research we needed. So, we decided to create a new Open Access publisher. A better one, where researchers like us could find the information they needed easily. The result is IntechOpen, an Open Access publisher that puts the academic needs of the researchers before the business interests of publishers.
",metaTitle:"Our story",metaDescription:"The company was founded in Vienna in 2004 by Alex Lazinica and Vedran Kordic, two PhD students researching robotics. While completing our PhDs, we found it difficult to access the research we needed. So, we decided to create a new Open Access publisher. A better one, where researchers like us could find the information they needed easily. The result is IntechOpen, an Open Access publisher that puts the academic needs of the researchers before the business interests of publishers.",metaKeywords:null,canonicalURL:"/page/our-story",contentRaw:'[{"type":"htmlEditorComponent","content":"
We started by publishing journals and books from the fields of science we were most familiar with - AI, robotics, manufacturing and operations research. Through our growing network of institutions and authors, we soon expanded into related fields like environmental engineering, nanotechnology, computer science, renewable energy and electrical engineering, Today, we are the world’s largest Open Access publisher of scientific research, with over 4,200 books and 54,000 scientific works including peer-reviewed content from more than 116,000 scientists spanning 161 countries. Our authors range from globally-renowned Nobel Prize winners to up-and-coming researchers at the cutting edge of scientific discovery.
\\n\\n
In the same year that IntechOpen was founded, we launched what was at the time the first ever Open Access, peer-reviewed journal in its field: the International Journal of Advanced Robotic Systems (IJARS).
\\n\\n
The IntechOpen timeline
\\n\\n
2004
\\n\\n
\\n\\t
Intech Open is founded in Vienna, Austria, by Alex Lazinica and Vedran Kordic, two PhD students, and their first Open Access journals and books are published.
\\n\\t
Alex and Vedran launch the first Open Access, peer-reviewed robotics journal and IntechOpen’s flagship publication, the International Journal of Advanced Robotic Systems (IJARS).
\\n
\\n\\n
2005
\\n\\n
\\n\\t
IntechOpen publishes its first Open Access book: Cutting Edge Robotics.
\\n
\\n\\n
2006
\\n\\n
\\n\\t
IntechOpen publishes a special issue of IJARS, featuring contributions from NASA scientists regarding the Mars Exploration Rover missions.
\\n
\\n\\n
2008
\\n\\n
\\n\\t
Downloads milestone: 200,000 downloads reached
\\n
\\n\\n
2009
\\n\\n
\\n\\t
Publishing milestone: the first 100 Open Access STM books are published
\\n
\\n\\n
2010
\\n\\n
\\n\\t
Downloads milestone: one million downloads reached
\\n\\t
IntechOpen expands its book publishing into a new field: medicine.
\\n
\\n\\n
2011
\\n\\n
\\n\\t
Publishing milestone: More than five million downloads reached
\\n\\t
IntechOpen publishes 1996 Nobel Prize in Chemistry winner Harold W. Kroto’s “Strategies to Successfully Cross-Link Carbon Nanotubes”. Find it here.
\\n\\t
IntechOpen and TBI collaborate on a project to explore the changing needs of researchers and the evolving ways that they discover, publish and exchange information. The result is the survey “Author Attitudes Towards Open Access Publishing: A Market Research Program”.
\\n\\t
IntechOpen hosts SHOW - Share Open Access Worldwide; a series of lectures, debates, round-tables and events to bring people together in discussion of open source principles, intellectual property, content licensing innovations, remixed and shared culture and free knowledge.
\\n
\\n\\n
2012
\\n\\n
\\n\\t
Publishing milestone: 10 million downloads reached
\\n\\t
IntechOpen holds Interact2012, a free series of workshops held by figureheads of the scientific community including Professor Hiroshi Ishiguro, director of the Intelligent Robotics Laboratory, who took the audience through some of the most impressive human-robot interactions observed in his lab.
\\n
\\n\\n
2013
\\n\\n
\\n\\t
IntechOpen joins the Committee on Publication Ethics (COPE) as part of a commitment to guaranteeing the highest standards of publishing.
\\n
\\n\\n
2014
\\n\\n
\\n\\t
IntechOpen turns 10, with more than 30 million downloads to date.
\\n\\t
IntechOpen appoints its first Regional Representatives - members of the team situated around the world dedicated to increasing the visibility of our authors’ published work within their local scientific communities.
\\n
\\n\\n
2015
\\n\\n
\\n\\t
Downloads milestone: More than 70 million downloads reached, more than doubling since the previous year.
\\n\\t
Publishing milestone: IntechOpen publishes its 2,500th book and 40,000th Open Access chapter, reaching 20,000 citations in Thomson Reuters ISI Web of Science.
\\n\\t
40 IntechOpen authors are included in the top one per cent of the world’s most-cited researchers.
\\n\\t
Thomson Reuters’ ISI Web of Science Book Citation Index begins indexing IntechOpen’s books in its database.
\\n
\\n\\n
2016
\\n\\n
\\n\\t
IntechOpen is identified as a world leader in Simba Information’s Open Access Book Publishing 2016-2020 report and forecast. IntechOpen came in as the world’s largest Open Access book publisher by title count.
\\n
\\n\\n
2017
\\n\\n
\\n\\t
Downloads milestone: IntechOpen reaches more than 100 million downloads
\\n\\t
Publishing milestone: IntechOpen publishes its 3,000th Open Access book, making it the largest Open Access book collection in the world
We started by publishing journals and books from the fields of science we were most familiar with - AI, robotics, manufacturing and operations research. Through our growing network of institutions and authors, we soon expanded into related fields like environmental engineering, nanotechnology, computer science, renewable energy and electrical engineering, Today, we are the world’s largest Open Access publisher of scientific research, with over 4,200 books and 54,000 scientific works including peer-reviewed content from more than 116,000 scientists spanning 161 countries. Our authors range from globally-renowned Nobel Prize winners to up-and-coming researchers at the cutting edge of scientific discovery.
\n\n
In the same year that IntechOpen was founded, we launched what was at the time the first ever Open Access, peer-reviewed journal in its field: the International Journal of Advanced Robotic Systems (IJARS).
\n\n
The IntechOpen timeline
\n\n
2004
\n\n
\n\t
Intech Open is founded in Vienna, Austria, by Alex Lazinica and Vedran Kordic, two PhD students, and their first Open Access journals and books are published.
\n\t
Alex and Vedran launch the first Open Access, peer-reviewed robotics journal and IntechOpen’s flagship publication, the International Journal of Advanced Robotic Systems (IJARS).
\n
\n\n
2005
\n\n
\n\t
IntechOpen publishes its first Open Access book: Cutting Edge Robotics.
\n
\n\n
2006
\n\n
\n\t
IntechOpen publishes a special issue of IJARS, featuring contributions from NASA scientists regarding the Mars Exploration Rover missions.
\n
\n\n
2008
\n\n
\n\t
Downloads milestone: 200,000 downloads reached
\n
\n\n
2009
\n\n
\n\t
Publishing milestone: the first 100 Open Access STM books are published
\n
\n\n
2010
\n\n
\n\t
Downloads milestone: one million downloads reached
\n\t
IntechOpen expands its book publishing into a new field: medicine.
\n
\n\n
2011
\n\n
\n\t
Publishing milestone: More than five million downloads reached
\n\t
IntechOpen publishes 1996 Nobel Prize in Chemistry winner Harold W. Kroto’s “Strategies to Successfully Cross-Link Carbon Nanotubes”. Find it here.
\n\t
IntechOpen and TBI collaborate on a project to explore the changing needs of researchers and the evolving ways that they discover, publish and exchange information. The result is the survey “Author Attitudes Towards Open Access Publishing: A Market Research Program”.
\n\t
IntechOpen hosts SHOW - Share Open Access Worldwide; a series of lectures, debates, round-tables and events to bring people together in discussion of open source principles, intellectual property, content licensing innovations, remixed and shared culture and free knowledge.
\n
\n\n
2012
\n\n
\n\t
Publishing milestone: 10 million downloads reached
\n\t
IntechOpen holds Interact2012, a free series of workshops held by figureheads of the scientific community including Professor Hiroshi Ishiguro, director of the Intelligent Robotics Laboratory, who took the audience through some of the most impressive human-robot interactions observed in his lab.
\n
\n\n
2013
\n\n
\n\t
IntechOpen joins the Committee on Publication Ethics (COPE) as part of a commitment to guaranteeing the highest standards of publishing.
\n
\n\n
2014
\n\n
\n\t
IntechOpen turns 10, with more than 30 million downloads to date.
\n\t
IntechOpen appoints its first Regional Representatives - members of the team situated around the world dedicated to increasing the visibility of our authors’ published work within their local scientific communities.
\n
\n\n
2015
\n\n
\n\t
Downloads milestone: More than 70 million downloads reached, more than doubling since the previous year.
\n\t
Publishing milestone: IntechOpen publishes its 2,500th book and 40,000th Open Access chapter, reaching 20,000 citations in Thomson Reuters ISI Web of Science.
\n\t
40 IntechOpen authors are included in the top one per cent of the world’s most-cited researchers.
\n\t
Thomson Reuters’ ISI Web of Science Book Citation Index begins indexing IntechOpen’s books in its database.
\n
\n\n
2016
\n\n
\n\t
IntechOpen is identified as a world leader in Simba Information’s Open Access Book Publishing 2016-2020 report and forecast. IntechOpen came in as the world’s largest Open Access book publisher by title count.
\n
\n\n
2017
\n\n
\n\t
Downloads milestone: IntechOpen reaches more than 100 million downloads
\n\t
Publishing milestone: IntechOpen publishes its 3,000th Open Access book, making it the largest Open Access book collection in the world
\n
\n"}]},successStories:{items:[]},authorsAndEditors:{filterParams:{"933869@":null},profiles:[],filtersByRegion:[{group:"region",caption:"North America",value:1,count:6601},{group:"region",caption:"Middle and South America",value:2,count:5906},{group:"region",caption:"Africa",value:3,count:2400},{group:"region",caption:"Asia",value:4,count:12541},{group:"region",caption:"Australia and Oceania",value:5,count:1008},{group:"region",caption:"Europe",value:6,count:17561}],offset:0,limit:12,total:null},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"1",sort:"dateEndThirdStepPublish",topicId:"8,9,10,11,14,15,17,20,22,24"},books:[{type:"book",id:"11546",title:"Smart and Sustainable Transportation",subtitle:null,isOpenForSubmission:!0,hash:"e8ea27a1ff85cde00efcb6f6968c20f8",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11546.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11554",title:"Information Systems Management",subtitle:null,isOpenForSubmission:!0,hash:"3134452ff2fdec020663f241c7a9a748",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11554.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11834",title:"Steppe Geography",subtitle:null,isOpenForSubmission:!0,hash:"363517fa6f079daf94c51ea1b91fed2a",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11834.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11836",title:"Estuary Research",subtitle:null,isOpenForSubmission:!0,hash:"ef822fc9eee5600aeb7e45492e04a6e7",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11836.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11837",title:"The Mediterranean",subtitle:null,isOpenForSubmission:!0,hash:"bbb25987a982d61da4f47fb13614ba3c",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11837.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11846",title:"Seabed",subtitle:null,isOpenForSubmission:!0,hash:"1b1698a2d8d36b5ec3571c20486eb2c9",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11846.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11913",title:"Scheduling Algorithms",subtitle:null,isOpenForSubmission:!0,hash:"da42ea7b678d715e23ffcae50ae47078",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11913.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11915",title:"Ontology in Computer Science",subtitle:null,isOpenForSubmission:!0,hash:"b52397215f6b5e05a22368f629695704",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11915.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11917",title:"Computational Semantics",subtitle:null,isOpenForSubmission:!0,hash:"bd9343348f2c50dbbc819a0b48a76591",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11917.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11938",title:"Ballistics",subtitle:null,isOpenForSubmission:!0,hash:"9c64ef67aac55216f08c65a2a179835c",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11938.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11941",title:"Advances in Turbomachinery",subtitle:null,isOpenForSubmission:!0,hash:"fe2c693976d70c5d0cc5f8003e6e73c5",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11941.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11942",title:"Updates on Spatial Audio",subtitle:null,isOpenForSubmission:!0,hash:"f4ac095defb765e0e9bfebc06dac719e",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11942.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:41},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:12},{group:"topic",caption:"Business, Management and Economics",value:7,count:7},{group:"topic",caption:"Chemistry",value:8,count:17},{group:"topic",caption:"Computer and Information Science",value:9,count:16},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:17},{group:"topic",caption:"Engineering",value:11,count:32},{group:"topic",caption:"Environmental Sciences",value:12,count:7},{group:"topic",caption:"Immunology and Microbiology",value:13,count:11},{group:"topic",caption:"Materials Science",value:14,count:11},{group:"topic",caption:"Mathematics",value:15,count:6},{group:"topic",caption:"Medicine",value:16,count:106},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:2},{group:"topic",caption:"Neuroscience",value:18,count:7},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:11},{group:"topic",caption:"Physics",value:20,count:2},{group:"topic",caption:"Psychology",value:21,count:8},{group:"topic",caption:"Robotics",value:22,count:2},{group:"topic",caption:"Social Sciences",value:23,count:32},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:12,limit:12,total:106},popularBooks:{featuredBooks:[{type:"book",id:"9974",title:"E-Learning and Digital Education in the Twenty-First Century",subtitle:null,isOpenForSubmission:!1,hash:"88b58d66e975df20425fc1dfd22d53aa",slug:"e-learning-and-digital-education-in-the-twenty-first-century",bookSignature:"M. Mahruf C. Shohel",coverURL:"https://cdn.intechopen.com/books/images_new/9974.jpg",editors:[{id:"94099",title:"Dr.",name:"M. Mahruf C.",middleName:null,surname:"Shohel",slug:"m.-mahruf-c.-shohel",fullName:"M. Mahruf C. Shohel"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11001",title:"Density Functional Theory",subtitle:"Recent Advances, New Perspectives and Applications",isOpenForSubmission:!1,hash:"82d53383af78ab41eb982086c02fb2bb",slug:"density-functional-theory-recent-advances-new-perspectives-and-applications",bookSignature:"Daniel Glossman-Mitnik",coverURL:"https://cdn.intechopen.com/books/images_new/11001.jpg",editors:[{id:"198499",title:"Dr.",name:"Daniel",middleName:null,surname:"Glossman-Mitnik",slug:"daniel-glossman-mitnik",fullName:"Daniel Glossman-Mitnik"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10251",title:"Plankton Communities",subtitle:null,isOpenForSubmission:!1,hash:"e11e441ca2d2d5f631b1b4704505cfb6",slug:"plankton-communities",bookSignature:"Leonel Pereira and Ana Marta Gonçalves",coverURL:"https://cdn.intechopen.com/books/images_new/10251.jpg",editors:[{id:"279788",title:"Dr.",name:"Leonel",middleName:null,surname:"Pereira",slug:"leonel-pereira",fullName:"Leonel Pereira"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10830",title:"Animal Feed Science and Nutrition",subtitle:"Production, Health and Environment",isOpenForSubmission:!1,hash:"79944fc8fbbaa329aed6fde388154832",slug:"animal-feed-science-and-nutrition-production-health-and-environment",bookSignature:"Amlan Kumar Patra",coverURL:"https://cdn.intechopen.com/books/images_new/10830.jpg",editors:[{id:"310962",title:"Dr.",name:"Amlan",middleName:"Kumar",surname:"Patra",slug:"amlan-patra",fullName:"Amlan Patra"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10356",title:"Natural Medicinal Plants",subtitle:null,isOpenForSubmission:!1,hash:"943e56ccaaf19ff696d25aa638ae37d6",slug:"natural-medicinal-plants",bookSignature:"Hany A. El-Shemy",coverURL:"https://cdn.intechopen.com/books/images_new/10356.jpg",editors:[{id:"54719",title:"Prof.",name:"Hany",middleName:null,surname:"El-Shemy",slug:"hany-el-shemy",fullName:"Hany El-Shemy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11752",title:"Natural Drugs from Plants",subtitle:null,isOpenForSubmission:!1,hash:"a0a83c0822608ef7592bf16a5ed0ada4",slug:"natural-drugs-from-plants",bookSignature:"Hany A. El-Shemy",coverURL:"https://cdn.intechopen.com/books/images_new/11752.jpg",editors:[{id:"54719",title:"Prof.",name:"Hany",middleName:null,surname:"El-Shemy",slug:"hany-el-shemy",fullName:"Hany El-Shemy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10853",title:"Recent Advances in Polynomials",subtitle:null,isOpenForSubmission:!1,hash:"9e8671bae09ccaa8b8e276c639a737fc",slug:"recent-advances-in-polynomials",bookSignature:"Kamal Shah",coverURL:"https://cdn.intechopen.com/books/images_new/10853.jpg",editors:[{id:"231748",title:"Dr.",name:"Kamal",middleName:null,surname:"Shah",slug:"kamal-shah",fullName:"Kamal Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10676",title:"Recent Applications in Graph Theory",subtitle:null,isOpenForSubmission:!1,hash:"900c60742d224080732bd16bd25ccba8",slug:"recent-applications-in-graph-theory",bookSignature:"Harun Pirim",coverURL:"https://cdn.intechopen.com/books/images_new/10676.jpg",editors:[{id:"146092",title:"Dr.",name:"Harun",middleName:null,surname:"Pirim",slug:"harun-pirim",fullName:"Harun Pirim"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10903",title:"Genetically Modified Plants and Beyond",subtitle:null,isOpenForSubmission:!1,hash:"4d7ed4faab99c92cd4d676dc86501df9",slug:"genetically-modified-plants-and-beyond",bookSignature:"Idah Sithole Niang",coverURL:"https://cdn.intechopen.com/books/images_new/10903.jpg",editors:[{id:"90172",title:"Prof.",name:"Idah",middleName:null,surname:"Sithole-Niang",slug:"idah-sithole-niang",fullName:"Idah Sithole-Niang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10904",title:"Fusarium",subtitle:"An Overview of the Genus",isOpenForSubmission:!1,hash:"49d9063e43f94bd1517d65fbc58b93c3",slug:"fusarium-an-overview-of-the-genus",bookSignature:"Seyed Mahyar Mirmajlessi",coverURL:"https://cdn.intechopen.com/books/images_new/10904.jpg",editors:[{id:"100573",title:"Dr.",name:"Seyed Mahyar",middleName:null,surname:"Mirmajlessi",slug:"seyed-mahyar-mirmajlessi",fullName:"Seyed Mahyar Mirmajlessi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10871",title:"Computed-Tomography (CT) Scan",subtitle:null,isOpenForSubmission:!1,hash:"966d8cf74fa27eea1b9cbc9a6ee94993",slug:"computed-tomography-ct-scan",bookSignature:"Reda R. Gharieb",coverURL:"https://cdn.intechopen.com/books/images_new/10871.jpg",editors:[{id:"225387",title:"Prof.",name:"Reda R.",middleName:"R.",surname:"Gharieb",slug:"reda-r.-gharieb",fullName:"Reda R. Gharieb"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11196",title:"New Updates in E-Learning",subtitle:null,isOpenForSubmission:!1,hash:"6afaadf68e2a0a4b370ac5ceb5ca89c6",slug:"new-updates-in-e-learning",bookSignature:"Eduard Babulak",coverURL:"https://cdn.intechopen.com/books/images_new/11196.jpg",editors:[{id:"10086",title:"Prof.",name:"Eduard",middleName:null,surname:"Babulak",slug:"eduard-babulak",fullName:"Eduard Babulak"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:4383},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9974",title:"E-Learning and Digital Education in the Twenty-First Century",subtitle:null,isOpenForSubmission:!1,hash:"88b58d66e975df20425fc1dfd22d53aa",slug:"e-learning-and-digital-education-in-the-twenty-first-century",bookSignature:"M. Mahruf C. Shohel",coverURL:"https://cdn.intechopen.com/books/images_new/9974.jpg",publishedDate:"May 18th 2022",numberOfDownloads:3340,editors:[{id:"94099",title:"Dr.",name:"M. Mahruf C.",middleName:null,surname:"Shohel",slug:"m.-mahruf-c.-shohel",fullName:"M. Mahruf C. Shohel"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11001",title:"Density Functional Theory",subtitle:"Recent Advances, New Perspectives and Applications",isOpenForSubmission:!1,hash:"82d53383af78ab41eb982086c02fb2bb",slug:"density-functional-theory-recent-advances-new-perspectives-and-applications",bookSignature:"Daniel Glossman-Mitnik",coverURL:"https://cdn.intechopen.com/books/images_new/11001.jpg",publishedDate:"May 18th 2022",numberOfDownloads:1845,editors:[{id:"198499",title:"Dr.",name:"Daniel",middleName:null,surname:"Glossman-Mitnik",slug:"daniel-glossman-mitnik",fullName:"Daniel Glossman-Mitnik"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10251",title:"Plankton Communities",subtitle:null,isOpenForSubmission:!1,hash:"e11e441ca2d2d5f631b1b4704505cfb6",slug:"plankton-communities",bookSignature:"Leonel Pereira and Ana Marta Gonçalves",coverURL:"https://cdn.intechopen.com/books/images_new/10251.jpg",publishedDate:"May 18th 2022",numberOfDownloads:1096,editors:[{id:"279788",title:"Dr.",name:"Leonel",middleName:null,surname:"Pereira",slug:"leonel-pereira",fullName:"Leonel Pereira"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10830",title:"Animal Feed Science and Nutrition",subtitle:"Production, Health and Environment",isOpenForSubmission:!1,hash:"79944fc8fbbaa329aed6fde388154832",slug:"animal-feed-science-and-nutrition-production-health-and-environment",bookSignature:"Amlan Kumar Patra",coverURL:"https://cdn.intechopen.com/books/images_new/10830.jpg",publishedDate:"May 18th 2022",numberOfDownloads:995,editors:[{id:"310962",title:"Dr.",name:"Amlan",middleName:"Kumar",surname:"Patra",slug:"amlan-patra",fullName:"Amlan Patra"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10356",title:"Natural Medicinal Plants",subtitle:null,isOpenForSubmission:!1,hash:"943e56ccaaf19ff696d25aa638ae37d6",slug:"natural-medicinal-plants",bookSignature:"Hany A. El-Shemy",coverURL:"https://cdn.intechopen.com/books/images_new/10356.jpg",publishedDate:"May 11th 2022",numberOfDownloads:3791,editors:[{id:"54719",title:"Prof.",name:"Hany",middleName:null,surname:"El-Shemy",slug:"hany-el-shemy",fullName:"Hany El-Shemy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11752",title:"Natural Drugs from Plants",subtitle:null,isOpenForSubmission:!1,hash:"a0a83c0822608ef7592bf16a5ed0ada4",slug:"natural-drugs-from-plants",bookSignature:"Hany A. El-Shemy",coverURL:"https://cdn.intechopen.com/books/images_new/11752.jpg",publishedDate:"May 11th 2022",numberOfDownloads:2982,editors:[{id:"54719",title:"Prof.",name:"Hany",middleName:null,surname:"El-Shemy",slug:"hany-el-shemy",fullName:"Hany El-Shemy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10853",title:"Recent Advances in Polynomials",subtitle:null,isOpenForSubmission:!1,hash:"9e8671bae09ccaa8b8e276c639a737fc",slug:"recent-advances-in-polynomials",bookSignature:"Kamal Shah",coverURL:"https://cdn.intechopen.com/books/images_new/10853.jpg",publishedDate:"May 18th 2022",numberOfDownloads:559,editors:[{id:"231748",title:"Dr.",name:"Kamal",middleName:null,surname:"Shah",slug:"kamal-shah",fullName:"Kamal Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10676",title:"Recent Applications in Graph Theory",subtitle:null,isOpenForSubmission:!1,hash:"900c60742d224080732bd16bd25ccba8",slug:"recent-applications-in-graph-theory",bookSignature:"Harun Pirim",coverURL:"https://cdn.intechopen.com/books/images_new/10676.jpg",publishedDate:"May 18th 2022",numberOfDownloads:546,editors:[{id:"146092",title:"Dr.",name:"Harun",middleName:null,surname:"Pirim",slug:"harun-pirim",fullName:"Harun Pirim"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10903",title:"Genetically Modified Plants and Beyond",subtitle:null,isOpenForSubmission:!1,hash:"4d7ed4faab99c92cd4d676dc86501df9",slug:"genetically-modified-plants-and-beyond",bookSignature:"Idah Sithole Niang",coverURL:"https://cdn.intechopen.com/books/images_new/10903.jpg",publishedDate:"May 18th 2022",numberOfDownloads:539,editors:[{id:"90172",title:"Prof.",name:"Idah",middleName:null,surname:"Sithole-Niang",slug:"idah-sithole-niang",fullName:"Idah Sithole-Niang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10904",title:"Fusarium",subtitle:"An Overview of the Genus",isOpenForSubmission:!1,hash:"49d9063e43f94bd1517d65fbc58b93c3",slug:"fusarium-an-overview-of-the-genus",bookSignature:"Seyed Mahyar Mirmajlessi",coverURL:"https://cdn.intechopen.com/books/images_new/10904.jpg",publishedDate:"May 18th 2022",numberOfDownloads:535,editors:[{id:"100573",title:"Dr.",name:"Seyed Mahyar",middleName:null,surname:"Mirmajlessi",slug:"seyed-mahyar-mirmajlessi",fullName:"Seyed Mahyar Mirmajlessi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"10251",title:"Plankton Communities",subtitle:null,isOpenForSubmission:!1,hash:"e11e441ca2d2d5f631b1b4704505cfb6",slug:"plankton-communities",bookSignature:"Leonel Pereira and Ana Marta Gonçalves",coverURL:"https://cdn.intechopen.com/books/images_new/10251.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"279788",title:"Dr.",name:"Leonel",middleName:null,surname:"Pereira",slug:"leonel-pereira",fullName:"Leonel Pereira"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10830",title:"Animal Feed Science and Nutrition",subtitle:"Production, Health and Environment",isOpenForSubmission:!1,hash:"79944fc8fbbaa329aed6fde388154832",slug:"animal-feed-science-and-nutrition-production-health-and-environment",bookSignature:"Amlan Kumar Patra",coverURL:"https://cdn.intechopen.com/books/images_new/10830.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"310962",title:"Dr.",name:"Amlan",middleName:"Kumar",surname:"Patra",slug:"amlan-patra",fullName:"Amlan Patra"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10853",title:"Recent Advances in Polynomials",subtitle:null,isOpenForSubmission:!1,hash:"9e8671bae09ccaa8b8e276c639a737fc",slug:"recent-advances-in-polynomials",bookSignature:"Kamal Shah",coverURL:"https://cdn.intechopen.com/books/images_new/10853.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"231748",title:"Dr.",name:"Kamal",middleName:null,surname:"Shah",slug:"kamal-shah",fullName:"Kamal Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10871",title:"Computed-Tomography (CT) Scan",subtitle:null,isOpenForSubmission:!1,hash:"966d8cf74fa27eea1b9cbc9a6ee94993",slug:"computed-tomography-ct-scan",bookSignature:"Reda R. Gharieb",coverURL:"https://cdn.intechopen.com/books/images_new/10871.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"225387",title:"Prof.",name:"Reda R.",middleName:"R.",surname:"Gharieb",slug:"reda-r.-gharieb",fullName:"Reda R. Gharieb"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10903",title:"Genetically Modified Plants and Beyond",subtitle:null,isOpenForSubmission:!1,hash:"4d7ed4faab99c92cd4d676dc86501df9",slug:"genetically-modified-plants-and-beyond",bookSignature:"Idah Sithole Niang",coverURL:"https://cdn.intechopen.com/books/images_new/10903.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"90172",title:"Prof.",name:"Idah",middleName:null,surname:"Sithole-Niang",slug:"idah-sithole-niang",fullName:"Idah Sithole-Niang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10904",title:"Fusarium",subtitle:"An Overview of the Genus",isOpenForSubmission:!1,hash:"49d9063e43f94bd1517d65fbc58b93c3",slug:"fusarium-an-overview-of-the-genus",bookSignature:"Seyed Mahyar Mirmajlessi",coverURL:"https://cdn.intechopen.com/books/images_new/10904.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"100573",title:"Dr.",name:"Seyed Mahyar",middleName:null,surname:"Mirmajlessi",slug:"seyed-mahyar-mirmajlessi",fullName:"Seyed Mahyar Mirmajlessi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10654",title:"Brain-Computer Interface",subtitle:null,isOpenForSubmission:!1,hash:"a5308884068cc53ed31c6baba756857f",slug:"brain-computer-interface",bookSignature:"Vahid Asadpour",coverURL:"https://cdn.intechopen.com/books/images_new/10654.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"165328",title:"Dr.",name:"Vahid",middleName:null,surname:"Asadpour",slug:"vahid-asadpour",fullName:"Vahid Asadpour"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10676",title:"Recent Applications in Graph Theory",subtitle:null,isOpenForSubmission:!1,hash:"900c60742d224080732bd16bd25ccba8",slug:"recent-applications-in-graph-theory",bookSignature:"Harun Pirim",coverURL:"https://cdn.intechopen.com/books/images_new/10676.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"146092",title:"Dr.",name:"Harun",middleName:null,surname:"Pirim",slug:"harun-pirim",fullName:"Harun Pirim"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11196",title:"New Updates in E-Learning",subtitle:null,isOpenForSubmission:!1,hash:"6afaadf68e2a0a4b370ac5ceb5ca89c6",slug:"new-updates-in-e-learning",bookSignature:"Eduard Babulak",coverURL:"https://cdn.intechopen.com/books/images_new/11196.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"10086",title:"Prof.",name:"Eduard",middleName:null,surname:"Babulak",slug:"eduard-babulak",fullName:"Eduard Babulak"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9974",title:"E-Learning and Digital Education in the Twenty-First Century",subtitle:null,isOpenForSubmission:!1,hash:"88b58d66e975df20425fc1dfd22d53aa",slug:"e-learning-and-digital-education-in-the-twenty-first-century",bookSignature:"M. Mahruf C. Shohel",coverURL:"https://cdn.intechopen.com/books/images_new/9974.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"94099",title:"Dr.",name:"M. Mahruf C.",middleName:null,surname:"Shohel",slug:"m.-mahruf-c.-shohel",fullName:"M. Mahruf C. Shohel"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"244",title:"Ant Robotics",slug:"ant-robotics",parent:{id:"22",title:"Robotics",slug:"physical-sciences-engineering-and-technology-robotics"},numberOfBooks:1,numberOfSeries:0,numberOfAuthorsAndEditors:1,numberOfWosCitations:24,numberOfCrossrefCitations:2,numberOfDimensionsCitations:26,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicId:"244",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"3641",title:"Swarm Robotics",subtitle:"from Biology to Robotics",isOpenForSubmission:!1,hash:null,slug:"swarm-robotics-from-biology-to-robotics",bookSignature:"Ester Martinez Martin",coverURL:"https://cdn.intechopen.com/books/images_new/3641.jpg",editedByType:"Edited by",editors:[{id:"5973",title:"Dr.",name:"Ester",middleName:null,surname:"Martínez-Martín",slug:"ester-martinez-martin",fullName:"Ester Martínez-Martín"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:1,seriesByTopicCollection:[],seriesByTopicTotal:0,mostCitedChapters:[{id:"9817",doi:"10.5772/8600",title:"Bio-Inspired Search Strategies for Robot Swarms",slug:"bio-inspired-search-strategies-for-robot-swarms",totalDownloads:2116,totalCrossrefCites:2,totalDimensionsCites:20,abstract:null,book:{id:"3641",slug:"swarm-robotics-from-biology-to-robotics",title:"Swarm Robotics",fullTitle:"Swarm Robotics from Biology to Robotics"},signatures:"James M. Hereford and Michael A. Siebold",authors:null},{id:"9816",doi:"10.5772/8599",title:"A New Hybrid Particle Swarm Optimization Algorithm to the Cyclic Multiple-Part Type Three-Machine Robotic Cell Problem",slug:"a-new-hybrid-particle-swarm-optimization-algorithm-to-the-cyclic-multiple-part-type-three-machine-ro",totalDownloads:1864,totalCrossrefCites:0,totalDimensionsCites:3,abstract:null,book:{id:"3641",slug:"swarm-robotics-from-biology-to-robotics",title:"Swarm Robotics",fullTitle:"Swarm Robotics from Biology to Robotics"},signatures:"Isa Nakhai Kamalabadi, Ali Hossein Mirzaei and Saeede Gholami",authors:null},{id:"9818",doi:"10.5772/8601",title:"Comparison of Swarm Optimization and Genetic Algorithm for Mobile Robot Navigation",slug:"comparison-of-swarm-optimization-and-genetic-algorithm-for-mobile-robot-navigation",totalDownloads:2989,totalCrossrefCites:0,totalDimensionsCites:1,abstract:null,book:{id:"3641",slug:"swarm-robotics-from-biology-to-robotics",title:"Swarm Robotics",fullTitle:"Swarm Robotics from Biology to Robotics"},signatures:"Petar Curkovic, Bojan Jerbic and Tomislav Stipancic",authors:null},{id:"9819",doi:"10.5772/8602",title:"Optimization Design Method of IIR Digital Filters for Robot Force Position Sensors",slug:"optimization-design-method-of-iir-digital-filters-for-robot-force-position-sensors",totalDownloads:3697,totalCrossrefCites:0,totalDimensionsCites:1,abstract:null,book:{id:"3641",slug:"swarm-robotics-from-biology-to-robotics",title:"Swarm Robotics",fullTitle:"Swarm Robotics from Biology to Robotics"},signatures:"Fuxiang Zhang",authors:null},{id:"9815",doi:"10.5772/8598",title:"Key Aspects of PSO-Type Swarm Robotic Search: Signals Fusion and Path Planning",slug:"key-aspects-of-pso-type-swarm-robotic-search-signals-fusion-and-path-planning",totalDownloads:2241,totalCrossrefCites:0,totalDimensionsCites:1,abstract:null,book:{id:"3641",slug:"swarm-robotics-from-biology-to-robotics",title:"Swarm Robotics",fullTitle:"Swarm Robotics from Biology to Robotics"},signatures:"Songdong Xue, Jianchao Zeng and Jinwei Guo",authors:null}],mostDownloadedChaptersLast30Days:[{id:"9815",title:"Key Aspects of PSO-Type Swarm Robotic Search: Signals Fusion and Path Planning",slug:"key-aspects-of-pso-type-swarm-robotic-search-signals-fusion-and-path-planning",totalDownloads:2238,totalCrossrefCites:0,totalDimensionsCites:1,abstract:null,book:{id:"3641",slug:"swarm-robotics-from-biology-to-robotics",title:"Swarm Robotics",fullTitle:"Swarm Robotics from Biology to Robotics"},signatures:"Songdong Xue, Jianchao Zeng and Jinwei Guo",authors:null},{id:"9817",title:"Bio-Inspired Search Strategies for Robot Swarms",slug:"bio-inspired-search-strategies-for-robot-swarms",totalDownloads:2116,totalCrossrefCites:2,totalDimensionsCites:20,abstract:null,book:{id:"3641",slug:"swarm-robotics-from-biology-to-robotics",title:"Swarm Robotics",fullTitle:"Swarm Robotics from Biology to Robotics"},signatures:"James M. Hereford and Michael A. Siebold",authors:null},{id:"9816",title:"A New Hybrid Particle Swarm Optimization Algorithm to the Cyclic Multiple-Part Type Three-Machine Robotic Cell Problem",slug:"a-new-hybrid-particle-swarm-optimization-algorithm-to-the-cyclic-multiple-part-type-three-machine-ro",totalDownloads:1862,totalCrossrefCites:0,totalDimensionsCites:3,abstract:null,book:{id:"3641",slug:"swarm-robotics-from-biology-to-robotics",title:"Swarm Robotics",fullTitle:"Swarm Robotics from Biology to Robotics"},signatures:"Isa Nakhai Kamalabadi, Ali Hossein Mirzaei and Saeede Gholami",authors:null},{id:"9819",title:"Optimization Design Method of IIR Digital Filters for Robot Force Position Sensors",slug:"optimization-design-method-of-iir-digital-filters-for-robot-force-position-sensors",totalDownloads:3694,totalCrossrefCites:0,totalDimensionsCites:1,abstract:null,book:{id:"3641",slug:"swarm-robotics-from-biology-to-robotics",title:"Swarm Robotics",fullTitle:"Swarm Robotics from Biology to Robotics"},signatures:"Fuxiang Zhang",authors:null},{id:"9820",title:"Visual Analysis of Robot and Animal Colonies",slug:"visual-analysis-of-robot-and-animal-colonies",totalDownloads:1905,totalCrossrefCites:0,totalDimensionsCites:0,abstract:null,book:{id:"3641",slug:"swarm-robotics-from-biology-to-robotics",title:"Swarm Robotics",fullTitle:"Swarm Robotics from Biology to Robotics"},signatures:"E. Martinez and A.P. del Pobil",authors:null}],onlineFirstChaptersFilter:{topicId:"244",limit:6,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},subscriptionForm:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:8,limit:8,total:0},allSeries:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:87,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:98,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:27,numberOfPublishedChapters:287,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:11,numberOfPublishedChapters:139,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:8,numberOfPublishedChapters:129,numberOfOpenTopics:0,numberOfUpcomingTopics:2,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!1},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:107,numberOfOpenTopics:3,numberOfUpcomingTopics:1,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:10,numberOfPublishedChapters:103,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:12,numberOfOpenTopics:2,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:0,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!1},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:0,numberOfPublishedChapters:10,numberOfOpenTopics:4,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],testimonialsList:[{id:"6",text:"It is great to work with the IntechOpen to produce a worthwhile collection of research that also becomes a great educational resource and guide for future research endeavors.",author:{id:"259298",name:"Edward",surname:"Narayan",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",slug:"edward-narayan",institution:{id:"3",name:"University of Queensland",country:{id:null,name:"Australia"}}}},{id:"13",text:"The collaboration with and support of the technical staff of IntechOpen is fantastic. The whole process of submitting an article and editing of the submitted article goes extremely smooth and fast, the number of reads and downloads of chapters is high, and the contributions are also frequently cited.",author:{id:"55578",name:"Antonio",surname:"Jurado-Navas",institutionString:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRisIQAS/Profile_Picture_1626166543950",slug:"antonio-jurado-navas",institution:{id:"720",name:"University of Malaga",country:{id:null,name:"Spain"}}}}]},series:{item:{id:"25",title:"Environmental Sciences",doi:"10.5772/intechopen.100362",issn:"2754-6713",scope:"
\r\n\tScientists have long researched to understand the environment and man’s place in it. The search for this knowledge grows in importance as rapid increases in population and economic development intensify humans’ stresses on ecosystems. Fortunately, rapid increases in multiple scientific areas are advancing our understanding of environmental sciences. Breakthroughs in computing, molecular biology, ecology, and sustainability science are enhancing our ability to utilize environmental sciences to address real-world problems. \r\n\tThe four topics of this book series - Pollution; Environmental Resilience and Management; Ecosystems and Biodiversity; and Water Science - will address important areas of advancement in the environmental sciences. They will represent an excellent initial grouping of published works on these critical topics.
",coverUrl:"https://cdn.intechopen.com/series/covers/25.jpg",latestPublicationDate:"April 13th, 2022",hasOnlineFirst:!1,numberOfPublishedBooks:1,editor:{id:"197485",title:"Dr.",name:"J. Kevin",middleName:null,surname:"Summers",slug:"j.-kevin-summers",fullName:"J. Kevin Summers",profilePictureURL:"https://mts.intechopen.com/storage/users/197485/images/system/197485.jpg",biography:"J. Kevin Summers is a Senior Research Ecologist at the Environmental Protection Agency’s (EPA) Gulf Ecosystem Measurement and Modeling Division. He is currently working with colleagues in the Sustainable and Healthy Communities Program to develop an index of community resilience to natural hazards, an index of human well-being that can be linked to changes in the ecosystem, social and economic services, and a community sustainability tool for communities with populations under 40,000. He leads research efforts for indicator and indices development. Dr. Summers is a systems ecologist and began his career at the EPA in 1989 and has worked in various programs and capacities. This includes leading the National Coastal Assessment in collaboration with the Office of Water which culminated in the award-winning National Coastal Condition Report series (four volumes between 2001 and 2012), and which integrates water quality, sediment quality, habitat, and biological data to assess the ecosystem condition of the United States estuaries. He was acting National Program Director for Ecology for the EPA between 2004 and 2006. He has authored approximately 150 peer-reviewed journal articles, book chapters, and reports and has received many awards for technical accomplishments from the EPA and from outside of the agency. Dr. Summers holds a BA in Zoology and Psychology, an MA in Ecology, and Ph.D. in Systems Ecology/Biology.",institutionString:null,institution:{name:"Environmental Protection Agency",institutionURL:null,country:{name:"United States of America"}}},editorTwo:null,editorThree:null},subseries:{paginationCount:4,paginationItems:[{id:"38",title:"Pollution",coverUrl:"https://cdn.intechopen.com/series_topics/covers/38.jpg",isOpenForSubmission:!0,editor:{id:"110740",title:"Dr.",name:"Ismail M.M.",middleName:null,surname:"Rahman",slug:"ismail-m.m.-rahman",fullName:"Ismail M.M. Rahman",profilePictureURL:"https://mts.intechopen.com/storage/users/110740/images/2319_n.jpg",biography:"Ismail Md. Mofizur Rahman (Ismail M. M. Rahman) assumed his current responsibilities as an Associate Professor at the Institute of Environmental Radioactivity, Fukushima University, Japan, in Oct 2015. He also has an honorary appointment to serve as a Collaborative Professor at Kanazawa University, Japan, from Mar 2015 to the present. \nFormerly, Dr. Rahman was a faculty member of the University of Chittagong, Bangladesh, affiliated with the Department of Chemistry (Oct 2002 to Mar 2012) and the Department of Applied Chemistry and Chemical Engineering (Mar 2012 to Sep 2015). Dr. Rahman was also adjunctly attached with Kanazawa University, Japan (Visiting Research Professor, Dec 2014 to Mar 2015; JSPS Postdoctoral Research Fellow, Apr 2012 to Mar 2014), and Tokyo Institute of Technology, Japan (TokyoTech-UNESCO Research Fellow, Oct 2004–Sep 2005). \nHe recei